

DRC-IHP Quarterly Report: January-March 2011

May, 2011

Keywords: Integrated Health Project; maternal, newborn, and child health; water, sanitation, and hygiene; family planning/reproductive health; malaria, tuberculosis, and nutrition

This report was made possible through support provided by the US Agency for International Development, under the terms of cooperative agreement number AID-OAA-A-10-00054. The opinions expressed herein are those of the author(s) and do not necessarily reflect the views of the US Agency for International Development.

Integrated Health Project (IHP) in the Democratic Republic of the Congo
Management Sciences for Health
784 Memorial Drive
Cambridge, MA 02139
Telephone: (617) 250-9500
www.msh.org

Integrated Health Project

in the Democratic Republic of Congo



USAID
FROM THE AMERICAN PEOPLE



DRC-IHP Quarterly Report: Year 1, Quarter 2 (January-March 2011)

USAID Cooperative Agreement Number: AID-OAA-A-10-00054

Submitted to USAID/DRC on May 6, 2011

Cover Photo: Community-based distributor in Tshumbe explaining how to use cycle beads to a client.

Project Name: Integrated Health Project in the Democratic Republic of Congo
Cooperative Agreement Number: AID-OAA-A-10-00054

Contact information in DRC:

1, Avenue OUA, Commune NGALIEMA , Kinshasa
Chief of Party: Dr. Ousmane FAYE, +243 0992006180
Fin/Admin Specialist: Lila Rabibisoa, +243 0992909670

Contact information in the U.S:

784 Memorial Drive, Cambridge, MA 02139
Director, Country Portfolio: Kristin Cooney, Tel: +1 617-250-9168

TABLE OF CONTENTS

TABLE OF CONTENTS	1
ACRONYMS	2
EXECUTIVE SUMMARY	4
I. PROJECT PERFORMANCE: ACTIVITIES AND ACHIEVEMENTS	6
I.1 COMPONENT 1: HEALTH SERVICES.....	6
I.1A (IR 1): ACCESS TO AND AVAILABILITY OF MINIMUM PACKAGE OF ACTIVITIES/COMPLEMENTARY PACKAGE OF ACTIVITIES PLUS (MPA/CPA-PLUS) SERVICES IN TARGETED HEALTH ZONES INCREASED	6
I.1B (IR 2): QUALITY OF MPA/CPA-PLUS SERVICES IN TARGET HEALTH ZONES INCREASED	9
I.1C (IR 3): KNOWLEDGE, ATTITUDES, AND PRACTICES (KAP) TO SUPPORT HEALTH-SEEKING BEHAVIORS INCREASED IN TARGET HEALTH ZONES.....	20
I.2 COMPONENT 2: HEALTH SYSTEMS STRENGTHENING	21
I.2A (IR 4): HEALTH SECTOR LEADERSHIP AND GOVERNANCE IN TARGET PROVINCES IMPROVED... ..	21
II. PROJECT MANAGEMENT	22
III. FAMILY PLANNING AND HIV STATUTORY REQUIREMENTS	24
IV. ENVIRONMENTAL MONITORING AND MITIGATION PLAN	25
V. CHALLENGES ENCOUNTERED	25
VI. PLANNED ACTIVITIES FOR NEXT QUARTER (APRIL - JUNE 2011)	28
VII. SUCCESS STORY	31
VIII. ANNEXES	32
ANNEX 1: IHP HEALTH INDICATORS PROJECT YEAR 1 QUARTER 2: JANUARY – MARCH 2011.....	33
ANNEX 2: PMP AS OF APRIL 8, 2011	42
ANNEX 3: MEDICINES AND MEDICAL SUPPLIES PROCUREMENT.....	53
ANNEX 4: INTERNATIONAL TRAVEL AND SHORT-TERM ASSISTANCE PLAN (ATTACHED AS EXCEL FILE)	117
ANNEX 5: INVENTORY OF EXISTING AND NEEDED SMALL MEDICAL EQUIPMENT FOR PROVISION OF MPA AND CPA-PLUS IN HEALTH ZONES (ATTACHED AS EXCEL FILE).....	117
ANNEX 6: MANAGEMENT TOOLS REQUESTED BY HEALTH ZONES (ATTACHED AS EXCEL FILE)	117
ANNEX 7: FAMILY PLANNING COMMODITIES RECEIVED FROM USAID AND DISTRIBUTED TO SUPPORTED HEALTH ZONES (ATTACHED AS EXCEL FILE)	117
ANNEX 8: WASH ASSESSMENT FORMS (ATTACHED AS EXCEL FILE)	117
ANNEX 9: IHP ACCRUALS REPORT (ATTACHED AS EXCEL FILE).....	117
ANNEX 10: DRC IHP SF425 JAN-MAR 2011 (ATTACHED AS PDF FILE).....	117

ACRONYMS

ACF	Action Against Hunger
AMTSL	Active Management of Third Stage Labor
APOC	African Programme for Onchocerciasis Control
ARV	antiretroviral
AS	health area
AXxes	Integrated Health Services Project in DRC
BCC	behavior change communication
BCZ	Bureaux centraux des zones de santé
CBD	community-based distribution or community-based distributor
CDMT	Medium-term expenditure framework
c-IMCI	Community Based Integrated Management of Childhood Illness
CODESA	Comité de Développement Sanitaire
CPA	Complementary Package of Activities
CDR	regional distribution center
CPR	contraceptive prevalence rate
DPT3	diphtheria, polio, tetanus
DPS	Division Provinciale de la Santé
DQS	Data Quality Self-Assessment
DRC	Democratic Republic of the Congo
ECZ	équipe cadres de zone (Health Zone Management Team)
EPI	Expanded Programme on Immunization
FBO	faith-based organization
FFSDP	Fully Functional Service Delivery Point (see FOSACOF below)
FOSACOF	Formation Sanitaire Complètement Fonctionnelle (used more frequently in DRC)
FP	family planning
GRH	General Referral Hospital
HA	health area
HC	health center
HIV	human immunodeficiency virus
IHP	Integrated Health Project
IMaD	Improving Malaria Diagnostics
IMCI	Integrated Management of Childhood Illness
IPS	Inspection provinciale de la santé
IPT	intermittent preventive treatment (of malaria) in pregnancy
IRC	International Rescue Committee
IT	Infirmier titulaire
ITN	Insecticide-treated nets
KAPs	knowledge, attitudes, and practices
KMC	Kangaroo Mother Care
LDP	Leadership Development Program
LLIN	long-lasting insecticide-treated net
LMS	Leadership, Management, and Sustainability Program
MOH	Ministry of Health
MNCH	maternal, newborn and child health
MIP	Provincial Medical Inspector
MLM	Mid-level management

MPA	Minimum Package of Activities
MSH	Management Sciences for Health
NGO	non-governmental organization
NTD	Neglected Tropical Diseases
OSC	Overseas Strategic Consulting, Inc.
PBF	performance-based financing
PEPFAR	President's Emergency Plan for AIDS Relief
PEV	Programme élargi de vaccination
PMP	Performance Monitoring Plan
PMTCT	prevention of mother-to-child transmission
PNDS	Plan National de Développement Sanitaire (National Health Development Plan)
PNLS	National AIDS Program
PNSR	National Reproductive Health Program
PPDS	Provincial Health Development Plan
RDC	Regional Distribution Center
RDT	Rapid diagnostic tests
RECO	relais communautaires (community health workers)
RH	reproductive health
RHC	Referral Health Center
RPR	rapid plasma reagin test for syphilis
SNIS	National health information system
SPS	Strengthening Pharmaceutical Systems Project
TB	tuberculosis
TFR	Training for Results Framework
USAID	United States Agency for International Development
USG	United States Government
UNFPA	United Nations Population Fund
UNICEF	United Nations Children's Fund
WASH	water /sanitation/hygiene
WHO	World Health Organization

EXECUTIVE SUMMARY

This report covers the second quarter reporting period of the first year of the five-year, USAID-funded Integrated Health Project (IHP) in the Democratic Republic of Congo (DRC), from January-March 2011. The DRC-IHP supports the National Health Development Program of the DRC. The project's two components – Component 1, “Services” and component 2, “Other Health Systems” – are designed to create better conditions for, and increase the availability and use of, high-impact health services, products, and practices in 80 target health zones in four provinces of DRC (Kasai Occidental, Kasai Oriental, Katanga and Sud Kivu).



The project's goal, purpose and objective is to improve the enabling environment for, and increase the availability and use of, high-impact services, products, and practices for family planning; maternal, newborn, and child health; nutrition, malaria, and tuberculosis; neglected tropical diseases; HIV; and water/sanitation/hygiene in the target health zones.

Component 1 supports the first strategic focus of the DRC's national health plan: health zone strengthening. Activities under Component 1 strengthen health zones' capacity to deliver services by addressing both the supply and demand sides of services. Under Component 1, there are three Intermediary Results (IRs):

- IR 1: Access to and availability of Minimum Package of Activities/Complementary Package of Activities plus (MPA/CPA-plus) services in targeted health zones increased
- IR 2: Quality of MPA/CPA-plus services in target health zones increased
- IR 3: Knowledge, attitudes, and practices (KAP) to support health-seeking behaviors increased in target health zones

Component 2 corresponds to the plan's second strategic pillar, support for health zone strengthening in six priority areas: human resource development; pharmaceutical management; health finance; construction/rehabilitation of infrastructure; equipment and new technologies; and improved health system management. Activities under Component 2 create an enabling environment for strong health zones, with particular emphasis on leadership and governance and the provision of resources. The DRC-IHP's fourth Intermediary Result is found under component 2:

- IR 4 : Health sector leadership and governance in target provinces improved

Implementing Partners: The implementing partners are Management Sciences for Health, the International Rescue Committee and Overseas Strategic Consulting (hereafter referred to, respectively, as MSH, the IRC, and OSC, Ltd.).

Key achievements for this quarter are as follows:

- IHP opened the four remaining coordination offices in Bukavu, Kamina, Kolwezi, and Uvira, and hosted a project orientation meeting for all staff.
- IHP placed the project's first order for essential medicines and essential medical supplies.
- Despite challenges collecting data for March 2011 from Bukavu, Uvira, and Kolwezi, overall the number of new family planning (FP) acceptors for modern methods increased by 47.7 percent from the beginning of the reporting period (from 26,844 in January to 39,663 in March), due to the education and outreach campaign led by community-based workers and the sensitization of community leaders through the Leadership Development Program (LDP) at the community level in the Kasaï Oriental and Occidental provinces.¹ Community level work and the LDP will begin in the Sud Kivu and Katanga provinces in the next quarter.
- Due to an IHP-supported campaign including education, outreach, and home visits conducted by the community-based distributors, the number of FP counseling visits increased by 100 percent during the quarter, from 10,064 in January to 20,156 in March.
- Despite a stock out in some storage sites of vaccines, the coverage rates for DPTHB3 in January, February, and March were 87.6 percent, 86.2 percent, and 86.9 percent respectively, for an average of 86.9 percent overall during the reporting period. This was largely due to IHP supporting the transportation of vaccines to the health zones.
- The number of reported new sputum smear positive pulmonary TB cases increased by 11.2 percent, from 748 in January to 866 in March.
- The number of partners/husbands of pregnant women who received HIV counseling and testing and received their results increased by 33.3 percent, from 762 in January to 1,016 in March.

¹ Information was collected from 1,467 health facilities in January and February and from 919 health facilities in March. Data were unavailable from health facilities served by the Bukavu and Uvira coordination offices in March; the IHP coordination offices in Bukavu and Uvira officially opened just in February and are not yet fully staffed; the staff in place are not yet able to ensure active data collection in the field; therefore, for January and February data, IHP extracted data from GESIS, the database available at the Provincial Health Division in Bukavu. Unfortunately, the GESIS did not yet have March data available from the health zones at the time this report was written.

I. PROJECT PERFORMANCE: ACTIVITIES AND ACHIEVEMENTS²

I.1 COMPONENT 1: HEALTH SERVICES

I.1A (IR 1): Access to and availability of Minimum Package of Activities/Complementary Package of Activities plus (MPA/CPA-plus) services in targeted health zones increased

Under this Intermediate Result, IHP is strengthening facility and community platforms for making services available and accessible and improving management capacity in health zones to make those services sustainable. As noted in the Q1 report, when we refer to “needs assessments,” in many cases this means ensuring appropriate review of existing evaluations and reports from predecessor projects as well as gathering information from regularly scheduled field visits, as opposed to “formal” assessments.

IR 1.1 Facility-based health care services and products (zonal hospitals and health centers) in target health zones increased

Activity 1: Conduct MPA/CPA-plus capacity and needs assessment of health centers and general reference hospitals (GRHs) in target health zones

IHP worked with health zone staff during supportive supervision visits to develop an inventory of existing and needed small medical equipment for provision of MPA and CPA-plus in health centers supported by the Bukavu, Uvira, and Kolwezi coordination offices. A similar exercise has now been carried out for all eight coordination offices. These non-exhaustive lists of materials for the health zones are provided in Annex 5. The Ministry of Health plans to conduct a health care provider training needs assessment for the use of diagnostic and treatment flowcharts, in collaboration with the provincial health division in Sud Kivu and Katanga and based on an analysis of the training schedule for trained personnel currently employed by the health zones. Information from this assessment will be used to inform IHP training plans.

Activity 2: Prioritize and implement infrastructure improvements to target health zone facilities.

Using a form developed by IHP staff and reviewed with the district and health zone staff, Ministry of Health staff from target health zones conducted a review of the condition of their existing medical facilities and equipment, and health zone management teams identified the health facilities in their zones that would benefit from rehabilitation by IHP. In addition, IHP developed an assessment form which was validated by the district and health zone staff that evaluates the availability and condition of water and sanitation infrastructures at the health facility level. This form was distributed to the facilities via the head zonal doctor (*médecin chef de zone*) in all 80 health zones, and the information collected will be analyzed and used to prioritize the rehabilitation of health facilities. This information will be verified during site visits in the next quarter, and health facilities will be prioritized for rehabilitation in consultation with local communities (CODESAs).

Activity 3: Improve the supply of medications, commodities and products at facilities

New procedures for the management of pharmaceuticals are currently being developed as part of the Strengthening Pharmaceutical Systems (SPS) Project and will be shared with IHP staff next quarter. In the meantime, health zones and the project warehouses will continue with the same pharmaceutical management policies that were used during the former LMS and AXxes projects.

² All activities in this achievement section are numbered in alignment with the DRC-IHP workplan. As a result, activities do not appear in numerical order, as some activities in the workplan may not be scheduled until a future reporting period.

An on-site assessment to review the availability of essential generic medicines revealed stock outs in many health structures. In the interval between the end of the LMS and AXxes projects and the start up of IHP, many former AXxes health zones ceased placing new orders of medicines, which led to shortages. Work has been undertaken to re-establish this process. In Kolwezi, for example, IHP staff took the district pharmacist and the head district doctor to visit the project warehouses so that they were both made aware that stocks are available and that each health zone has sufficient funds allocated in their lines of credit to purchase these medicines. Procurement of medicines by the health zones is now continuing as planned, with orders being placed for items already in stock.

In Sud Kivu, IHP has access to the warehouse of the Bureau Diocesain des Oeuvres Medicales (BDOM), which houses medicines ordered but not used during the former AXxes Project, valued at \$357,236 (as of February 28, 2011). Distribution of these medicines began during this quarter and will continue to the 28 IHP-supported health zones in Sud Kivu. In addition, distribution of mosquito nets and Artemisinin-based Combination Therapies (ACT) from the Presidential Malaria Initiative (PMI) began during this quarter and will continue into the next quarter. For Sud Kivu, the bed nets arrived in February with distribution beginning in March/April.

In Kolwezi, the Central de Distribution de Medicaments de Kolwezi (CDMEK) warehouse contains medicines that were purchased under the former AXxes Project that are valued at \$119,655 (as of February 28, 2011). During the quarter, IHP began distributing these medicines to several health zones, and they will continue to be delivered next quarter. PMI commodities were also transported to the district level, and some of these commodities were already distributed directly to Fungurume health zone to address a total stock out of these products (since the truck was heading to Kolwezi, it was easy to stop at Fungurume, which is on the way to the final destination). The remaining health zones will receive these items in the coming quarter.

IHP worked with SPS to prepare the procurement of pharmaceuticals for the first year. Based on an assessment of actual stocks of essential drugs and supplies, a technical team finalized the quantification of pharmaceuticals to be procured. The updated national list of essential drugs and supplies was used as reference for the quantification exercise. IHP requested and obtained the needed waiver from USAID within 2 weeks. IHP staff thoroughly analyzed the bids from IDA Foundation and MissionPharma A/S and issued awards to the two vendors. A list of the pharmaceutical items split between the two awardees is provided in Annex 3.

Activity 4: Reinforce logistic and management systems for medicines, family planning commodities, LLITNs and consumable medical equipment

SPS staff evaluated the storage conditions in the CDR (regional distribution centers) depots for essential medicines and other equipment. They also evaluated the capacity of the CDR to distribute medical and non-medical commodities to health zones. In Kolwezi, due to the inadequacies of the current health zone warehouse conditions, another site was identified and rehabilitation work will be carried out in the coming quarter. In the next quarter, IHP will decide on which CDR depots to continue using and whether or not new depots will be needed.

Activity 5: Improve the capacities of human resources to deliver MPA and CPA-plus packages

IHP coordination office staff held joint supervisory visits with health district management teams and health zone management teams. It is expected that the support from IHP will contribute to the effective implementation of the Ministry of Health supervision system, as seen in the table on the following page.

Level	Frequency of visits	Category of supervisors involved
Community	Weekly	RECOs, CODESA Members + IT + BCZS representative
HC, RHC and GRH	Monthly	Health zones management teams + District representative / IHP staff
Health Zone Central Office	Monthly	IPS and district representatives, representative of local authorities + partners
HC, RHC, GRH, BCZ	Monthly/Quarterly	IPS and district representatives, representative of local authorities

Key: BCZ - Bureaux centraux des zones de santé; CODESA - Comité de Développement Sanitaire; GRH - General Referral Hospital; HC – Health Center; IPS - *Inspection provinciale de la santé*; IT – *infirmier titulaire*, head of health center; RECO - Relais Communautaires (Community Health Workers); RHC – Referral Health Center

The challenge for IHP is to change the way Ministry of Health supervisory activities are carried out. Currently, supervisory visits neither include a precise scope of work nor clear and specific SMART objectives for the visit. Supervisory visits are also not systematically documented, and when problems are identified, action plans for quality improvement are not always created. Consequently, information from field visit reports is not consistently collected or used to make decisions. This quarter, IHP organized a workshop to revise the management tools including the Fully Functional Service Delivery Point (known by the French acronym FOSACOF), the supervision guide, and supervisory checklists in order to strengthen the supervisory system in the 80 health zones supported by the IHP. In addition, on-the-job refresher trainings are ongoing and will continue through July 2011 during supportive supervision.

IR 1.2 Community-based health care services and products in target health zones increased.

Activity 2: Train, equip, and mobilize community distributors of family planning commodities

IHP trained 76 Community-based Distributors (CBDs) in 19 health areas in the Dekese health zone. The training reinforced the CBDs' skills in identifying risk factors of maternal deaths and conducting counseling to encourage utilization of family planning (FP) services in the community. IHP staff produced and distributed referral cards (*jetons de référence*) to 1,480 active CBDs (out of the 1,536 they trained) in 23 health zones of Kasai Occidental and Kasai Oriental.

Activity 3: Scale up community case management and treatment of childhood illnesses (e.g., malaria, diarrhea, and pneumonia)

IHP organized two Integrated Management of Childhood Illness (IMCI) partner meetings aimed to harmonize annual workplans between the Maternal and Child Health Integrated Program (MCHIP) and the Ministry of Health (MOH). The process of workplan harmonization gives IHP the opportunity to promote IMCI activities and reinforce the leadership of the MOH IMCI unit. These two meetings helped the IMCI coordination unit to produce an annual operational plan that focused on priority activities.

Activity 4: Scale up evidence-based community WASH pilots

IHP finalized the water, sanitation, and hygiene (WASH) strategy in collaboration with USAID. Additionally, IHP hired the WASH advisor who will begin working with the project next quarter. During this quarter, though, the Regional IRC WASH Technical Advisor worked with the IHP team on strategic planning and on coordinating and harmonizing the WASH action plan with the action plans for other

technical areas. In addition, IHP staff provided a breakdown of the WASH budget by health zone and developed a procurement plan for certain WASH materials such as GPS for data collection, water quality testing material (pathogen screen), hygiene promotion materials, and cameras.

IRC's Environmental Health Technical Advisor finalized a review of available documents as part of the process of assessing the existence, specifications, and quality of sanitation in villages served by IHP. The Advisor used the information collected from the review to develop an assessment to collect baseline information on WASH indicators (see Annex 8). The assessment was distributed to the relais communautaire in each potential target village in all project health zones to collect the baseline information. In the next quarter, data collected from the baseline assessment will be verified.

In addition, IHP staff met with the United Nations Children's Fund (UNICEF) and representatives from the relevant local authorities to discuss adaptation and integration of the "Clean Villages" approach into IHP activities and to brainstorm ideas for future collaboration.

I.1B (IR 2): Quality of MPA/CPA-plus services in target health zones increased

Under IR 2, IHP activities focus on quality improvement tools that have an evidence basis, particularly for provider competency, performance according to norms/standards, referral systems for the continuum of care, and response to sexual/gender-based violence (S/GBV). In addition, we are scaling up the FOSACOF approach. On a number of activities we coordinate and meet regularly with other USAID implementing partners to harmonize approaches in the same settings. As much as possible, formal training will be complemented or even replaced by on-the-job training conducted during regular supportive supervision visits.

IR 2.1 Clinical and managerial capacity of health care providers increased

Activity 4: Family Planning

IHP trained 42 health care providers from health centers and general referral hospitals in Dekese health zone in FP from March 19-25, 2011. The training covered topics such as FP counseling, ensuring safety in contraceptive distribution, managing FP information and resources, and methods in behavior change communication for FP. Although the long-acting and permanent methods (LAPM) were not presented during this training due to the lack of FP anatomic models and the lack of sufficient LAPM patients, LAPM training will be offered during subsequent post-training follow up sessions and during supervisory visits. These follow-up sessions will also reinforce the healthcare worker FP knowledge and skills.


IHP staff gave Tiaht posters to 979 of the 1,543 health facilities with which it works, and will distribute posters to the remaining facilities in the next quarter. All IHP staff are in the process of taking the Tiaht Global Health eLearning course, and all staff will be certified by the end of the next quarter.

IHP contributed to several additional FP coordination activities including:

- A workshop on telling success stories in FP organized by UNFPA in Matadi: This workshop was organized by UNFPA, and IHP shared its experiences, approaches, success stories, and lessons learned. Other USAID implementing partners—such as PSI and C-Change—also participated.
- A meeting organized by the National Reproductive Health Program/Ministry of Health (PNSR/MOH) and the United Nations Population Fund (UNFPA): This meeting focused on ways to collaborate and harmonize FP plans and interventions between MOH and its partners, and covered FP commodity management, improving utilization of FP services, and mapping FP interventions supported by partners nationwide.

- A workshop organized by PNSR/MOH and C-Change to develop the national behavior change communication strategic plan for 2011-2015: IHP will continue to be involved in finalizing this plan, as the IHP BCC Technical Advisor participates in the working group tasked with its completion.


Figure 1. New Acceptors of modern FP methods



Despite the fact that Bukavu, Uvira, and Kolwezi were unable to provide the most recent data for March, the number of new family planning (FP) acceptors for modern methods increased by 47.7 percent as compared with the figure at the beginning of the reporting period (from 26,844 in January to 39,663 in March), as seen in Figure 1, above. This was largely due to the education and outreach campaign led by community-based workers and the sensitization of community leaders through the Leadership Development Program (LDP) at the community level in the Kasai Occidental and Oriental provinces. Community level work and the LDP will begin in the Sud Kivu and Katanga provinces in the next quarter.


During this quarter, the most frequently used FP methods were the Lactational Amenorrhea Method (LAM, known by its French acronym, MAMA; 30 percent of reported methods) and the male condom (18 percent of reported methods). All family planning methods shown in Figure 2 on the following page are available in the health facilities.

Figure 2: Family planning new acceptors by method



The figure below clearly demonstrates that the number of women counseled on FP/RH during the reporting period greatly increased. The improvement is in large part due to an IHP-supported campaign that included education, outreach, and home visits conducted by the community-based distributors. The number of FP counseling visits increased by 100 percent during the quarter, from 10,064 in January to 20,156 in March.

Figure 3: Number of counseling visits for FP/RH



Activity 5: Immunizations

Staff from the Ministry of Health (MOH), World Health Organization (WHO), MCHIP, and IHP worked together to update the Mid-level management (MLM) and the Data Quality Self Assessment (DQS) courses and used these materials in a vaccination management training they offered jointly in Sankuru district this quarter. Thirty-four health care workers attended the training including two officers from each *bureaux centraux des zones de santé* (BCZ), two officers from the Lodja *Programme élargi de vaccination* (PEV) unit, and the PEV sub-unit manager of Tshumbe. In addition to the MLM and DQS

materials, participants were introduced to a database management tool that enables the Health Zone Management Team to monitor monthly, quarterly, or semi-annual data from each health area and use the data to make decisions about the cold chain, for example.

IHP staff also supported a polio vaccination campaign in seven health zones in Kasai Oriental that were identified as high risk for a polio epidemic. Staff targeted women of reproductive age in Kanda Kanda, Kamiji, and Lusambo (covered by Mwene Ditu IHP office), and Dikungu-Tshumbe, Ototo, and Lomela (covered by Tshumbe IHP office). IHP teams participated in coordination and planning meetings at provincial and district levels, in collaboration with the health zone and health areas, and they also provided logistic support such as transportation of vaccines from the Lodja PEV Unit to the health zones in the catchment area of the Tshumbe coordination office and transportation of vaccines to storage sites in the Mwene Ditu coordination office. These activities not only included the 11 health zones of the IHP Mwene Ditu office but also the 37 health zones of the provincial coordination of the immunization national program in Mbuji Mayi.


IHP also supported the supervision of poliomyelitis vaccination campaigns during January and February in Kasai Occidental.

During the quarter, 17 health zones were affected by a measles epidemic, and IHP supported the organization of the measles response in Dibindi, Mpokolo, and Bibanga health zones in Kasai Oriental. The campaign exceeded its targets, and 114,213 children aged 6-59 months were vaccinated as compared to the target of 107,339 children. Targets were exceeded because children from neighboring health zones were also vaccinated. When the IHP target was established, it included as the denominator only the number of children targeted in the three health zones. Follow-up vaccination campaigns are planned for remaining health zones for May 17-21, 2011. The follow-up vaccination campaign will be planned not only for the remaining 14 health zones but for all health zones in the respective provinces where the measles response has not been organized.

The IHP Child Health Advisor attended the annual Expanded Programme on Immunization (EPI) manager's meeting for Central African countries held in Libreville, Gabon, March 2-3, 2011. At the meeting, the Child Health Advisor learned about three critical immunization issues: the polio eradication initiative, the accelerated control of the diseases (measles and maternal and neonatal tetanus), and reaching all target groups through routine vaccination. Special focus was placed on DRC due to the continuous circulation of the wild polio virus as well as the overall low levels of vaccinated children. IHP also participated in the planning for African Vaccination Week, which will be held April 25-30, 2011. The purpose of the Vaccination Week is to reinforce the National Vaccination Program by using a participatory approach that focuses on advocacy, community mobilization, BCC, catch-up of unvaccinated children, and integration of vaccinations with other interventions related to child survival.

IHP also helped the MOH National Vaccination Program address one of its major logistical challenges in vaccination campaigns – transportation. During the quarter, IHP financed the transport of vaccines and vaccination supplies to the Kasai Oriental (5864 kgs) and Sud Kivu (5293 kgs) provinces. IHP also helped maintain the cold chain for vaccines by supplying 35,910 liters of petroleum for 285 refrigerators in addition to 600 liters of gasoline for generators at the health zone PEV units and at the health zone vaccine storage sites.

Figure 4: Percentage of children less than 12 months of age who received DPCHePBHib3



The coverage rates for DPTHB3 were 87.6 percent, 86.2 percent and 86.9 percent respectively in January, February, and March, with an average of 86.9 percent during the quarter (see Figure 4, above). These levels are due to stock outs of vaccines at the national level and transportation challenges from Kinshasa to the provinces. On two occasions, IHP supported the transportation costs of vaccines and vaccination supplies to Kasai provinces, once to Mbuji Mayi and once to Kananga.

Activity 6: Mother, child, and neonatal health


Staff from the IHP Luiza coordination office trained 34 health care providers from 6 health zones in integrated mother and newborn health from March 14–26, 2011. The participants, who came from the Yangala, Ndeksha, Bilomba, Luiza, Dibaya, and Kalomba health zones, learned about basic obstetrical and neonatal care and management of the third stage of labor and the postpartum period.

In collaboration with MCHIP, IHP held a planning meeting related to introducing the Kangaroo Mother Care (KMC) strategy in the health zones. The KMC strategy aims to regulate a newborn’s body temperature, improve weight gain, and reduce morbidity and mortality by placing the low birth weight (LBW) newborn directly on the mother’s chest so that there is skin-to-skin contact. The planning meeting also focused on plans for revitalizing the centers of excellence³ that were previously supported by MCHIP and the former AXxes Project, and for offering a TOT to train health facility providers in the KMC method. IHP staff also conducted coaching sessions on the active management of third stage of labor (AMTSL), essential newborn care, and best practices for maternal and neonatal care, during supervision visits for 29 nurses and 20 midwives at 14 health facilities in Katakokombe and Wembonyama health zones.

As illustrated in Figure 5, on the following page, the number of new ANC visits increased from January to February but decreased between February and March. As noted earlier in this report, the data for Bukavu and Uvira were not available for March and therefore not reported. In Kolwezi as well, the reporting is not yet complete as many of the health facilities have not yet provided their data for the month. It was also noted during this reporting period that, due to work on the annual operational plans in many health zones, health care providers were not available for some of their previously scheduled antenatal care visits.


³ The MCHIP project set up two centers of excellence in KMC, located in Panzi, Sud Kivu, and Dilala, Kolwezi, but the centers are not currently functional; therefore MCHIP and IHP have agreed to collaborate on revitalizing these centers.

Figure 5: Number of antenatal care (ANC) visits by skilled providers



During the quarter, 51,158 of 68,199 of women who delivered at health facilities had a skilled birth attendant present at their delivery; this equates to around 75 % coverage for AMTSL.

Figure 6. Number of women receiving Active Management of the Third Stage of Labor (AMTSL)/ compared to deliveries with a skilled birth attendant (SBA)



Activity 12: Distribution of IPT and LLINs

IHP distributed long-lasting insecticide-treated Nets (LLINs) that it received from the President's Malaria Initiative (PMI) in 4 provinces (as seen in the distribution table on the following page).

Distribution of LLINs	
Province	Quantity
Sud Kivu	150,000
Katanga	100,000
Kasaï Occidental	100,000
Kasaï Oriental	24,700
Total	374,700

Activity 18: Malaria

IHP provided logistical support to the Improving Malaria Diagnostics (IMaD) project for the training it offered on good microscopy practices and scopes of work for lab technicians at general referral hospitals.


IHP conducted a field visit to Sud Kivu to assess the availability and use of PMI medicines and supplies and worked with the DPS management team to finalize distribution plans for these products. IHP staff planned to begin distribution in the next quarter.

In all IHP-supported provinces, SPS supported the DPS to develop distribution plans for malaria medicines and supplies. As displayed in the table below, IHP paid for the distribution of Artemisinin-based Combination Therapies (ACTs) and Rapid Diagnosis Tests (RDTs).

Distribution of ACTs	
Province	Quantity
Sud Kivu	1,368,600
Katanga	771,450
Kasaï Occidental	411,176
Kasaï Oriental	0
Total	2,551,226

Distribution of RDTs	
Province	Quantity
Sud Kivu	181,025
Katanga	114,775
Kasaï Occidental	54,000
Kasaï Oriental	149,000
Total	498,800

Figure 7. Percentage of pregnant women in target health zones who received IPT



The rate of IPT 2 is decreased in March in comparison with the rate in February for two reasons:

1. Due to work on the annual operational plans in many health zones, health providers were not available for some of their previously scheduled antenatal care visits.
2. Data from the Bukavu and Uvira coordination offices is not included in the March figures, and data from the Kolwezi coordination office only includes a subset of the health facilities it supports.

Activity 20: Nutrition rehabilitation

IHP attended various meetings with partners such as Action Against Hunger (ACF-USA) in Luiza health zone and UNICEF in Sankuru district to coordinate and collaborate on nutrition interventions in those areas. In addition harmonizing activities and building on evidence-based successes of partner organizations, IHP is particularly interested in securing food supplies for acute malnutrition treatment in the 80 health zones it supports. IHP staff members are planning additional technical meetings with ACF-USA and UNICEF to further discuss coordination of nutrition activities.

Activity 27: Fistula awareness and prevention

IHP and EngenderHealth met during the quarter to collaborate and share information on the need for improved reporting and monitoring on the number of cured vesico-vaginal fistula cases in the Panzi general referral hospital in Sud Kivu to avoid double counting. Fistula care activities are planned to start in the next quarter.

Activity 33: Oral rehydration therapy and diarrheal disease control

In the 80 health zones IHP contributed to the distribution and promotion of MOH directives concerning the use and storage of zinc sulfate for case management of diarrhea in children under 5. Regular distribution of zinc sulfate and ORS is ensured as part of the health zone requisition for essential drugs and medical supplies.

Activity 40: Management of Health information

IHP harmonized and validated its data collection tools with the MOH tools in February 2011. Final versions of the tools are in the process of being printed for health zones according to their needs (requests for copies of tools included in Annex 6).

IHP staff are working to improve data quality at the health zone level; therefore in collaboration with the 5th Direction of the Division Provinciale de la Santé (DPS) in Kasai Oriental, the project trained 132 health workers from Luputa, Kalenda, Wikong, and Kamiji health zones on the framework of the national health information system (known by its French acronym, SNIS).

The MSH headquarters Director of Monitoring and Evaluation assessed the needs of the 5th Department of the MOH in terms of strengthening the SNIS. Next quarter, IHP will define the priorities in working with the 5th Direction including presenting options for online collection of SNIS such as GESIS or DHIS.

Activity 41: Leadership Development Program (LDP)


During the quarter, IHP developed a Training for Results Framework (TFR) which will serve as a guide for the development, implementation and evaluation of all IHP training programs. The aim of this framework is to ensure that training programs offered by the project are effective, improve performance by addressing identified gaps, and lead to the achievement of expected results. During its development, the framework was vetted with project leadership and revised to incorporate their ideas and respond to their concerns. The project will host a one-day orientation to the Training for Results Framework in the next quarter, and the framework will be operationalized in all IHP trainings through the application of a set of TFR tools including a training program management checklist, a TFR guide, an observation checklist, and a competency self-evaluation.

During the quarter, IHP began planning for the implementation of Leadership Development Programs (LDPs) in 57 health zones. In Sud Kivu province, IHP will carry out five parallel LDPs for zonal management teams from 28 health zones, and in Katanga province, IHP will offer another three parallel LDPs for teams from 17 health zones. Facilitators of the LDPs, who are from the Provincial Health Division (DPS), are also planning to deliver LDPs for six zones not covered by IHP with financing from DFID and the Belgian Development Cooperation. IHP will consider the inclusion of these activities in its cost share plan that will be developed during the next reporting period. IHP staff members are also developing an approach that will ensure complementarity between the LDP and the FOSACOF approaches at the health facility level, such as developing a one-day LDP module that would be added to monitoring visits by the Zonal Management Teams.

Activity 45: Disease surveillance: TB, NTDs, etc.

IHP contributed to the needs assessment conducted by the Neglected Tropical Diseases (NTD) team that is made up of USAID, WHO, the African Programme for Onchocerciasis Control (APOC), the National Program Against Onchocerciasis, and the MOH in Lubumbashi. The assessment noted several strengths that included the following: strong appropriation of the strategy for CBD of mectizan implemented in DRC; availability of mectizan in sufficient quantities at the community level, sustained by a strong supply chain; health zones and health facilities are able to provide support easily to the program. The assessment also noted an absence of mapping at the Province level. The participants also noted the lack of IEC materials and equipment for community distributors. Finally, the participants in the assessment noted the absence of an integrated plan to fight against NTDS at the country level. The proposed next steps include the strategic integration of NTD activities in routine health facility and community interventions.

Figure 8: TB high detection distribution by coordination office



Health zones that exceeded 100 percent of rate of detection during this quarter are as follows:

- **Kamina** : Kinkondja, Kitenge, Mulongo, Lwamba, Malemba Nkulu, and Mukanga health zones
- **Mween Ditu**: Mpanya Mutombo, Mpokolo, Dibindi, Mwene Ditu, and Kalenda health zones
- **Kole** : Dibele, Lodja, and Omendjadji health zones
- **Tshumbe** : Ototo health zone
- **Luiza** : Lubondaie health zone


The situation in Mwene Ditu, Kole, Tshumbe, and Luiza is due essentially to the number of clients who came from other health zones to be treated in these zones. In Kamina, the former AXxes Project had initiated a study in collaboration with the national program and has yet to provide a copy. IHP plans to audit these data during the next quarter to verify these findings.

Activity 51: PMTCT PLUS

In collaboration with the Integrated HIV/AIDS Project (PROVIC), the National AIDS Program (PNLS) and the National Reproductive Health Program (PNSR), IHP is preparing an assessment of the functionality of PMTCT sites in the 80 health zones. IHP staff are in the process of designing the assessment protocol and questionnaires, and the assessment will be conducted next quarter.


IHP and PROVIC also reviewed PMTCT data collection tools to align them with President's Emergency Plan for AIDS Relief (PEPFAR) and Global Fund to Fight AIDS, TB, and Malaria (GFATM) indicators. A workshop to validate the revised tools will be jointly supported by PROVIC and IHP in the next quarter.

Figure 9: Number of pregnant women receiving HIV counseling and testing and receiving their test results



The number of pregnant women receiving HIV counseling and testing and receiving their test results increased to 9,598 women this quarter as compared to 4,807 women last quarter due to an effort by health facilities to provide HIV test results the same day patients are tested. See Figure 9, above. Numbers from this quarter are likely underestimated due to the fact that data from Bukavu and Uvira coordination offices are not included.

Figure 10: Rate of use health services



The overall rate of health services utilization averaged 32 percent during this period, as shown in Figure 10, above. The rate increased compared to the last quarter during which it was 29.3 percent. In March, however, the rate is only 30.8 percent due to the lack of data reported from Bukavu, Uvira, and Kolwezi.

IR 2.2 Minimum quality standards for health facilities (provincial hospitals and zonal health centers) and services adopted

Activity 2: Design and implement a PBF program

The Health Financing Technical Advisor was hired at the end of March. PBF activities will begin in the next quarter.

IR 2.3 Referral system for primary health care prevention, care and treatment between community structures and health facilities (provincial and zonal levels) institutionalized

In Sud Kivu, the selection process for potential hospitals to be supported to provide referral for fistula repair began, based on an evaluation of technical capacities and facilities and the drawing up of a work plan for facilities. This work will be completed in the next quarter.

I.1C (IR 3): Knowledge, attitudes, and practices (KAP) to support health-seeking behaviors increased in target health zones

Under IR 3, IHP focuses on activities that integrate KAP messaging with work at the facility and community service delivery points, helping to ensure that citizens know how to *act* on consistent information about health. While recognizing that the major challenges remain in maternal, newborn and child health (MNCH), we will give special attention to the most vulnerable groups, whose need for specialized information (e.g., on HIV counseling and testing) and assistance is often under-recognized. IHP will operate alongside major social marketing and public health communications efforts led by PSI, C-CHANGE, and other implementing partners in the same geographic target areas. We will spearhead regular meetings to identify priority public health communications challenges, and how IHP can effectively integrate and add value to current health education activities. For example, IHP will ensure that existing research data on the DRC is used to establish KAP baseline metrics in target health zones whenever possible, and that behavior change communication (BCC) and public health communication capacity building avoids overlap and complements USAID and other donor-funded programs. IHP will leverage existing civil society networks and influential stakeholders, including faith-based organizations (FBOs) and indigenous networks, before creating “new” networks for information dissemination. We will concentrate KAP activities on research-based and flexible approaches to create demand for services, unifying messages and themes and using locally produced, sustained, health-related media coverage through existing channels.

The IHP team has initiated its BCC activities with a review of existing BCC campaign strategies and materials being utilized by other implementing organizations operating in the DRC. C-Change is foremost among the organizations doing this work, and IHP held initial discussions with C-Change and other organizations supporting BCC. Upon completion of this review, the IHP Senior BCC specialist will organize a coordination meeting in Kinshasa to discuss opportunities for collaboration, leveraging resources, and sharing existing materials. This initial meeting will also be used to develop and agree upon a mechanism (face-to-meetings, phone calls, SharePoint site, etc.) and timeline (bi-weekly, monthly, etc.) for ongoing coordination between IHP’s BCC activities and those of C-Change and other implementing organizations. IHP would be pleased to retain responsibility for organizing this ongoing coordination, but that will be discussed at the initial coordination meeting.

IR 3.3 Behavior change campaigns involving opinion leaders and cultural influences (people and technologies) launched

Activity 3: Design and implement health communications campaigns

During the quarter, IHP focused on BCC planning, strategy, and campaign development. Consultants Waverly Rennie and Andrei Sinioukov traveled to DRC for an assessment trip from February 14-March 4, 2011. During the trip, Andrei Sinioukov supported IHP work in Kasai Oriental province, and Waverly Rennie supported IHP work in the Sud Kivu province. After the assessment trip, Waverly Rennie returned for a follow-up trip to work with IHP staff in the Kinshasa office from March 28-April 1, 2011. During these two BCC preparation STTAs, the consultants:

- Reviewed and collected existing data and identified priority public health communication challenges in the DRC
- Conducted an initial assessment of the civil society and media landscape in the health zones and provided recommendations to collect more data
- Developed a community activity mapping matrix for BCC planning that outlines partners, technical interventions and communication channels
- Provided feedback on IHP baseline survey questions and indicators and suggested approaches to monitoring and evaluation of IHP BCC activities

The review of communication channels revealed that only around 60 percent of the population of the Sud Kivu province is covered by media channels (which include radio broadcasting stations—private and government, television, newspapers), and the IHP team is therefore exploring the use of other media for the BCC campaigns.

I.2 COMPONENT 2: HEALTH SYSTEMS STRENGTHENING

I.2A (IR 4): Health sector leadership and governance in target provinces improved

Under this IR, IHP focuses on activities that institutionalize community involvement in health policy and service delivery, especially the involvement of women. Toward this end we will explore with USAID and others whether minimum levels of gender parity should be formalized for RCs, CACs, and CODESAs. Under its Community Driven Reconstruction project, IRC is conducting an evaluation to determine whether quotas for women on such committees can have an impact on governance or social cohesion outcomes or change attitudes about women as leaders. The results of this evaluation will inform IHP's approach. A common argument against parity requirements is that community representatives must be literate; there are solutions, such as paired members, that can overcome that difficulty.

IR 4.1 Provincial health sector policies and national-level policies aligned

Activity 5: Support the Health Zones to write a health development plan (strategic plan) and an operational plan that align with MOH health policies, which will be provided to the participants (for Health Zones without these plans)

During this reporting period, the IHP team organized and financed workshops aimed at aligning partner financing with the Provincial Health Development Plan (PPDS) in Kasai Occidental, Kasai Oriental, Sud Kivu, and Katanga provinces. During the workshops, participants, who included representatives of the provincial, district, and health zone offices, and partner organizations, developed the Medium-Term

Expenditure Framework (CDMT) for these provinces. These activities are aligned with the framework of the national financial alignment process and with the National Health Development Plan (PNDS) and are also mandatory for each province (as decreed by the National Ministry of Health).

The project supported the improvement of health zone operational action plans and development plans during biannual health zone administrative council meetings, to bring them in line with new templates that were issued by the national health authorities was undertaken in meetings of, which are held twice a year. This presented the opportunity for additional harmonization of IHP priorities and work plan with the health zone plans. Nearly half of the target health zones held administrative council meetings and issued recommendations for the revision of plans. The remaining meetings will be held in the coming quarter, when all revised plans will be adopted in meetings of the health zone management teams.

II. PROJECT MANAGEMENT

During the second quarter, IHP staff continued start-up activities and participated in a number of key USAID-supported activities.

Management and Start Up: IHP completed the following activities:

- Orientation workshop held for all staff in Kinshasa, January 24-28, 2011, to align the staff on the IHP vision and objectives, on required procedures and regulations to be followed during the course of project implementation, and on the workplan for the first year of the project.
- Joint field visit to Kole, conducted February 2011: the IHP Senior Technical Advisor and the Provincial Medical Inspector (MIP) met with the community in Kole to confirm that IHP will continue to support the health zone through the Kole-based coordination office (to assuage concerns that the office might be relocated to Lodja). The MIP sensitized community leaders, local authorities, and the population about their respective roles and responsibilities in supporting the implementation of IHP activities, noting that their achievements would lead to improving health outcomes in their communities. The MIP also stressed that all health zone needs could not be addressed by IHP; therefore, provincial authorities expect that local resources will be mobilized as the community's contribution to address the needs in the health zones and health areas.
- Successfully established coordination offices in Kamina, Bukavu, Uvira, and Kolwezi: Directors for each of these offices were recruited and have begun preliminary activities and continue to recruit staff. Recruitment is expected to be fully completed in May, and full staffing will enable IHP to accelerate activities and scale up.
- IHP Branding and Marking Plan approved by USAID on February 4, 2011.
- Year 1 workplan conditionally approved by USAID on March 15, 2011, for the period March-May 2011.

USAID/USG Meetings:

- In January, IHP staff participated in a four-day USAID-sponsored workshop intended to support the Mission in the design of performance monitoring systems to provide Mission staff and implementing partners with the background needed to revise and develop Results Frameworks and Performance Monitoring Plans (PMPs) in each technical area. The workshop covered data usage for management and decision-making, construction of Results Frameworks and PMPs,

indicators and target setting, and best methods for data collection. The training consists of two plenary sessions that cover the relationship between these different elements, strengths and weakness of the USAID system for performance monitoring in an unstable environment, and the connection between results management systems and other M&E systems commonly used in the international development context (log frames versus results frameworks).

- In February, IHP hosted the USAID BEST team from Washington that was composed of specialists in key GHI technical areas such as nutrition, child health, family planning and reproductive health, maternal and neonatal health, and WASH. IHP held a meeting with all USAID implementing partners and the BEST team to share evidence-based best practices, challenges encountered, and opportunities and strategies in integrating and further expanding successful interventions. Meetings with the BEST team were also held at provincial and zonal levels in Kasai Occidental and Kasai Oriental. The BEST team provided recommendations to improve the IHP workplan in terms of defining priority interventions and activities and considering integration of evidence-based best practices in MOH policies.
- Per Modification of Assistance Number 2, signed on January 13, 2011, the procurement and administration responsibilities and duties for IHP were transferred from USAID/ Washington to the Regional Agreement Officer at USAID/Nairobi. Therefore the USAID/DRC Mission organized a second post-award meeting with IHP in Kinshasa with two representatives of USAID/EA/RAAO, Joseph McGee and Ketan Sood, to focus on any remaining contractual/ procurement issues that were not adequately addressed in the November 2010 meeting held in Washington, DC.

Baseline Survey Preparation:

- IHP prepared to conduct a baseline study that includes a cost-effective population-based survey to establish baseline figures for key performance indicators in the project's 80 target health zones. This study will establish a solid point of reference by which success and results from priority health interventions that IHP will deliver at facility and community levels can be measured reliably. Results from the baseline study will help IHP, its partners – including the MOH at both central and provincial levels – and other USAID implementing partners to strengthen the DRC health system and its many sub-systems, including DRC's service delivery, health workforce, HMIS, supply chain, and leadership and governance. Baseline results will also reveal current knowledge and behaviors among women/caretakers that will help define appropriate strategies for increasing the demand of priority health services. IHP will employ the Lot Quality Assurance Sampling (LQAS) methodology, a cost-effective yet robust survey methodology to assess knowledge, attitudes, practices and coverage of key primary health care indicators for the entire project area.

The baseline survey will use a small but large enough representative sample of the entire 80 health zones to produce statistically significant results (i.e., 90 percent precision level, with 95 percent confidence interval for the indicators to be calculated through the population-based survey). The LQAS methodology will provide vital information at the local level for IHP managers and key stakeholders to make informed management decisions that will support maximizing the use of resources (human, financial, and commodities), and accomplishing the project's anticipated results, particularly in the eight coordinating offices that IHP will use to deliver health interventions throughout the life of the project.

Finally, this population-based survey will only ask questions needed for those indicators that require population-based data. IHP will work together with its partners and other implementing agencies currently implementing public health programs in the IHP target health zones (i.e., MCHIP, C-CHANGE, etc.) to avoid any duplication of efforts and to use any available population-based data that may have been recently captured. IHP will not conduct a health facility assessment as part of this baseline study. The project is using the FOSACOF approach to assess the quality and readiness of priority health services offered by health facilities in the 80 target health zones as part of IHP implementation during year 1.

III. FAMILY PLANNING AND HIV STATUTORY REQUIREMENTS

IHP is aware of the requirement for all project staff, in Kinshasa and in the field offices, to be knowledgeable about all the family planning and HIV-related statutes enacted by the USG for which the project must ensure compliance.

The project ordered and received wall charts on clients' rights and informed choice in FP, sometimes referred to as "Tiahrt wall charts." As described elsewhere in this report, IHP has to date distributed 979 of these wall charts to health facilities. An additional shipment of the wall charts will cover the additional health facilities in the IHP health zones.

As planned, the project's technical staff has been briefed on the FP policy requirements, including Tiahrt in the context of performance-based financing (PBF). The project leadership has proactively sought additional information on this topic from countries that have implemented PBF and have conveyed the potential challenges to the project's technical staff.

IHP technical staff have received information on Tiahrt and each of the coordination offices has been directed to hold a local meeting to discuss the following points:

- Implementation and enforcement of the Tiahrt Amendment
- Main terms of the Tiahrt Amendment
- Responsibilities for imparting comprehensive information on the terms
- Incentives, bribes, bonuses, and financial rewards

As part of its orientation, the project leadership shared with the technical staff recent documentation about Tiahrt violations in Egypt, as well as the DRC action plan developed at the Kigali FP Conference on contraceptive security, government commitment, and how to improve FP services. All technical staff will take the online FP statutory requirements course and provide the certificate of completion to the IHP leadership team.

IV. ENVIRONMENTAL MONITORING AND MITIGATION PLAN

During this reporting period, IHP submitted revised Environmental Monitoring and Mitigation Plans for the project for review by USAID's Regional Environmental Compliance Advisor. The Advisor has requested additional revisions to the plan which will be submitted during the next quarter. As evidenced in this report, IHP has already implemented the suggestion that in each quarterly report we document 1) the reporting done from the field as promised in the EMMP, 2) the issues raised, and 3) the resolution of these issues.

During the training sessions organized under IR2.1, participants were sensitized to medical waste disposal, and follow-up training offered through supportive supervision will include recommended practices for infection prevention. The IHP WASH strategy includes implementing a medical waste management system in health facilities. The implementation will start in the next quarter.

V. CHALLENGES ENCOUNTERED

A number of challenges were addressed during this reporting period.

Measles epidemic: Seventeen health zones were affected by the measles epidemic, and at the request of the Provincial Minister of Health, IHP supported a vaccination campaign in Dibindi, Mpokolo and Bibanga health zones in Kasai Oriental. Not only did IHP provide technical input to the design of the response plan, but it also provided logistical support to the Division Provinciale de la Santé (DPS). Overall, IHP contributed \$22,435 to the measles response, which included support for the organization of the campaign, logistics, supervision, and fuel. The vaccination campaign surpassed its intended results by 106.4 percent, with 114,213 children aged 6-59 months vaccinated, as compared to the target of 107,339 children. Targets were exceeded because children from neighboring health zones were also vaccinated, and the denominator is simply the number of children in the three initially targeted health zones. Follow-up vaccination campaigns are planned for May 17-21, 2011 in the remaining 14 health zones, as well as in all health zones in the respective Provinces where no USAID implementing partner has yet come forward to respond to the measles outbreak.

Furthermore, other partners contributed to the vaccination campaign such as MSF France, which supported Dilala, Fungurume, and Manika health zones in Kolwezi, MSF Holland, which supported Uvira and Nundu health zones, and MSF Spain, which supported Ruzizi and Lemera health zones.

Measles epidemic in health zones supported by the Kolwezi coordination office in Katanga province

#	Province	District	Coordination Office	Health Zone	# of suspected cases EW 50 to EW 13 ⁴	# deaths EW 50 to EW 13	Mortality rate
1	Katanga	Kolwezi	Kolwezi	Bunkeya	86	0	0
2	Katanga	Kolwezi	Kolwezi	Dilala	1,238	11	0.9
3	Katanga	Kolwezi	Kolwezi	Fungurume	2,437	29	1.2
4	Katanga	Kolwezi	Kolwezi	Kanzeze	838	5	0.6
5	Katanga	Kolwezi	Kolwezi	Lualaba	1,142	8	0.7
6	Katanga	Kolwezi	Kolwezi	Lubudi	52	3	5.8
7	Katanga	Kolwezi	Kolwezi	Manika	7,657	57	0.7
8	Katanga	Kolwezi	Kolwezi	Mutshatsha	25	0	0
TOTAL					13,475	113	

Measles epidemic in health zones supported by the Uvira and Bukavu coordination offices in Sud Kivu province

#	Province	District	Coordination Office	Health zone	# of suspected cases EW 50 to EW 13	# deaths EW 50 to EW 13	Mortality rate
1	Sud Kivu	Sud	Uvira	Uvira	1,293	1	0.1
2	Sud Kivu	Sud	Uvira	Ruzizi	489	1	0.2
3	Sud Kivu	Sud	Uvira	Lemera	126	1	0.8
4	Sud Kivu	Sud	Uvira	Nundu	114	1	0.9
5	Sud Kivu	Bukavu	Bukavu	Kadutu	207	1	0.5
6	Sud Kivu	Ouest	Bukavu	Kamituga	48	1	2.1
TOTAL					2,277	6	

⁴ EW=Epidemiological week. EW 50=2nd week December 2010; EW 13=3rd week March 2011.

Measles epidemic in health zones supported by the Mwene Ditu coordination office in Kasai Oriental province

#	Province	District	Coordination Office	Zone de santé	# of suspected cases EW 50 to EW 13	# deaths EW 50 to EW 13	Mortality rate
1	Kasai Oriental	Tshilenge	Mwene Ditu	Bibanga	1	0	0
2	Kasai Oriental	Mbuji Mayi	Mwene Ditu	Dibindi	31	0	0
3	Kasai Oriental	Mbuji Mayi	Mwene Ditu	Mpokolo	5	0	0
TOTAL					37	0	

These recent measles outbreaks in several health zones led IHP leadership to reflect on the possibility of reallocating funds to allow for urgent response to future epidemics. Having funds available for emergency responses is relevant to IHP's work, as during this quarter, four of the five target health zones in Uvira had a measles epidemic. Cholera is also endemic in the region, and a cholera epidemic that began in Kolwezi in late 2010 is still ongoing. Although IHP is willing to respond to epidemics in the health zones it supports, the Provincial contingency plans must take into account the financial limitations of IHP, especially in those health zones where IHP is the sole development partner.

Managing drug stocks: In Kolwezi, the district medicine warehouse manager lacked the capacity to manage the stocks of medicines. To overcome this challenge in the short term, IHP requested that the SPS representatives support the warehouse manager in his work, particularly assisting the manager in unpacking the PMI commodities that arrived in March and recording the correct stock figures. IHP will offer capacity building to this warehouse manager as a longer-term solution.

Furthermore, ACT stock outs were observed in the majority of Kolwezi target health zones. To overcome the particularly severe need in Fungurume, IHP provided this health zone with enough ACT commodities for the next six months.

Delays in reporting health information: Most health zones submitted national health information system (SNIS) reports late to the health districts. For example, by March 18, only six of eight health zones in Kolwezi had submitted the data from January. IHP has encouraged health districts to actively collect data and submit it in a timely fashion to SNIS.

VI. PLANNED ACTIVITIES FOR NEXT QUARTER (APRIL - JUNE 2011)

Component 1, IR 1 (Access to and availability of Minimum Package of Activities/Complementary Package of Activities plus (MPA/CPA-plus) services in targeted health zones increased):

- Coordinate with the MOH and implementing partners to develop a needs assessment tool to determine the current status of health facilities (based on the FOSACOF guide and MOH standards, and taking into consideration evaluations and technical assistance efforts undertaken by USAID implementing partners and other donors such as the World Bank, European Union, Cordaid, Germany, DFID, GFATM, etc.) and finalize FOSACOF tools
- Coordinate with the MOH and implementing partners to evaluate MPA- and CPA-plus implementation, noting critical gaps in delivery capacity (skill levels, supportive supervision, logistics and supplies, physical plant, outreach, communications, etc.) in the health centers and reference hospitals in the target health zones
- Set up procedures for local procurement of non-medical commodities
- Contract with CDRs (regional distribution centers)/warehouses for procurement of non-medical commodities
- Ensure the quality control of drugs at the port of entry, in the CDRs, and in the health facilities
- Support the tracking of financial and pharmaceutical management indicators at health facility
- Adapt the standard procedures (technical documents) to the current situation at all levels
- Provide CDRs in Bukavu, Lodja, Kamina, and Lodja with Apisoft software (the standard for PNAM) (Note: the other CDRs in Mbuji Mayi and Kananga received this software through a European Union project)
- Support and implement more frequent and effective supportive supervision and mentoring from the ECZ (specific activities located in IR 2.1)
- Community mobilization specialists assess a selected number of CODESAs in each health zone in collaboration with MOH at health zone level
- Develop a tool to assess the performance of CBDs working under previous projects in all of the health zones, as well as their access to the necessary materials and supplies to carry out their work
- Support/collaborate with MOH IMCI unit at DPS and partner with MOH strategic planning committee to develop a community-based IMCI (c-IMCI) training plan for each province, drawing on the five-step approach
- Train Provincial-level management team (Equipe Cadre) as well as the District-level team in FOSACOF to enable them to supervise implementation of these activities
- Support the Provincial and District levels in carrying out supportive supervision at the Zonal level (one supervision visit per health zone per quarter), to include supervision of the integration of leadership and management development at the health zone level (Ref: IR 2.1, Activity 2)
- Support meetings of the Provincial Steering Committee (CPP), in coordination with other implementing partners working in target Provinces
- Support the mid-level (DPS, DS et EPI unit) and local level (health zones and reference hospitals) in the coordination of their activities by providing for selected operating costs

Component 1, IR 2 (Quality of MPA/CPA-plus services in target health zones increased):

- Reinforce competency-based training for specific identified skills

- Evaluate quality improvement needs at health facilities, with zonal and community authorities, using FOSACOF tools, to guide ECZs in developing training and supportive supervision plans and budgets specific to the needs of their zones (in relation with IR 1 , Activity 1.1)
- Reinforce supportive supervision skills in support of ECZ monitoring health facilities
- Assess, with the ECZ and as part of the quality improvement evaluation, supportive supervision skills needed to adequately monitor health zone activities
- Conduct joint supervision visits to model effective application of new knowledge and skills to realities in health facilities
- Implement both pre-service and in-service training and refresher training programs in the areas of MPA and CPA-plus in the targeted health zones, aligned with ongoing SPS training on pharmaceutical management and supervision
- Select the specific training to be conducted in each health zone, with the ECZ, based on the FOSACOF baseline assessments that will identify gaps or weaknesses in service provision in each zone (in relation with IR 1, Activity 1.1 and IR2 Activity 2.1)
- Continue to distribute Tiahr posters to all health facilities covered by the project; integrate distribution of posters into other ongoing activities
- Train 3 ECZ members in each health zone in the EPI Mid-level Management (MLM) course
- Identify gaps in the expanded program of immunization (PEV) through FOSACOF and provide on-the-job training during supervisory visits to health care providers in PEV
- Train health care providers in mother, child, and neonatal health in the Dekese health zone
- Provide on-the-job training through supportive supervision visits to ensure inclusion and strengthening of AMSTL, essential newborn care, and other best practices related to mother, child, and neonatal health, including training 12 doctors and nurses from two center of excellence and eight IHP coordination offices on KMC
- Integrate complete prenatal counseling into all activities related to maternal, infant, and neonatal health including distribution of IPT and LLINs
- Train providers at the reference hospitals in PMTCT, including universal precautions for infection prevention and PMTCT, focusing on facilities that have not yet been trained
- Train lab technicians in six reference hospitals (1 per hospital) and in 16 health centers (1 per health center) in rapid testing in the context of the PMTCT program (Mwene Ditu)
- Provide 22 PMTCT sites with three types of HIV tests, needles, plasters, etc.
- Train health care providers in the clinical aspects of IMCI in the Dekese Health Zone
- Train health care providers and supervisors in Essential Nutrition Actions, including Community Management of Acute Malnutrition (CMAM)
- Review existing materials and strategies used to promote clean village approach in coordination with other implementing organizations.
- Develop, test and launch BCC campaign to promote the environmental sanitation behaviors required by the clean village approach (See IR 1.2 for Clean Village scale up; see IR 3.3 for BCC activities)
- Promote exclusive breastfeeding in the community according to national and international norms and as part of the Essential Nutrition Actions included in c-IMCI activities
- Organize breastfeeding days at the community level
- Provide private health care provider facilities with standard management tools (consultation sheets and registers, such as those for prenatal consultation, CPN; postnatal consultation, CPoN; and preschool consultation, CPS, etc.)
- Invite private health provider facilities into monitoring meetings

- Integrate the monthly reports of activities from private health facilities into the overall report for the health zones
- Organize LDP workshops for ECZ that have not yet been trained in LDP
- Conduct two five-day LDP TOTs in Sud Kivu and Katanga (in early April in Sud Kivu; in early June in Katanga)
- Conduct two Senior Alignment meetings in Sud Kivu and Katanga (two days in Sud Kivu in the second week of April; two days in Katanga in the second week of June)
- Conduct LDP Workshop 1 on Scanning (three days in Sud Kivu in the second week of April; three days in Katanga in the second week of June)
- Scale up a whole-site, standards-based quality improvement approach at target facilities (FOSACOF), coordinated with LDP workshops
- Train selected health team members in FOSACOF and quality assurance
- Conduct quality assurance workshop for members of the quality assurance sub-commission at the provincial level for 3 days
- Conduct quarterly monitoring and evaluation at all health zones
- Design and implement the PBF program
- Support one internal workshop with USAID and other implementing agencies funded by USAID (HS 20/20, MCHIP, PROVIC, C-Change, etc.)
- Develop PBF procedures manual and tools
- Hold validation meeting to create ownership of and commitment to the selected PBF model
- Reinforce the reference system for CBD family planning clients to obtain family planning methods in health facilities in the 80 health zones
- Select, train and equip 480 CBDs/community outreach agents in the health areas supported by the Kamina Coordination office
- Reinforce the monitoring and supervision of head nurse of the health center (IT) in CBD activities in the 80 health zones
- Continue to support regular supervision of CBDs from health center (*infirmier titulaire*) in their activities

Component 1, IR 3 (Knowledge, attitudes, and practices (KAP) to support health-seeking behaviors increased in target health zones):

- Conduct assessment of CODESAs in 80 health zones
- Conduct training of trainers in governance principles for CODESA trainers
- Conduct rapid assessment of communications capacity and media landscape in 80 health zones
- Analyze data and produce/disseminate results report
- Review existing research data (including earned media activities and phone-based communications campaigns)
- Conduct coordination meeting with stakeholders (including covering earned media activities and phone-based communications activities)
- Consult/collaborate with MOH communications focal points at provincial and district level
- Review existing research data
- Hold coordination meeting with other implementing organizations

Component 2, IR 4 (Health sector leadership and governance in target provinces improved):

- Complete an inventory with the MOH of all of the existing health policy documents, including norms, standards, and policies for specialized programs

- Support the MOH to develop and/or finalize policy documents, norms, and strategies including the meeting per province level to discuss about IHP workplan
- Advocate for policies specifically focusing on the health of women to ensure that they are implemented (such as supporting the MOH in the development and dissemination of the mother and newborn health standards and norms documents, which include defining protocols on reproductive health; ensuring that the CCSAS is adopted by the GDRC; advocating for resources for PMTCT to be implemented below the referral hospital level and ensuring that PMTCT drugs are available; advocating for resources for the CCSAS and the availability of PEP kits in all facilities; advocating for the availability of fistula victim reintegration kits at the community level; and requiring sex-disaggregated data in all reporting)
- Conduct an assessment of the current status of MIS (people trained and level of implementation) and computer kits in the health zone, provincial, and health district levels
- Support monthly monitoring meetings at the Health Area level and at the BCZ level to share information and discuss best practices (one monthly meeting at each level)
- Support international and national health days, such as International Women's Day, International AIDS Day, Roll Back Malaria, blood donation, fight against tobacco, illiteracy, etc.

Project Management:

- Ensure ongoing operations, management, and monitoring support of IHP
- Complete recruitment and train new staff
- Conduct baseline study
- Finalize PMP and EMMP for USAID/DRC approval
- Produce Quarterly Reports for USAID/DRC, including data for special reports such as PMI, GHI, etc.
- Produce Semi-annual and Annual PEPFAR Reports to USG
- Complete IHP Success Stories to submit with Quarterly Reports

VII. SUCCESS STORY

The DRC-IHP Success Story appears on the following page.



SUCCESS STORY

Leadership Skills Increase Patient Visits

A rehabilitated clinic, steady supply of essential medicines, and community awareness campaign are bringing new patients to Opombo



Photo: Courtesy of DRC-IHP

Charge Nurse Okendembo Pierre Yoto has worked at the Opombo Health Center in for seven years, and credits leadership training as a key reason the center is now providing health care services to a greater number of patients.

In October 2010, just 81 new patients visited the Opombo Health Center (representing 17% of its target goal, 477 patients). Just five months later, in February 2011, that number had jumped to 235 new patients.

In the Dikungu Health Zone, people face health challenges related to maternal and child health, malaria, HIV/AIDS and other illnesses. For years, the Opombo Health Center had offered health services to address these problems, but the majority of the community residents did not seek treatment there, because the clinic was small, cramped and patient services were inefficient. But in 2010, things began to change.

Under the Democratic Republic of Congo-Integrated Health Project (DRC-IHP), service providers are making changes to improve the basic health conditions of the Congolese people. Head Nurse Okendembo Pierre Yoto, who has been working at the Opombo Health Center for seven years, confirms that the number of new patients being treated at the clinic is on the rise.

“Although we had many sick people in our community, their visits to the clinic were infrequent,” says Nurse Yoto. “Then last year, our clinic was physically rehabilitated with the support of USAID, and we began to receive a regular, reliable supply of medicines. These we were able to prescribe for our patients at prices that were affordable to them.”

According to Nurse Yoto, these two changes were just the beginning. While taking part in a Leadership Development Program funded by USAID, he and his colleagues were invited to select a work place challenge and create a plan to improve that particular situation. His team decided to focus on increasing the number of new patients utilizing curative services.

Together, the nurses launched a ‘community mobilization’ effort that began with raising awareness of the clinic’s needs among local political leaders, which resulted in a contribution of considerable funding to help equip the center. In addition, the team spent much time with local residents, hosting events to raise awareness of the many services available in the center.

“In October 2010, we had just 81 new patients who were provided with curative services but by February, that number was 235, representing a move from 17% to 48.7% of our overall target,” says Nurse Yoto. “All of us on the nursing team are very proud of these results.”

VIII. ANNEXES

ANNEX 1: IHP HEALTH INDICATORS PROJECT YEAR 1 QUARTER 2: JANUARY – MARCH 2011

IHP HEALTH INDICATORS PROJECT YEAR 1 QUARTER 2: JANUARY – MARCH 2011							
<p>This table summarizes the data collected and reported by all 8 coordination offices in January and February 2011. Information was collected from 1,467 health facilities in January and February and from 919 health facilities in March. Data were unavailable from health facilities served by the Bukavu and Uvira coordination offices in March; the IHP coordination offices in Bukavu and Uvira officially opened just in February and are not yet fully staffed; the staff in place are not yet able to ensure active data collection in the field; therefore, for January and February data, IHP extracted data from GESIS, the database available at the Provincial Health Division in Bukavu. Unfortunately, the GESIS did not yet have March data available from the health zones at the time this report was written.</p>							
Target Population on 2011 = Pop 2010*1.03					11,665,409		
INDICATORS	Formula	11-Jan	11-Feb	11-Mar	Total Q2Y1	Target for the quarter (Denominator)	Achievement (Numerator)
FAMILY PLANNING							
1. Couple years of protection (CYP) for FP USG-supported programs		27,644	41,748	26,542	95,934	630,807	95,934
1a. Couple years of protection (CYP) after exclusion of LAM and self-observation methods for USG-supported FP programs *		8,418	11,636	8,352	28,407		
2. Number of new FP acceptors in USG supported family planning clinics	(Pop/4)*21%	9,171	14,271	9,035	32,477	630,807	32,477
2a. Number of new acceptors of modern FP methods in USG supported family planning clinics	(Pop/4)*21%	26,844	33,706	39,663	100,213		
3. Number of counseling visits for FP/RH as result of USG assistance		10,064	12,093	20,156	42,313		
4. Number of USG-assisted services delivery points providing FP counseling or services		1,467	1,467	919			

Comments:

Despite the fact that Bukavu, Uvira, and Kolwezi were unable to provide the most recent data for March, the number of new family planning (FP) acceptors for modern methods increased by 47.7 percent as compared with the figure at the beginning of the reporting period (from 26,844 in January to 39,663 in March), due to the education and outreach campaign led by community-based workers and the sensitization of community leaders through the Leadership Development Program (LDP) at the community level in Kasai Occidental and Kasai Oriental provinces. Community level work and the LDP will begin in the Sud Kivu and Katanga provinces in the next quarter.

Due to an IHP-supported campaign including education, outreach, and home visits conducted by the community-based distributors, the number of FP counseling visits increased by 100 percent during the quarter, from 10,064 in January to 20,156 in March. Of the 42,313 counseling visits held during the quarter, 33,596 were carried out by health service providers, and the remaining 8,717 carried out by community-based distributors during home visits in their respective area. Community-based activities will begin in the South Kivu and Katanga provinces next quarter.

Only 919 USG-assisted services delivery points providing FP counseling are reported in March because data from the Bukavu and Uvira coordination offices are not included.

MATERNAL AND CHILD HEALTH

1. Number of antenatal care (ANC) visits by skilled providers from USG-assisted facilities	(Pop/4)*4%	31,711	34,455	22,851	89,017	120,154	89,017
2. Number of deliveries with a skilled birth attendant(SBA) in USG- assisted programs	(Pop/4)*4%	23,259	26,185	18,755	68,199	120,154	68,199
3. Number of women receiving Active Management of the Third Stage of Labor (AMTSL) through USG-supported programs	(Pop/4)*4%*75% of assisted deliveries	17,285	20,684	13,189	51,158	90,115	51,158
4. Number of postpartum newborn visits within 3 days of birth in USG-assisted programs	(Pop/4)*4%*75% of assisted deliveries	19,636	22,518	17,076	59,230	90,115	59,230
5. Number of newborns receiving essential newborn care through USG-supported programs	(Pop/4)*4%*75% of assisted deliveries	19,997	22,913	16,045	58,995	90,115	58,995

6. Number of newborns receiving antibiotic treatment for infection from appropriate health workers through USG-supported programs	(Pop/4)*4%*5%	2,307	2,220	2,337	6,864	6,008	6,864
7. Number cases of child pneumonia treated with antibiotics by trained facility or community health workers in USG-supported programs		14,801	15,539	20,147	50,487		
8. Number of cases of child diarrhea treated in USAID- assisted programs		10,302	12,893	11,327	34,522		
9. Number of children less than 12 months of age who received DPTHB3 from USG-supported programs	(Pop/4)*3.49%	29,710	29,253	29,493	88,456	104,834	88,456
10. Dropout rate in DPCHepBHib3	(#DPCHepbHip1- #DPCHepbHip3)*100/ #DPCHepbHip1	7	9	7	7.5	95,609	715,300
11. Number of children less than 12 months of age who received vaccine for measles	(Pop/4)*3.49%	31,071	32,664	28,413	92,148	104,834	92,148
12. Number of children under 5 years of age who received vitamin A from USG-supported programs*		1,118	0	0	1,118		
13. Number of pregnant women who received VAT 2+ from USG- supported programs	(Pop/4)*4%	33,734	39,179	31,991	107,904	120,154	107,904
14. Rate of use of health services *	(Pop/4)*100% excluding Bukavu and Uvira	30.8	34.4	30.8	32	1,928,697	617,539

Comments:

Most health facilities supported by IHP have integrated the AMTSL process. During the quarter, 51,158 of 68,199 of women who delivered at health facilities had a skilled birth attendant present at their delivery; this equates to around 75 % coverage for AMTSL.

The average of rate of use health services is around 32 %; although this rate is still below the national projection, it is an increase when compared with the rate from the previous reporting quarter (29, 3%). It is also important to note that this rate of 30.8 % in March is at least partly explained by frequent interruptions of health center activities due to personnel involvement in the setting up and organization of all supported health zones operational action plans (OAP) and micro planning processes.

The number of children less than 12 months of age who received DPTHB3 was 29,710, 29,253, and 29,493 respectively in January, February, and March, with a total of 88,456 children vaccinated during the quarter, representing 84% of the target of 104,834 children. This can be attributed to stock outs of vaccines at the national level and transportation challenges from Kinshasa to the provinces. On two occasions, IHP supported the transportation costs of vaccines and vaccination supplies to Kasai provinces, once to Mbuji Mayi and once to Kananga.

MALARIA

1. Number of Insecticide Treated Nets distributed that were purchased or subsidized with USG support	(Pop/4)*8%	17,033	29,773	25,283	72,089	240,307	72,089
2. Number of improvements to laws, policies, regulations or guidelines related to improve access to and use of health services drafted with USG support.		0	0	0	0		
3. Number of USG-assisted service delivery points experiencing stock-outs of specific tracer drugs :ASAQ (Artesunate+ Amodiaquine) 50 mg (1 - 5 years)		25	25	0	25		
3 a. Number of USG-assisted services delivery points experiencing stock-outs of specific tracer drugs : ASAQ (Artesunate+ Amodiaquine) 25 mg (< 1 year)		25	25	0	25		

4. Number of artemisinin -based combination treatments (ACTs) purchased with USG-support		0	1,779,776 *	771,450 **	2,551,226		
5. Number of children under five with malaria treated correctly following the national protocol		41,115	52,385	46,585	140,085		
6. Percent of pregnant women in target health zones who received IPT	(Pop/4)*4% excluding Bukavu, Uvira and Kolwezi	53.9	57.1	54.8	55.3	77,148	42,645
7. Number of pregnant women with malaria treated correctly following national protocol		9,963	8,779	12,893	31,635		

Comments:

There are no data available for malaria indicators from the Bukavu and Uvira coordination offices during the quarter. The 25 health facilities that experienced stock outs during the reporting period are under the supervision of the Kolwezi coordination office. It is important to note that some of health zones under this coordination office have benefitted from other suppliers such as the Global Fund to Fight AIDS, TB, and Malaria (GFATM). ASAQ provided by the President's Malaria Initiative (PMI) arrived and were distributed at the beginning of February in South Kivu and Kasai Occidental and in March in the Katanga province.

The rate of IPT 2 decreased in March in comparison with the rate in February for two reasons :

1. Due to work on the annual operational plans in many health zones, health providers were not available for some of their previously scheduled antenatal care visits.
2. Data from the Bukavu and Uvira coordination offices is not included in the March figure, and data from the Kolwezi coordination office only includes a subset of the health facilities it supports.

* From PMI and delivered in South Kivu and Kasai Occidental

** From PMI and delivered in Katanga

TUBERCULOSIS							
1. Case notification in new sputum smear positive pulmonary TB cases in USG-supported areas	(Pop/4)*150/100000	749	807	866	2,422	2,597	2,422
1a. Case notification in new sputum smear positive pulmonary TB cases in USG-supported areas without health zones with high detection rate	TB cases in the health zones that have more than 100% detection rate	156	175	162	493		
2. Percentage of all registered TB patients who are tested for HIV through USG-supported programs	(# TB cases receiving HIV counseling and testing)/# PTB+ cases	62	43	69	58	2,422	1,413
3. Percent of the estimated number of new smear-positive pulmonary TB cases that were detected under DOTS (i.e., Case Detection rate)	(# new PTB+ cases)/# estimated TB patients	86.5	93.2	100	93.3	2,597	2,422
4. Percent of sputum smear positive pulmonary TB patients that were cured and completed treatment under USG-funded DOTS.	(# cured TB cases)/(# cases TB put on treatment 6 months ago)	67.4	84.7	57.4	70	5,236	3,668
5. Treatment success rate in USG-assisted DOTS Plus programs to treat MDR TB patients		ND	ND	ND	ND		
<p>Comments:</p> <p>During the quarter, 16 health zones reported that their detection rates were over 100%. Six of those health zones are supported by the Kamina coordination office.</p> <p>The percentage of sputum smear positive pulmonary TB patients that were cured and completed treatment under USG-funded DOTS decreased from 67.4% in January to 57.4% in March due to shortages of drugs and laboratories supplies such as isoniazid and Ziehl Nielsen.</p> <p>IHP plans to data audit TB data during the next quarter as well as verify that TB target calculations are correct.</p> <p>ND means that there are no MDR TB cases reported cured or treatment failed during the period.</p>							

PMTCT							
1.Number of Pregnant women seen for ANC in PMTCT facilities *	(Pop of 57 health zones covered by the PMTCT sites/4) *4%	7,349	8,396	4,799	20,544	25,902	
2.Number of pregnant women receiving HIV counseling ***	# of women seen for ANC in PMTCT facilities *100%	5,345	6,929	3,613	15,887	25,902	
3.Number of pregnant women receiving HIV counseling and testing ***	# of women receiving HIV counseling *0.75	3,819	4,082	2,977	10,878	19,426	
4.Number of pregnant women receiving HIV counseling and testing; and receiving test results*	# of women tested * 100%	3,591	3,501	2,506	9,598	19,426	
5.Number of pregnant women who tested positive*	# of women tested * 1.6%	43	53	29	125	311	
6.Number of pregnant women tested HIV positive who receive test result*	# of women tested * 1.6%	43	53	29	125	311	
7.Number of PMTCT health facilities offering PMTCT services*		84	87	92			
8.Number of pregnant women provided with a complete course of antiretroviral prophylaxis for PMTCT*	# of women tested HIV positive delivered in maternity	26	27	7	60		
9.Number of newborns who received a complete course of antiretroviral prophylaxis* **	# of women tested HIV positive* 95%	30	21	18	69	295	
10.Number of partners/husbands of pregnant women who receive HIV counseling and testing and receive results*	# of pregnant women tested * 20%	762	634	1,016	2,412	3,885	

11.Number of women receiving CTX and MVI post counseling*	# of women tested HIV positive* 100%	16	17	8	41	311	
12.Number of newborns receiving CTX and MVI *	# of women tested HIV positive* 95% (surviving babies)	4	8	5	17	295	

Comments:

The number of pregnant women receiving HIV counseling, testing and receiving test results (new and old cases combined) is 9,598, an increase from last quarter; these women received group counseling. Moreover, It is also important to note that the number of partners/husbands of pregnant women who received HIV counseling and testing and receive results has also increased compared to last quarter, totaling 2,412 men this quarter. The number of men who received counseling, testing, and received their result amounts to 25% of the number of women who received counseling, testing, and received their result. These improvements are the result of the education and outreach campaign led by the community-based workers and opinion leaders at the community level. In order to motivate pregnant women and their respective partners to receive counseling and testing, these patients were given priority over other patients regarding waiting times for their results. A total 88% of pregnant women who were tested and counseled received their test results, because hospitals made efforts to deliver the result the same day. However, the total number of women receiving their test results represents 49% of the projected figure for the quarter; this is due to stock outs of rapid HIV tests in some health facilities, and this is why IHP placed an emergency order for HIV testing supplies.

Among the 125 pregnant women who tested HIV+ during the quarter, 41 are eligible to cotrimoxazole prophylaxis through clinic criteria. Also during the quarter, 17 newborns exposed to HIV benefitted from cotrimoxazole prophylaxis starting at 6 weeks after birth.

Of the 137 PMTCT sites supported by the project, only 84 provided reports in January, 87 in February, and 92 in March. As a result, data from an average of only 64% of PMTCT sites supported by IHP are included. A major challenge during the next quarter is to motivate all PMTCT sites (100%) to report.

WATER AND SANITATION

1.Number of people in target areas with access to improved drinking water supply as a result of USG assistance* (Cumulative during the year)		0	0	0	0		
2.Number of people in target areas with access to improved sanitation facilities as a result of USG assistance*		0	0	0	0		

3.Liters of drinking water disinfected with USG-supported point-of-use treatment products		NA	NA	NA	NA		
---	--	----	----	----	----	--	--

Comments:
 Current WASH data are not currently being collected, as the IHP WASH strategy and action plan were still under development and the WASH advisor was just hired during this reporting period. The WASH data collection sheet found in Annex 8 of this report was also developed and disseminated to coordination offices.

ANNEX 2: PMP AS OF APRIL 8, 2011

The following is an illustrative performance monitoring plan (PMP) that MSH and its partners will use to monitor, assess and report on the overall performance of the Integrated Health Project (IHP). The PMP includes performance indicators according to the project results framework. Upon completion of the baseline study, baseline and end-of-project target figures will be confirmed and/or established, and annual benchmarks will be determined. The PMP will be a living document throughout the implementation of the IHP and will serve to support management decision making to ensure accomplishment of IHP intermediate results and the project objective. Actual figures for performance indicators will be included and updated according to the means of verification. Upon completion of the mid-term review and with input from USAID, MSH and its partners will review and revise end-of-project targets as necessary.

Indicator	Definition	Base-line*	Annual Benchmarks					End-of-Project Target*	Means of Verification		
			Yr 1	Yr 2	Yr 3	Yr 4	Yr 5		Data Source	Frequency	Person Responsible
USAID/DRC/IHP Objective: increase use of high-impact health services, products, and practices for FP, MNCH, nutrition, malaria, NTDs, TB, HIV&AIDS, and WASH in target health zones											
FP: Couple years of protection (CYP) provided by family planning (FP) services	The estimated protection provided by FP services during a one year period, based upon the volume of all contraceptives provided to clients in the IHP target areas during that period.	315,697	318,854	322,043	325,263	328,516	331,801	331,801	HMIS	Annually	M&E Specialist HMIS Officers
FP: # of new family planning (FP) acceptors of modern method in FP clinics	New FP acceptors of a modern method will be calculated based upon records from USG-supported FP clinics in the IHP target areas.	364,152	375,077	386,329	397,919	409,856	422,152	422,152	HMIS	Annually	M&E Specialist HMIS Officers
FP: Number of service delivery points providing family planning (FP) counseling or services	Number of USG-supported service delivery points (excluding door-to-door CBD) providing FP counseling or services, disaggregated by type of service.	1,321	1,423	1,423	1,423	1,423	1,423	1,423	HMIS	Annually	M&E Specialist HMIS Officers
MNCH: # of antenatal care (ANC) visits by skilled providers from	# of antenatal care (ANC) visits by skilled providers from USG-assisted health	433,227	446,224	459,611	473,399	487,601	502,229	502,229	HMIS	Annually	M&E Specialist HMIS

health facilities	facilities in the IHP target areas.										Officers
MNCH: Number of deliveries with a skilled birth attendant (SBA)	Number of deliveries with a skilled birth attendant (SBA) in the IHP target area.	351,073	365,116	379,721	394,909	410,706	427,134	427,134	HMIS	Annually	M&E Specialist HMIS Officers
MNCH: # of women receiving Active Management of the Third Stage of Labor (AMTSL)	Number of women giving birth who received Active Management of the Third Stage of Labor (AMSTL) through USG-supported programs/IHP target area.	258,938	277,064	296,458	317,210	339,415	363,174	363,174	HMIS	Annually	M&E Specialist HMIS Officers
MNCH: Number of postpartum newborn visits within 3 days of birth	Number of postpartum/newborn visits within 3 days of birth in USG-assisted programs/IHP target area.	334,636	348,021	361,942	376,420	391,477	407,136	407,136	HMIS	Annually	M&E Specialist HMIS Officers
MNCH: Number of newborn receiving essential newborn care	Number of new infants who received essential newborn care from trained facility, outreach or community health workers through USG-support programs/IHP target area.	323,516	336,457	349,915	363,912	378,468	393,607	393,607	HMIS	Annually	M&E Specialist HMIS Officers
MNCH: Number of newborns receiving antibiotic treatment for infection from appropriate health workers	Number of newborn infants identified as having possible infection who received antibiotic treatment from appropriate trained facility, outreach or community health workers through USG-support programs/IHP target area.	14,529	14,965	15,414	15,876	16,353	16,843	16,843	HMIS	Annually	M&E Specialist HMIS Officers
MNCH: Number cases of child pneumonia treated with antibiotics by trained facility or community health workers	Number of cases of child pneumonia treated with antibiotics by trained facility or community health worker in USG-supported programs/IHP target area.	430,171	451,680	474,264	497,977	522,876	549,019	549,019	HMIS	Annually	M&E Specialist HMIS Officers

MNCH: Number of cases of child diarrhea treated	Number of cases of child diarrhea treated through USG-support programs/IHP target area with: a) Oral Rehydration Therapy (ORT) b) Zinc supplements	292,675	307,309	322,674	338,808	355,748	373,536	373,536	HMIS	Annually	M&E Specialist HMIS Officers
MNCH: Number of children less than 12 months of age who received DPT3	Number of children less than 12 months who received DPT3 in a given year from USG supported programs/IHP target area.	324,772	344,258	364,914	386,809	410,017	434,618	434,618	HMIS	Annually	M&E Specialist HMIS Officers
MNCH: Number of children under 5 years of age who received vitamin A	Number of children under 5 years of age who received vitamin A from USG-supported programs/IHP target area.	2,239,288	2,306,467	2,375,661	2,446,930	2,520,338	2,595,949	2,595,949	HMIS	Annually	M&E Specialist HMIS Officers
TB: Case notification rate in new sputum smear positive pulmonary TB cases per 100,000	<u>Numerator:</u> Number of new sputum smear positive pulmonary TB cases reported in the past year <u>Denominator:</u> Total population in the specified geographic area (x 100,000)	17115	17626	18156	18700	19261	19839	19839	Health facility records	Annually	M&E Specialist HMIS Officer
TB: Percentage of all registered TB patients who are tested for HIV	<u>Numerator:</u> Number of registered TB patients (over a given time period) who are tested for HIV <u>Denominator :</u> Total number of registered TB patients (over the same time period)	50%	50%	60%	70%	80%	90%	90%	Health facility records	Annually	M&E Specialist HMIS Officer
TB: Percent of the estimated number of new smear-positive pulmonary TB cases that were detected under DOTS	<u>Numerator:</u> Number of new smear positive TB cases detected under DOTS programs <u>Denominator :</u> Estimate number of new smear positive TB cases country wide	83%	85%	87%	90%	93%	95%	95%	Health facility records	Annually	M&E Specialist HMIS Officer
TB: Treatment success rate in USG-assisted DOTS Plus programs to	<u>Numerator:</u> Number of category IV TB patients registered in a specific time	50%	55%	60%	65%	70%	75%	75%	Health facility records	Annually	M&E Specialist HMIS

treat MDR TB patients	period that were cured plus the number that completed treatment in the same specified time period. <u>Denominator</u> : Total number of category IV TB cases registered in the same specified time period										Officer
<u>Fistula treatment</u> : #/% of fistula cases repaired with appropriate reintegration support	<u>Numerator</u> : # of fistula cases repaired <u>Denominator</u> : Total # of women with fistula cases reported in IHP target area	514	75	300	300	480	480	1635	Health facility records	Annually	M&E Specialist HMIS Officer
<u>HIV/PMCT</u> : Number of pregnant women seen for ANC in PMTCT facilities	Number of pregnant women seen for ANC in the facilities who offering the advices to prevent mother-to-child transmission	89,082	96,209	102,943	110,149	117,860	126,110	126,110	Health facility records	Semi-annually	M&E Specialist HMIS Officer
<u>HIV/PMCT</u> : Number of pregnant women receiving HIV counseling ***	Number of pregnant women who received a counseling services for HIV (advices to prevent mother-to-child transmission)	87,639	96,209	102,943	110,149	117,860	126,110	126,110	Health facility records	Semi-annually	M&E Specialist HMIS Officer
<u>HIV/PMCT</u> : Number of pregnant women receiving HIV counseling and testing ***	Number of pregnant women who received testing for HIV and counseling for safe infant feeding practices	76,216	76,967	82,354	88,119	94,288	100,888	100,888	Health facility records	Semi-annually	M&E Specialist HMIS Officer
<u>HIV/PMCT</u> : Number of pregnant women receiving HIV counseling and testing; and receiving their test results*	Number of pregnant women who were tested for HIV and know their results	75,091	76,967	82,354	88,119	94,288	100,888	100,888	Health facility records	Semi-annually	M&E Specialist HMIS Officer
<u>HIV/PMCT</u> :Number of pregnant women who tested positive*	Number of pregnant women who were tested positive HIV	659	1,231	1,318	1,410	1,509	1,614	1,614	Health facility records	Semi-annually	M&E Specialist HMIS Officer
<u>HIV/PMCT</u> : Number of pregnant women tested HIV positive who receive test result*	The number of women with know (positive) HIV infection attending ANC for a new pregnancy over the last	585							Health facility records	Semi-annually	M&E Specialist HMIS Officer
			1206	1292	1382	1494	1598	1598			

	reporting period											
<u>HIV/PMTCT</u> : Number of PMTCT health facilities offering PMTCT services*	PMCT+ sites is a service outlet that provides a minimum package of services which includes HIV counseling and testing for pregnant women	137	137	187	250	350	400	400	Health facility records	Semi-annually	M&E Specialist HMIS Officer	
<u>HIV/PMTCT</u> : Number of pregnant women provided with a complete course of antiretroviral prophylaxis for PMTCT*	Number of HIV-positive pregnant women who received and complete course antiretrovirals to reduce risk of mother-to-child transmission	413	985	1,054	1,128	1,207	1,291	1,291	Health facility records	Semi-annually	M&E Specialist HMIS Officer	
<u>HIV/PMTCT</u> : Number of newborns who received a complete course of antiretroviral prophylaxis***	Number of HIV-positive newborns who received antiretrovirals to reduce risk of mother-to-child transmission	273	1,170	1,252	1,339	1,433	1,533	1,533	Health facility records	Semi-annually	M&E Specialist HMIS Officer	
<u>HIV/PMTCT</u> : Number of partners/husbands of pregnant women who receive HIV counseling and testing and receive their results*	Number of husbands of pregnant women positive HIV who received antiretrovirals	7,783	15,513	17,431	19,451	21,575	23,810	23,810	Health facility records	Semi-annually	M&E Specialist HMIS Officer	
<u>HIV/PMTCT</u> : Number of women receiving CTX and MVI post counseling*	Number of women positive HIV who received CTX and MVI	756	1,231	1,318	1,410	1,509	1,614	1,614	Health facility records	Semi-annually	M&E Specialist HMIS Officer	
<u>HIV/PMTCT</u> : Number of newborns receiving CTX and MVI *	Number of newborns who received CTX and MVI	203	1,170	1,252	1,339	1,433	1,533	1,533	Health facility records	Semi-annually	M&E Specialist HMIS Officer	
IR 1: Access to and availability of key family health care services and products in target health zones increased (Component 1)												
IR 1.1: Facility-based health care services and products (provincial hospitals and district health centers) in target health zones increased												
#/% of GRHs implementing CPA-plus	<u>Numerator</u> : # of GRHs implementing CPA-plus <u>Denominator</u> : Total # of GRHs	9%	20%	40%	50%	60%	70%	70%	Rapid health facility (GRH and HC) survey	Quarterly	M&E Specialist GRH Manager	
#/% of Health Centers implementing MPA-plus	<u>Numerator</u> : # of Health Centers implementing MPA-	16%	35%	50%	60%	70%	80%	80%	Rapid health facility	Quarterly	M&E Specialist	

	plus <u>Denominator:</u> Total # of Health Centers								(GRH and HC) survey		HC Director
# of USG-assisted service delivery points experiencing stock-outs of specific tracer drugs	Number of USG-assisted service delivery points (SDPs) experiencing stock-out at any time during the defined reporting period of specific tracer drugs offered by the SDP in IHP target area.	16%	12%	10%	8%	6%	5%	5%	Facility (GRH and HC) records	Quarterly	M&E Specialist HMIS Officer
# of insecticide treated nets (ITNs) distributed that were purchased or subsidized with USG funds	# of ITNs purchased or subsidized with USG funds that were distributed within the IHP target area	589,753	800,000	800,000	800,000	tbd	tbd	tbd	HMIS, IHP records	Annually	M&E Specialist, HMIS Officers
#/% of General Referral Hospitals (GRHs) offering fistula repair	<u>Numerator:</u> # of GRHs that offer fistula repair <u>Denominator:</u> Total # of GRHs in the IHP target area	3	3	5	5	8	8	8	IHP records	Semi-annually	M&E Specialist HMIS Officer
IR 1.2: Community-based health care services and products in target health zones increased											
#/% of communities with CODESAs actively involved in management of priority health services	<u>Numerator:</u> # of communities with CODESAs with active involvement in management of priority health services for their communities <u>Denominator:</u> Total # of communities in IHP target area	50%	55%	70%	80%	90%	100%	100%	IHP records	Quarterly	M&E Specialist CODESA leader
#/% of communities with FP commodities distribution system	<u>Numerator:</u> # of IHP target communities using a distribution system for FP commodities <u>Denominator:</u> Total # of communities in IHP target area	28%	38%	40%	50%	55%	60%	60%	IHP records	Quarterly	M&E Specialist
# of people in target areas with access to improved drinking water supply as a result of USG assistance	Improved drinking water technologies are those more likely to provide safe drinking water than those characterized as unimproved.	233,580	262,380	291,180	319,980	348,780	377,580	377,580	IHP records	Annually	M&E Specialist

# of people in target areas with access to improved sanitation facilities as a result of USG assistance	Improved sanitation facilities include those more likely to ensure privacy and hygienic use, i.e., connection to a public sewer, connection to a septic system, pour-flush latrine, simple pit latrine, and ventilated improved pit (VIP) latrine.	123,284	124,784	126,284	127,784	129,284	130,784	130,784	IHP records	Annually	M&E Specialist
IR 1.3: Engagement of provincial management with health zones and facilities to improve service delivery increased											
#/% of senior LDP teams that have achieved their desired performance according to indicators in their action plans within six months of completing the LDP	Desired results achieved by senior LDP teams improves organizational performance and service delivery of health zones and facilities	23 (29%)	23 (29%)	35 (44%)	52 (65%)	80 (100%)	80 (100%)	80 (100%)	LDCP training reports	Semi-annually	LDP Coordinator M&E Specialist
#/% of health zones with validated action plans	<u>Numerator</u> : # health zones with validated actions plans <u>Denominator</u> : Total # health zones in IHP target area	80%	90%	100%	100%	100%	100%	100%	IHP records	Annually	M&E Specialist
IR 2: Quality of key family health care services in target health zones increased (Component 1)											
IR 2.1: Clinical and management capacity of health care providers increased											
# of health care providers at GRHs and HCs following IMCI protocols for childhood illness	# of health care providers at GRHs and HCs correctly classifying and treating childhood illnesses, disaggregated by childhood illness	15%	25%	35%	45%	55%	65%	65%	Rapid health facility (GRH and HC) survey	Semi-annually	M&E Specialist HMIS Officer
# of facilities with accurate and up-to-date inventory records, disaggregated by type of facility	Accurate means that the records correctly reflect the inventory of essential drugs and supplies that are currently in-stock	5%	30%	50%	75%	90%	100%	100%	Rapid health facility (GRH and HC) survey	Semi-annually	M&E Specialist HMIS Officer

IR 2.2: Minimum quality standards for health facilities (provincial hospitals and district health centers) and services developed and adopted											
#/% of health facilities meeting all nine FOSACOF minimum standards, disaggregated by type of health facility	<u>Numerator:</u> # of health facilities meeting all nine FOSACOF minimum standards <u>Denominator:</u> Total # of facilities	8%	22%	36%	51%	65%	79%	79%	HF (GRH and HC) records	Semi-annually	M&E Specialist HMIS Officer
IR 2.3: Referral system for primary health care prevention, care and treatment between community structures and health facilities (district and provincial levels) institutionalized											
#/% of patients referred to HCs, disaggregated by illness, gender, and age	# of patients (adults and children) referred to Health Centers by a CHW	15%	20%	25%	30%	35%	40%	40%	HF records	Quarterly	HMIS Officer
#/% of patients referred to GRHs, disaggregated by illness, gender, and age	# of patients (adults and children) referred to GRHs by a CHW or health care provider	5%	10%	15%	20%	25%	25%	25%	HF records	Quarterly	HMIS Officer
IR 3: Knowledge, attitudes, and practices to support health-seeking behaviors in target health zones increased (Component 1)											
IR 3.1: Evidence-based health sector-community outreach linkages –especially for women, youth and vulnerable populations– established											
# local NGO coordination meetings	# of local NGO coordination meetings organized by Sr. BCC specialist	ND	4	16	16	16	16	68	IHP records	Annually	BCC Technical Advisor
% of NGOs representing women, youth and vulnerable groups participating in coordination meetings	<u>Numerator:</u> # of NGOs representing women, youth, and vulnerable groups attending NGO coordination meetings <u>Denominator:</u> # of NGOs representing women, youth and vulnerable groups registered in DRC	ND	15%	20%	25%	30%	40%	40%	IHP records	Annually	BCC Technical Advisor
# Community Champions selected and trained	# Community Champions completing capacity building program led by IHP community mobilizers	0	500	1,200	2,000	3,000	4,000	10,700	IHP records	Quarterly	BCC Technical Advisor
# Community health action plans created	# Community health action plans developed by community members and reviewed by IHP staff	ND	250	350	700	1,200	1,423	1,423	IHP records	Quarterly	BCC Technical Advisor

# Youth organizations participating in youth education outreach strategy	# Youth organizations conducting member outreach and health education as part of IHP youth health education strategy	ND	30	50	120	120	120	120	IHP records	Quarterly	BCC Technical Advisor
IR 3.2: Health advocacy and community mobilization organizations strengthened											
# CODESAs trained in Community Driven Reconstruction methodology	# CODESAs completing training in CDR methodology	0	0	tbd	tbd	tbd	tbd	tbd	IHP records	Annually	BCC Technical Advisor
IR 3.3: Behavior change campaigns involving opinion leaders and cultural influences (people and technologies) launched											
# /%Field staff, Community Relays, and community mobilization organizations integrating BCC tools into activities	# of organizations adopting BCC tools with key messages to adopt healthy practices by targeted population groups	0	100	300	700	1000	1000	1000	IHP records	Quarterly	BCC Technical Advisor
# Health-related stories/reports appearing/broadcasted in local media	# Stories/reports covering health topics promoted through BCC and media outreach activities	0	20	20	60	100	100	100	Media monitoring reports	Quarterly	BCC Technical Advisor
# Communities/people members receiving Education Through Listening (ETL)	# Communities/people completing ETL course	0	tbd	tbd	tbd	tbd	tbd	tbd	IHP records	Quarterly	BCC Technical Advisor
IR 4: Health sector leadership and governance in target provinces improved (Component 2)											
IR 4.1: Provincial health sector policies and national level policies aligned											
#/% of Health Zones adopting health sector policies in alignment with national MOH policies	<u>Numerator:</u> # of Health Zones with policies developed and adopted in line with national MOH policies <u>Denominator:</u> Total # of Health Zones	12%	20%	50%	80%	100%	100%	100%	Health zones records	Annually	M&E Specialist Health Zone Manager
#/% of Health Zones implementing a well-developed strategic plan in alignment with national MOH strategies	<u>Numerator:</u> # of Health Zones implementing a well-developed strategic plan in line with national MOH policies <u>Denominator:</u> Total # of Health Zones	10%	20%	50%	80%	100%	100%	100%	Health zones records	Annually	M&E Specialist Facilitators Health Zone Manager

IR 4.2: Evidence-based tools for strategic planning and management decision-making adopted											
# /% of GRHs implementing a well-developed strategic plan in alignment with provincial MOH strategies	A “strategic plan” is a written document that defines how an organization aims to reach its goals and objectives through a series of inputs, activities, and results. The strategic plan usually covers a period of 3 to 5 years, set forth the mission and goals of the organization, prioritizes strategies, and formulates the financial basis for achieving the goals.	5%	20%	50%	80%	100%	100%	100%	GRH records	Annually	Facilitators
% of organizational planning units in GRHs using MIS data as the basis for annual input/output projections	<u>Numerator:</u> # of organizational units having access to and using MIS data as the basis for annual plans during the last planning cycle <u>Denominator:</u> Total # of organizational units that prepared annual plans during the last planning cycle	15%	20%	50%	80%	100%	100%	100%	GRH records	Annually	M&E Specialist HMIS Officer
#/% of Health Zones with a current human resource plan	<u>Numerator:</u> # of Health Zones with a human resource plan that provides the human capacity required to meet the organization's goals <u>Denominator:</u> Total # of Health Zones	20%	20%	50%	80%	100%	100%	100%	Health zone human resource documents	Annually	M&E Specialist Health Zone Manager
#/% of Health Zones with a performance management system that includes all essential components	<u>Numerator:</u> # of Health Zones with a performance management system that includes three essential components: up-to-date job descriptions, lines of supervision, and joint work planning and performance review <u>Denominator:</u> Total # of Health Zones	10%	20%	50%	80%	100%	100%	100%	Health zone human resource documents	Annually	M&E Specialist Health Zone Manager
IR 4.3: Community involvement in health policy and service delivery institutionalized											

#/% of Health Zones implementing community-outreach policies promoting health prevention and use of health services developed and implemented	<u>Numerator:</u> # of Health Zones with community outreach policies promoting health prevention and use of health services in place and implemented <u>Denominator:</u> Total # of Health Zones	7%	10%	15%	20%	30%	40%	40%	Health zone records	Annually	M&E Specialist Health Zone Manager
#/% of community leaders actively involved in health management and services	<u>Numerator:</u> # of community leaders trained and involved in health management and services <u>Denominator:</u> Total # of community leaders	15%	20%	30%	40%	50%	60%	60%	IHP records	Annually	M&E Specialist

* Available baseline and end-of-project target figures included in this illustrative PMP are estimates and will be confirmed and/or established upon completion of the baseline study.

ANNEX 3: MEDICINES AND MEDICAL SUPPLIES PROCUREMENT

Draft Task Orders 106 and 107 were submitted to IDA Foundation and MissionPharma A/S during the current reporting quarter. Next quarter, task orders will be finalized and the medicines and medical supplies will be purchased by IHP.

ANNEX OVERVIEW: MEDICINES AND MEDICAL SUPPLIES PROCUREMENT

- I. List of medicines and medical supplies found in Task Order 106 issued to IDA Foundation
 - Shipment A. Products for Surface Shipment CIP (Incoterms 2000) to Kinshasa, DRC
 - Shipment B. Products for Air shipment CIP (Incoterms 2000) to Kinshasa, DRC
- II. List of medicines and medical supplies found in Task Order 106 issued to MissionPharma A/S
 - Shipment A. Products for Air Shipment CIP (Incoterms 2000) to CDR CEDIMEK KAMINA
 - Shipment B. Products for Air shipment CIP (Incoterms 2000) to DEPOT PHARMACEUTIQUE CDMEK KOLWEZI
 - Shipment C. Products for Air shipment CIP (Incoterms 2000) to CDR CADIMEK KANANGA
 - Shipment D. Products for Air shipment CIP (Incoterms 2000) to CDR CADMEKO MBUJIMAYI
 - Shipment E. Products for Air shipment CIP (Incoterms 2000) to DEPOT PHARMACEUTIQUE FODESA
 - Shipment F. Products for Air shipment CIP (Incoterms 2000) to APAMESK ASBL
 - Shipment G. Products for Air shipment CIP (Incoterms 2000) to DEPOT PHARMACEUTIQUE BDOM BUKAVU
 - Shipment H. Products for Air shipment CIP (Incoterms 2000) to DEPOT CENTRAL MEDICO-PHARMACEUTIQUE 8è CEPAC BUKAVU
 - Shipment I. Products for Air shipment CIP (Incoterms 2000) to MSH, KINSHASA
- III. List of medicines and medical supplies found in Task Order 107 issued to IDA Foundation
 - Shipment A. Products for Surface Shipment CIP (Incoterms 2000) to CDR CEDIMEK KAMINA
 - Shipment B. Products for SURFACE shipment CIP (Incoterms 2000) to DEPOT PHARMACEUTIQUE CDMEK KOLWEZI
 - Shipment C. Products for SURFACE shipment CIP (Incoterms 2000) to CDR CADIMEK KANANGA
 - Shipment D. Products for SURFACE shipment CIP (Incoterms 2000) to CDR CADMEKO MBUJIMAYI
 - Shipment E. Products for SURFACE shipment CIP (Incoterms 2000) to DEPOT PHARMACEUTIQUE FODESA
 - Shipment F. Products for SURFACE shipment CIP (Incoterms 2000) to APAMESK ASBL
 - Shipment G. Products for SURFACE shipment CIP (Incoterms 2000) to DEPOT PHARMACEUTIQUE BDOM BUKAVU
 - Shipment H. Products for SURFACE shipment CIP (Incoterms 2000) to DEPOT CENTRAL MEDICO-PHARMACEUTIQUE 8è CEPAC BUKAVU
- IV. List of medicines and medical supplies found in Task Order 107 issued to MissionPharma A/S
 - Shipment A. Products for SURFACE Shipment CIP (Incoterms 2000) to CDR CEDIMEK KAMINA
 - Shipment B. Products for SURFACE shipment CIP (Incoterms 2000) to DEPOT PHARMACEUTIQUE CDMEK KOLWEZI
 - Shipment C. Products for SURFACE shipment CIP (Incoterms 2000) to CDR CADIMEK KANANGA
 - Shipment D. Products for SURFACE shipment CIP (Incoterms 2000) to CDR CADMEKO MBUJIMAYI
 - Shipment E. Products for SURFACE shipment CIP (Incoterms 2000) to DEPOT PHARMACEUTIQUE FODESA
 - Shipment F. Products for SURFACE shipment CIP (Incoterms 2000) to APAMESK ASBL
 - Shipment G. Products for SURFACE shipment CIP (Incoterms 2000) to DEPOT PHARMACEUTIQUE BDOM BUKAVU
 - Shipment H. Products for SURFACE shipment CIP (Incoterms 2000) to DEPOT CENTRAL MEDICO-PHARMACEUTIQUE 8è CEPAC BUKAVU

I. List of medicines and medical supplies found in Task Order 106 issued to IDA Foundation

Shipment A. Products for Surface Shipment CIP (Incoterms 2000) to Kinshasa, DRC:

SURFACE SHIPMENT CIP (INCOTERMS 2010) TO CADMEKO

Item No.	Item Description	Total Qty	No. of Packs	Pack Size	Pack Price	Unit Price	Total Price USD	Manufacturer	Origin
3	Aluminium Hydroxide 120mg + Magnesium Trisilicate 250mg	1,579,000	1,579	1000 tablets	3.3125	0.0033125	5230.44	Fourrts	India
4	Amoxicillin 250mg/5ml, 100ml	36,000	36,000	1 bottle	0.5313	0.5313	19,126.80	Medicamen - Bhiwadi	India
5	Amoxicillin 500mg	2,434,600	2,434.6	1000 capsules	27.875	0.027875	67,864.48	CSPC Zhongnuo Pharma Workshop 204	China
6	Chlorphenamine Maleate 4mg	1,579,000	1,579	1000 tablets	1.733	0.001733	2,736.41	Medicamen - Bhiwadi	India
8	Ciprofloxacin 500mg, film-coated	2,608,500	26,085	100 tablets	3.4375	0.034375	89,667.19	Nanjing Baijingyu - General	China
10	Cotrimoxazole 480mg	6,519,800	6,519.8	1000 tablets	9.5	0.0095	61,938.10	Guilin Pharma - Workshop 2	China
12	Diclofenac Sodium 50mg, enteric coated	1,579,000	1,579	1000 tablets	3.44	0.00344	5,431.76	Medicamen - Bhiwadi	India
14	Doxycycline 100mg, as Hyclate	912,800	912.8	1000 tablets	10.333	0.010333	9,431.96	Nanjing Baijingyu - General	China
16	Erythromycin 125mg/5ml, 100ml as Ethyl Succinate	16,000	1,6000	1 bottle	0.6875	0.6875	11,000.00	Medicamen - Bhiwadi	India
23	Mebendazole, 100mg, Tab, 1000, Vrac	3,231,900	3,231.9	1000 tablets	3.75	0.00375	12,119.63	Medopharm - Malur Plant	India
24	Methyldopa 250mg, coated	56,000	56	1000 tablets	40	0.04	2,240.00	Medicamen - Bhiwadi	India
25	Metronidazole 250mg	2,322,600	2,322.6	1000 tablets	5.449	0.005449	12,655.85	Nanjing Baijingyu - General	China
27	Paracetamol 500mg	9,474,000	9,474	1000 tablets	5	0.005	47,370.00	Medicamen - Bhiwadi	India
29	Phenoxymethylpenicillin 250mg	1,161,300	1,161.3	1000 tablets	14.5	0.0145	16,838.85	Medicamen - Bhiwadi	India
30	Prednisolone 5mg	1,659,000	1,659	1000 tablets	7.75	0.00775	12,857.25	Medicamen - Bhiwadi	India
33	Lysine Acetylsalicylate 1.8g eq. to 1g ASA	48,000	960	50 vials	20.25	0.405	19,440.00	Reyoung Pharmaceutical, workshop 304	China
34	Ampicillin 1g, as Sodium	261,100	5,222	50 vials	5.95	0.119	31,070.90	Reyoung Pharmaceutical, workshop 305	China
37	Ciprofloxacin 2mg/ml, 100ml	12,800	16,000	1 bottle	0.36	0.36	4,608.00	Fresenius Kabi - Pune site	India

40	Diclofenac Sodium 25mg/ml, 3ml	103,000	1,030	100 ampoules	5.4217	0.054217	5,584.35	Gland - Pally Plant	India
43	Ephedrine HCl 30mg/ml, 1ml	8,000	800	10 ampoules	5.9625	0.59625	4,770.00	Lab. Aguetant, Unité de Chantecaille	France
48	Hyoscine Butylbromide 20mg/ml, 1ml	83,000	830	100 ampoules	9.9398	0.099398	8,250.03	Gland - Pally Plant	India
56	Metronidazole 125mg/5ml, 100ml, as Benzoate	36,000	36,000	1 bottle	0.3375	0.3375	12,150.00	Medicamen - Bhiwadi	India
61	Vitamin K1 10mg/ml, 1ml (Phytomenadione)	166,000	1,660	100 ampoules	29.9733	0.299733	49,755.68	Rotexmedica GmbH	Germany
64	Tetracycline HCl 1%, 5g, eye ointment	75,000	75,000	1 tube	0.1	0.1	7,500.00	Nanjing Baijingyu - Ointment, Creams,	China
65	Chlorhexidine 1.5% + Cetrimide 15%, 1L	2,400	2,400	1 bottle	3.0625	3.0625	7,350.00	Sirmaxo Chemicals - Palghar plant	India
67	Povidone Iodine 10%, 200ml	8,000	8,000	1 bottle	0.825	0.825	6,600.00	Sirmaxo Chemicals - Palghar plant	India
68	Benzyl Benzoate 25%, 1L, application	5,000	5,000	1 bottle	3	3	15,000.00	Sirmaxo Chemicals - Palghar plant	India
69	Nystatin 100,000 IU, pessaries	545,700	5,457	100 vagitories	1.5625	0.015625	8,526.56	Medicamen - Bhiwadi	India
70	Salbutamol 100mcg/dose, 200 doses CFC free	8,000	8,000	1 inhaler	1.1875	1.1875	9,500.00	Jewim Pharmaceutical, Taian High tech. Workshop 1 Steroids	China
82	Gauze bandage 5cm x 5m, BP17, individually pack, self-edged	135,000	135,000	1 roll	0.1	0.1	13,500.00	Shaoxing Fuqing Health - Shaoxing	China
85	Polyamide 2/0, 75cm w/needle-monofil 3/8circl,35mm-tapercut	94,000	7,834	12 pieces	1.4625	0.121875	11,457.23	Shanghai Pudong Jinhuan Medical Co., Ltd	China
86	Polyglycolic Acid 2/0, 75cm w/needle 1/2 circle, RB, 30mm	94,000	7,834	12 pieces	9.146304	0.762192	71,652.15	Shanghai Pudong Jinhuan Medical Co., Ltd	China
89	Catheter Foley, CH 20	3,000	3,000	1 piece	0.3467	0.3467	1,040.10	Zhanjiang Star Enterprise - Jinchuan Rd.	China
							Product Total	\$664,263.72	

Shipment B. Products for Air shipment CIP (Incoterms 2000) to Kinshasa, DRC

AIR SHIPMENT CIP (INCOTERMS 2000) TO Kinshasa, DRC									
Item No.	Item Description	Total Qty	No. of Packs	Pack Size	Pack Price	Unit Price	Total Value USD	Manufacturer	Origin
3	Aluminium Hydroxide 500mg, chewable	473,700	473.7	1000 tablets	4.063	0.004063	1,924.64	Medicamen - Bhiwadi	India
5	Amoxicillin 500mg	1,043,400	1,043.4	1000 capsules	27.875	0.027875	29,084.78	CSPC Zhongnuo Pharma Workshop 204	China
10	Cotrimoxazole 480mg	2,794,200	2,794.2	1000 tablets	9.5	0.0095	26,544.90	Guilin Pharma - Workshop 2	China
14	Doxycycline 100mg, as Hyclate	391,200	391.2	1000 tablets	10.333	0.010333	4,042.27	Nanjing Baijingyu - General	China
23	Mebendazole, 100mg, Tab, 1000, Vrac	1,385,100	1,385.1	1000 tablets	3.75	0.00375	5,194.13	Medopharm - Malur Plant	India
24	Methyldopa 250mg, coated	24,000	24	1000 tablets	40	0.04	960.00	Medicamen - Bhiwadi	India
25	Metronidazole 250mg	995,400	995.4	1000 tablets	5.449	0.005449	5,423.93	Nanjing Baijingyu - General	China
29	Phenoxymethylpenicillin 250mg	497,700	497.7	1000 tablets	14.5	0.0145	7,216.65	Medicamen - Bhiwadi	India
34	Ampicillin 1g, as Sodium	111,900	2,238	50 vials	5.95	0.119	13,316.10	Reyoung Pharmaceutical, workshop 305	China
37	Ciprofloxacin 2mg/ml, 100ml	3,200	16,000	1 bottle	0.36	0.36	1,152.00	Fresenius Kabi - Pune site	India
49	Insulin Soluble HM 40 IU/ml, 10ml	4,000	4,000	1 vial	3.4125	3.4125	13,650.00	Novo Nordisk, Bagsvaerd	Denmark
50	Insulin Isophane NPH HM 40 IU/ml, 10ml	4,000	4,000	1 vial	7.27	7.2667	29,066.80	Novo Nordisk, Bagsvaerd	Denmark
51	Insulin Isophane NPH HM 100 IU/ml, 10ml	2,000	2,000	1 vial	7.2667	7.2667	14,533.40	Novo Nordisk, Bagsvaerd	Denmark
57	Oxytocin 10 IU/ml, 1ml	665,700	6,657	100 ampoules	6.02	0.060241	40,102.43	Gland - Pally Plant	India
59	Pentazocine 30mg/ml, 1ml	12,000	1,200	10 ampoules	7.27	0.72667	8,720.04	Fresenius Kabi - Bodene	South Africa
60	Phenobarbital Sodium 100mg/ml, 2ml	4,000	40	100 ampoules	36.7867	0.367867	1,471.47	Wholesaler in Europe	
95	Lopinavir 200mg + Ritonavir 50mg	177,600	1,480	120 tablets	42.1687027	0.351406	62,409.68	Aurobindo - Unit-III, Block IV	India
96	Levonorgestrel 0.75mg	2,960	1,480	2 tablets	4.375	2.1875	6,475.00	Cipla Verna Inld. Estate, Unit V-VIII	India

100	Lamivudine 150mg + Zidovudine 300mg	16,020	267	60 tablets	10.62498	0.177083	2,836.87	Aurobindo - Unit-III, Block IV	India
103	Lamivudine 150mg + Zidovudine 300mg	65,820	1,097	60 tablets	10.62500456	0.177083	11,655.63	Aurobindo - Unit-III, Block IV	India
106	Cotrimoxazole 240mg/5ml, 100ml	116,100	116,100	1 bottle	0.3914	0.3914	45,441.54	Medicamen - Bhiwadi	India
108	Test kit, Syphilis, RPR, 250 tests	88,000	352	1 kit = 250 tests	17.1875	0.06875	6,050.00	Tulip Diagnostics Pvt. Ltd. - Verna, Goa	India
109	Test kit, Syphilis, TP-HA, 100 tests	88,000	880	1 kit = 100 tests	132.5301136	1.325301	46,650.50	Abbott Laboratories - UK	United Kingdom
110	Test kit, HIV 1+2 (Determine), 100 tests without chase buffer	88,000	880	1 kit = 100 tests	45	0.45	39,600.00	InTec PRODUCTS, Xiamen	China
111	Test kit, HIV 1+2 (DoubleCheck Gold), 100 tests, Rapid test	3,500	35	1 kit = 100 tests	173.3334286	1.733334	6,066.67	Inverness Medical Japan- Chiba plant	Japan
112	Test kit, HIV 1+2 (Uni-Gold), 20 tests Rapid test	3,500	175	1 kit = 20 tests	10.90131429	0.545066	1,907.73	Trinity Biotech PLC	Ireland
113	Test kit, Hepatitis B (ELISA), 96 tests	76,992	802	1 kit = 96 tests	96.19	1.001979	77,144.38	Human	Germany
					Product Total		\$508,641.54		

II. List of medicines and medical supplies found in Task Order 106 issued to Mission Pharma A/S

Shipment A. Products for Air Shipment CIP (Incoterms 2000) to CDR CEDIMEK KAMINA:

AIR SHIPMENT CIP (INCOTERMS 2000) TO CDR CEDIMEK KAMINA									
Item No.	Item Description	Total Qty	No. of Packs	Pack Size	Pack Price	Unit Price	Total Value USD	Manufacturer	Origin
3	Aluminium Hydroxide 120mg + Magnesium Trisilicate 250mg	59,000	59	1000 tablets	\$3.31	\$0.00	\$195.44	Fourrts	India
5	Amoxicillin 500mg	131,000	131	1000 capsules	27.88	0.03	3,651.63	CSPC Zhongnuo Pharma Workshop 204	China
10	Cotrimoxazole 480mg	349,000	349	1000 tablets	9.50	0.01	3,315.50	Guilin Pharma - Workshop 2	China
14	Doxycycline 100mg, as Hyclate	49,000	49	1000 tablets	10.33	0.01	506.32	Nanjing Baijingyu - General	China
23	Mebendazole, 100mg, Tab, 1000, Vrac	174,000	174	1000 tablets	3.75	0.00	652.50	Medopharm - Malur Plant	India
24	Methyl dopa 250mg, coated	3,000	3	1000 tablets	40.00	0.04	120.00	Medicamen - Bhiwadi	India
25	Metronidazole 250mg	125,000	125	1000 tablets	5.45	0.01	681.13	Nanjing Baijingyu - General	China
29	Phenoxymethylpenicillin 250mg	63,000	63	1000 tablets	14.50	0.01	913.50	Medicamen - Bhiwadi	India
34	Ampicillin 1g, as Sodium	14,000	280	50 vials	5.95	0.12	1,666.00	Reyoung Pharmaceutical, workshop 305	China
37	Ciprofloxacin 2mg/ml, 100ml	200	200	1 bottle	0.36	0.36	72.00	Fresenius Kabi - Pune site	India
49	Insulin Soluble HM 40 IU/ml, 10ml	500	500	1 vial	3.41	3.41	1,706.25	Novo Nordisk, Bagsvaerd	Denmark
50	Insulin Isophane NPH HM 40 IU/ml, 10ml	500	500	1 vial	7.27	7.27	3,635.00	Novo Nordisk, Bagsvaerd	Denmark
51	Insulin Isophane NPH HM 100 IU/ml, 10ml	280	280	1 vial	6.49	6.49	1,816.67	Novo Nordisk, Bagsvaerd	Denmark
57	Oxytocin 10 IU/ml, 1ml	83,200	832	100 ampoules	6.02	0.06	5,008.64	Gland - Pally Plant	India
59	Pentazocine 30mg/ml, 1ml	1,500	150	10 ampoules	7.27	0.73	1,090.50	Fresenius Kabi - Bodene	South Africa
60	Phenobarbital Sodium 100mg/ml, 2ml	500	5	100 ampoules	36.79	0.37	183.93	Wholesaler in Europe	
95	Lopinavir 200mg + Ritonavir 50mg	22,200	185	120 tablets	42.17	0.35	7,801.21	Aurobindo - Unit-III, Block IV	India
96	Levonorgestrel 0.75mg	370	185	2 tablets	4.38	2.19	809.38	Cipla Verna Indl.	India

								Estate, Unit V-VIII	
100	Lamivudine 150mg + Zidovudine 300mg	2,040	34	60 tablets	10.62	0.18	361.25	Aurobindo - Unit-III, Block IV	India
103	Lamivudine 150mg + Zidovudine 300mg	8,220	137	60 tablets	10.63	0.18	1,455.63	Aurobindo - Unit-III, Block IV	India
106	Cotrimoxazole 240mg/5ml, 100ml	14,513	14513	1 bottle	0.39	0.39	5,680.39	Medicamen - Bhiwadi	India
108	Test kit, Syphilis, RPR, 250 tests	11,000	44	1 kit = 250 tests	17.19	0.07	756.25	Tulip Diagnostics Pvt. Ltd. - Verna, Goa	India
109	Test kit, Syphilis, TP-HA, 100 tests	1,100	11	1 kit = 100 tests	132.53	1.33	1,457.83	Tulip Diagnostics Pvt. Ltd. - Verna, Goa	India
110	Test kit, HIV 1+2 (Determine), 100 tests without chase buffer	11,000	110	1 kit = 100 tests	45.00	0.45	4,950.00	Inverness Medical Japan- Chiba plant	Japan
111	Test kit, HIV 1+2 (DoubleCheck Gold), 100 tests, Rapid test	500	5	1 kit = 100 tests	173.33	1.73	866.67	Inverness Medical Japan- Chiba plant	Japan
112	Test kit, HIV 1+2 (Uni-Gold), 20 tests Rapid test	220	11	1 kit = 20 tests	54.51	2.73	599.57	Trinity Biotech PLC	Ireland
113	Test kit, Hepatitis B (ELISA), 96 tests	9,600	100	1 kit = 96 tests	96.19	1.00	9,619.00	Tulip Diagnostics Pvt. Ltd. - Verna, Goa	India
					Product Total		\$59,572.17		

Shipment B. Products for Air shipment CIP (Incoterms 2000) to DEPOT PHARMACEUTIQUE CDMEK KOLWEZI:

AIR SHIPMENT CIP (INCOTERMS 2000) TO DEPOT PHARMACEUTIQUE CDMEK KOLWEZI									
Item No.	Item Description	Total Qty	No. of Packs	Pack Size	Pack Price	Unit Price	Total Value USD	Manufacturer	Origin
3	Aluminium Hydroxide 120mg + Magnesium Trisilicate 250mg	59,000	59	1000 tablets	\$3.31	\$0.00	\$195.44	Fourrts	India
5	Amoxicillin 500mg	131,000	131	1000 capsules	27.88	0.03	3,651.63	CSPC Zhongnuo Pharma Workshop 204	China
10	Cotrimoxazole 480mg	350,000	350	1000 tablets	9.50	0.01	3,325.00	Guilin Pharma - Workshop 2	China
14	Doxycycline 100mg, as Hyclate	49,000	49	1000 tablets	10.33	0.01	506.32	Nanjing Baijingyu - General	China
23	Mebendazole, 100mg, Tab, 1000, Vrac	173,000	173	1000 tablets	3.75	0.00	648.75	Medopharm - Malur Plant	India
24	Methyldopa 250mg, coated	3,000	3	1000 tablets	40.00	0.04	120.00	Medicamen - Bhiwadi	India
25	Metronidazole 250mg	124,000	124	1000 tablets	5.45	0.01	675.68	Nanjing Baijingyu - General	China
29	Phenoxymethylpenicillin 250mg	63,000	63	1000 tablets	14.50	0.01	913.50	Medicamen - Bhiwadi	India
34	Ampicillin 1g, as Sodium	14,000	280	50 vials	5.95	0.12	1,666.00	Reyoung Pharmaceutical, workshop 305	China
37	Ciprofloxacin 2mg/ml, 100ml	200	200	1 bottle	0.36	0.36	72.00	Fresenius Kabi - Pune site	India
49	Insulin Soluble HM 40 IU/ml, 10ml	500	500	1 vial	3.41	3.41	1,706.25	Novo Nordisk, Bagsvaerd	Denmark
50	Insulin Isophane NPH HM 40 IU/ml, 10ml	500	500	1 vial	7.27	7.27	3,635.00	Novo Nordisk, Bagsvaerd	Denmark
51	Insulin Isophane NPH HM 100 IU/ml, 10ml	280	280	1 vial	6.49	6.49	1,816.67	Novo Nordisk, Bagsvaerd	Denmark
57	Oxytocin 10 IU/ml, 1ml	83,200	832	100 ampoules	6.02	0.06	5,008.64	Gland - Pally Plant	India
59	Pentazocine 30mg/ml, 1ml	1,500	150	10 ampoules	7.27	0.73	1,090.50	Fresenius Kabi - Bodene	South Africa
60	Phenobarbital Sodium 100mg/ml, 2ml	500	5	100 ampoules	36.79	0.37	183.93	Wholesaler in Europe	
95	Lopinavir 200mg + Ritonavir 50mg	22,200	185	120 tablets	42.17	0.35	7,801.21	Aurobindo - Unit-III, Block IV	India
96	Levonorgestrel 0.75mg	370	185	2 tablets	4.38	2.19	809.38	Cipla Verna Indl. Estate, Unit V-VIII	India
100	Lamivudine 150mg + Zidovudine 300mg	2,040	34	60 tablets	10.62	0.18	361.25	Aurobindo - Unit-III, Block IV	India
103	Lamivudine 150mg +	8,220	137	60 tablets	10.63	0.18	1,455.63	Aurobindo - Unit-III,	India

	Zidovudine 300mg							Block IV	
106	Cotrimoxazole 240mg/5ml, 100ml	14,513	14513	1 bottle	0.39	0.39	5,680.39	Medicamen - Bhiwadi	India
108	Test kit, Syphilis, RPR, 250 tests	11,000	44	1 kit = 250 tests	17.19	0.07	756.25	Tulip Diagnostics Pvt. Ltd. - Verna, Goa	India
109	Test kit, Syphilis, TP-HA, 100 tests	1,100	11	1 kit = 100 tests	132.53	1.33	1,457.83	Tulip Diagnostics Pvt. Ltd. - Verna, Goa	India
110	Test kit, HIV 1+2 (Determine), 100 tests without chase buffer	11,000	110	1 kit = 100 tests	45.00	0.45	4,950.00	Inverness Medical Japan- Chiba plant	Japan
111	Test kit, HIV 1+2 (DoubleCheck Gold), 100 tests, Rapid test	500	5	1 kit = 100 tests	173.33	1.73	866.67	Inverness Medical Japan- Chiba plant	Japan
112	Test kit, HIV 1+2 (Uni-Gold), 20 tests Rapid test	220	11	1 kit = 20 tests	54.51	2.73	599.57	Trinity Biotech PLC	Ireland
113	Test kit, Hepatitis B (ELISA), 96 tests	9,600	100	1 kit = 96 tests	96.19	1.00	9,619.00	Tulip Diagnostics Pvt. Ltd. - Verna, Goa	India
							Product Total	\$59,572.47	

Shipment C. Products for Air shipment CIP (Incoterms 2000) to CDR CADIMEK KANANGA:

AIR SHIPMENT CIP (INCOTERMS 2000) TO CDR CADIMEK KANANGA									
Item No.	Item Description	Total Qty	No. of Packs	Pack Size	Pack Price	Unit Price	Total Value USD	Manufacturer	Origin
3	Aluminium Hydroxide 120mg + Magnesium Trisilicate 250mg	60,000	60	1000 tablets	\$3.31	\$0.00	\$198.75	Fourrts	India
5	Amoxicillin 500mg	131,000	131	1000 capsules	27.88	0.03	3,651.63	CSPC Zhongnuo Pharma Workshop 204	China
10	Cotrimoxazole 480mg	350,000	350	1000 tablets	9.50	0.01	3,325.00	Guilin Pharma - Workshop 2	China
14	Doxycycline 100mg, as Hyclate	49,000	49	1000 tablets	10.33	0.01	506.32	Nanjing Baijingyu - General	China
23	Mebendazole, 100mg, Tab, 1000, Vrac	173,000	173	1000 tablets	3.75	0.00	648.75	Medopharm - Malur Plant	India
24	Methyldopa 250mg, coated	3,000	3	1000 tablets	40.00	0.04	120.00	Medicamen - Bhiwadi	India
25	Metronidazole 250mg	124,000	124	1000 tablets	5.45	0.01	675.68	Nanjing Baijingyu - General	China
29	Phenoxyethylpenicillin 250mg	63,000	63	1000 tablets	14.50	0.01	913.50	Medicamen - Bhiwadi	India
34	Ampicillin 1g, as Sodium	14,000	280	50 vials	5.95	0.12	1,666.00	Reyoung Pharmaceutical, workshop 305	China
37	Ciprofloxacin 2mg/ml, 100ml	200	200	1 bottle	0.36	0.36	72.00	Fresenius Kabi - Pune site	India
49	Insulin Soluble HM 40 IU/ml, 10ml	500	500	1 vial	3.41	3.41	1,706.25	Novo Nordisk, Bagsvaerd	Denmark
50	Insulin Isophane NPH HM 40 IU/ml, 10ml	500	500	1 vial	7.27	7.27	3,635.00	Novo Nordisk, Bagsvaerd	Denmark
51	Insulin Isophane NPH HM 100 IU/ml, 10ml	280	280	1 vial	6.49	6.49	1,816.67	Novo Nordisk, Bagsvaerd	Denmark
57	Oxytocin 10 IU/ml, 1ml	83,200	832	100 ampoules	6.02	0.06	5,008.64	Gland - Pally Plant	India
59	Pentazocine 30mg/ml, 1ml	1,500	150	10 ampoules	7.27	0.73	1,090.50	Fresenius Kabi - Bodene	South Africa
60	Phenobarbital Sodium 100mg/ml, 2ml	500	5	100 ampoules	36.79	0.37	183.93	Wholesaler in Europe	
95	Lopinavir 200mg + Ritonavir 50mg	22,200	185	120 tablets	42.17	0.35	7,801.21	Aurobindo - Unit-III, Block IV	India
96	Levonorgestrel 0.75mg	370	185	2 tablets	4.38	2.19	809.38	Cipla Verna Indl. Estate, Unit V-VIII	India
100	Lamivudine 150mg + Zidovudine 300mg	2,040	34	60 tablets	10.62	0.18	361.25	Aurobindo - Unit-III, Block IV	India

103	Lamivudine 150mg + Zidovudine 300mg	8,280	138	60 tablets	10.63	0.18	1,466.25	Aurobindo - Unit-III, Block IV	India
106	Cotrimoxazole 240mg/5ml, 100ml	14,513	14513	1 bottle	0.39	0.39	5,680.39	Medicamen - Bhiwadi	India
108	Test kit, Syphilis, RPR, 250 tests	11,000	44	1 kit = 250 tests	17.19	0.07	756.25	Tulip Diagnostics Pvt. Ltd. - Verna, Goa	India
109	Test kit, Syphilis, TP-HA, 100 tests	1,100	11	1 kit = 100 tests	132.53	1.33	1,457.83	Tulip Diagnostics Pvt. Ltd. - Verna, Goa	India
110	Test kit, HIV 1+2 (Determine), 100 tests without chase buffer	11,000	110	1 kit = 100 tests	45.00	0.45	4,950.00	Inverness Medical Japan- Chiba plant	Japan
111	Test kit, HIV 1+2 (DoubleCheck Gold), 100 tests, Rapid test	500	5	1 kit = 100 tests	173.33	1.73	866.67	Inverness Medical Japan- Chiba plant	Japan
112	Test kit, HIV 1+2 (Uni-Gold), 20 tests Rapid test	220	11	1 kit = 20 tests	54.51	2.73	599.57	Trinity Biotech PLC	Ireland
113	Test kit, Hepatitis B (ELISA), 96 tests	9,696	101	1 kit = 96 tests	96.19	1.00	9,715.19	Tulip Diagnostics Pvt. Ltd. - Verna, Goa	India
					Product Total		\$59,682.59		

Shipment D. Products for Air shipment CIP (Incoterms 2000) to CDR CADMEKO MBUJIMAYI:

AIR SHIPMENT CIP (INCOTERMS 2000) TO CDR CADMEKO MBUJIMAYI									
Item No.	Item Description	Total Qty	No. of Packs	Pack Size	Pack Price	Unit Price	Total Value USD	Manufacturer	Origin
3	Aluminium Hydroxide 120mg + Magnesium Trisilicate 250mg	60,000	60	1000 tablets	\$3.31	\$0.00	\$198.75	Fourrts	India
5	Amoxicillin 500mg	131,000	131	1000 capsules	27.88	0.03	3,651.63	CSPC Zhongnuo Pharma Workshop 204	China
10	Cotrimoxazole 480mg	350,000	350	1000 tablets	9.50	0.01	3,325.00	Guilin Pharma - Workshop 2	China
14	Doxycycline 100mg, as Hyclate	49,000	49	1000 tablets	10.33	0.01	506.32	Nanjing Baijingyu - General	China
23	Mebendazole, 100mg, Tab, 1000, Vrac	174,000	174	1000 tablets	3.75	0.00	652.50	Medopharm - Malur Plant	India
24	Methyldopa 250mg, coated	3,000	3	1000 tablets	40.00	0.04	120.00	Medicamen - Bhiwadi	India
25	Metronidazole 250mg	125,000	125	1000 tablets	5.45	0.01	681.13	Nanjing Baijingyu - General	China
29	Phenoxymethylpenicillin 250mg	62,000	62	1000 tablets	14.50	0.01	899.00	Medicamen - Bhiwadi	India
34	Ampicillin 1g, as Sodium	14,000	280	50 vials	5.95	0.12	1,666.00	Reyoung Pharmaceutical, workshop 305	China
37	Ciprofloxacin 2mg/ml, 100ml	200	200	1 bottle	0.36	0.36	72.00	Fresenius Kabi - Pune site	India
49	Insulin Soluble HM 40 IU/ml, 10ml	500	500	1 vial	3.41	3.41	1,706.25	Novo Nordisk, Bagsvaerd	Denmark
50	Insulin Isophane NPH HM 40 IU/ml, 10ml	500	500	1 vial	7.27	7.27	3,635.00	Novo Nordisk, Bagsvaerd	Denmark
51	Insulin Isophane NPH HM 100 IU/ml, 10ml	280	280	1 vial	6.49	6.49	1,816.67	Novo Nordisk, Bagsvaerd	Denmark
57	Oxytocin 10 IU/ml, 1ml	83,200	832	100 ampoules	6.02	0.06	5,008.64	Gland - Pally Plant	India
59	Pentazocine 30mg/ml, 1ml	1,500	150	10 ampoules	7.27	0.73	1,090.50	Fresenius Kabi - Bodene	South Africa
60	Phenobarbital Sodium 100mg/ml, 2ml	500	5	100 ampoules	36.79	0.37	183.93	Wholesaler in Europe	
95	Lopinavir 200mg + Ritonavir 50mg	22,200	185	120 tablets	42.17	0.35	7,801.21	Aurobindo - Unit-III, Block IV	India
96	Levonorgestrel 0.75mg	370	185	2 tablets	4.38	2.19	809.38	Cipla Verna Indl. Estate, Unit V-VIII	India
100	Lamivudine 150mg + Zidovudine 300mg	1,980	33	60 tablets	10.62	0.18	350.62	Aurobindo - Unit-III, Block IV	India
103	Lamivudine 150mg +	8,220	137	60 tablets	10.63	0.18	1,455.63	Aurobindo - Unit-III,	India

	Zidovudine 300mg							Block IV	
106	Cotrimoxazole 240mg/5ml, 100ml	14,513	14513	1 bottle	0.39	0.39	5,680.39	Medicamen - Bhiwadi	India
108	Test kit, Syphilis, RPR, 250 tests	11,000	44	1 kit = 250 tests	17.19	0.07	756.25	Tulip Diagnostics Pvt. Ltd. - Verna, Goa	India
109	Test kit, Syphilis, TP-HA, 100 tests	1,100	11	1 kit = 100 tests	132.53	1.33	1,457.83	Tulip Diagnostics Pvt. Ltd. - Verna, Goa	India
110	Test kit, HIV 1+2 (Determine), 100 tests without chase buffer	11,000	110	1 kit = 100 tests	45.00	0.45	4,950.00	Inverness Medical Japan- Chiba plant	Japan
111	Test kit, HIV 1+2 (DoubleCheck Gold), 100 tests, Rapid test	400	4	1 kit = 100 tests	173.33	1.73	693.33	Inverness Medical Japan- Chiba plant	Japan
112	Test kit, HIV 1+2 (Uni-Gold), 20 tests Rapid test	220	11	1 kit = 20 tests	54.51	2.73	599.57	Trinity Biotech PLC	Ireland
113	Test kit, Hepatitis B (ELISA), 96 tests	9,600	100	1 kit = 96 tests	96.19	1.00	9,619.00	Tulip Diagnostics Pvt. Ltd. - Verna, Goa	India
							Product Total	\$59,386.52	

Shipment E. Products for Air shipment CIP (Incoterms 2000) to DEPOT PHARMACEUTIQUE FODESA:

AIR SHIPMENT CIP (INCOTERMS 2000) TO DEPOT PHARMACEUTIQUE FODESA									
Item No.	Item Description	Total Qty	No. of Packs	Pack Size	Pack Price	Unit Price	Total Value USD	Manufacturer	Origin
3	Aluminium Hydroxide 120mg + Magnesium Trisilicate 250mg	60,000	60	1000 tablets	\$3.31	\$0.00	\$198.75	Fourrts	India
5	Amoxicillin 500mg	131,000	131	1000 capsules	27.88	0.03	3,651.63	CSPC Zhongnuo Pharma Workshop 204	China
10	Cotrimoxazole 480mg	350,000	350	1000 tablets	9.50	0.01	3,325.00	Guilin Pharma - Workshop 2	China
14	Doxycycline 100mg, as Hyclate	49,000	49	1000 tablets	10.33	0.01	506.32	Nanjing Baijinyu - General	China
23	Mebendazole, 100mg, Tab, 1000, Vrac	174,000	174	1000 tablets	3.75	0.00	652.50	Medopharm - Malur Plant	India
24	Methyldopa 250mg, coated	3,000	3	1000 tablets	40.00	0.04	120.00	Medicamen - Bhiwadi	India
25	Metronidazole 250mg	125,000	125	1000 tablets	5.45	0.01	681.13	Nanjing Baijinyu - General	China
29	Phenoxymethylpenicillin 250mg	63,000	63	1000 tablets	14.50	0.01	913.50	Medicamen - Bhiwadi	India
34	Ampicillin 1g, as Sodium	14,000	280	50 vials	5.95	0.12	1,666.00	Reyoung Pharmaceutical, workshop 305	China
37	Ciprofloxacin 2mg/ml, 100ml	200	200	1 bottle	0.36	0.36	72.00	Fresenius Kabi - Pune site	India
49	Insulin Soluble HM 40 IU/ml, 10ml	500	500	1 vial	3.41	3.41	1,706.25	Novo Nordisk, Bagsvaerd	Denmark
50	Insulin Isophane NPH HM 40 IU/ml, 10ml	500	500	1 vial	7.27	7.27	3,635.00	Novo Nordisk, Bagsvaerd	Denmark
51	Insulin Isophane NPH HM 100 IU/ml, 10ml	280	280	1 vial	6.49	6.49	1,816.67	Novo Nordisk, Bagsvaerd	Denmark
57	Oxytocin 10 IU/ml, 1ml	83,200	832	100 ampoules	6.02	0.06	5,008.64	Gland - Pally Plant	India
59	Pentazocine 30mg/ml, 1ml	1,500	150	10 ampoules	7.27	0.73	1,090.50	Fresenius Kabi - Bodene	South Africa
60	Phenobarbital Sodium 100mg/ml, 2ml	500	5	100 ampoules	36.79	0.37	183.93	Wholesaler in Europe	
95	Lopinavir 200mg + Ritonavir 50mg	22,200	185	120 tablets	42.17	0.35	7,801.21	Aurobindo - Unit-III, Block IV	India
96	Levonorgestrel 0.75mg	370	185	2 tablets	4.38	2.19	809.38	Cipla Verna Indl. Estate, Unit V-VIII	India
100	Lamivudine 150mg + Zidovudine 300mg	1,980	33	60 tablets	10.62	0.18	350.62	Aurobindo - Unit-III, Block IV	India
103	Lamivudine 150mg +	8,220	137	60 tablets	10.63	0.18	1,455.63	Aurobindo - Unit-III,	India

	Zidovudine 300mg							Block IV	
106	Cotrimoxazole 240mg/5ml, 100ml	14,513	14513	1 bottle	0.39	0.39	5,680.39	Medicamen - Bhiwadi	India
108	Test kit, Syphilis, RPR, 250 tests	11,000	44	1 kit = 250 tests	17.19	0.07	756.25	Tulip Diagnostics Pvt. Ltd. - Verna, Goa	India
109	Test kit, Syphilis, TP-HA, 100 tests	1,100	11	1 kit = 100 tests	132.53	1.33	1,457.83	Tulip Diagnostics Pvt. Ltd. - Verna, Goa	India
110	Test kit, HIV 1+2 (Determine), 100 tests without chase buffer	11,000	110	1 kit = 100 tests	45.00	0.45	4,950.00	Inverness Medical Japan- Chiba plant	Japan
111	Test kit, HIV 1+2 (DoubleCheck Gold), 100 tests, Rapid test	400	4	1 kit = 100 tests	173.33	1.73	693.33	Inverness Medical Japan- Chiba plant	Japan
112	Test kit, HIV 1+2 (Uni-Gold), 20 tests Rapid test	220	11	1 kit = 20 tests	54.51	2.73	599.57	Trinity Biotech PLC	Ireland
113	Test kit, Hepatitis B (ELISA), 96 tests	9,600	100	1 kit = 96 tests	96.19	1.00	9,619.00	Tulip Diagnostics Pvt. Ltd. - Verna, Goa	India
							Product Total	\$59,401.02	

Shipment F. Products for Air shipment CIP (Incoterms 2000) to APAMESK ASBL:

AIR SHIPMENT CIP (INCOTERMS 2000) TO APAMESK ASBL									
Item No.	Item Description	Total Qty	No. of Packs	Pack Size	Pack Price	Unit Price	Total Value USD	Manufacturer	Origin
3	Aluminium Hydroxide 120mg + Magnesium Trisilicate 250mg	60,000	60	1000 tablets	\$3.31	\$0.00	\$198.75	Fourrts	India
5	Amoxicillin 500mg	131,000	131	1000 capsules	27.88	0.03	3,651.63	CSPC Zhongnuo Pharma Workshop 204	China
10	Cotrimoxazole 480mg	350,000	350	1000 tablets	9.50	0.01	3,325.00	Guilin Pharma - Workshop 2	China
14	Doxycycline 100mg, as Hyclate	49,000	49	1000 tablets	10.33	0.01	506.32	Nanjing Baijingyu - General	China
23	Mebendazole, 100mg, Tab, 1000, Vrac	174,000	174	1000 tablets	3.75	0.00	652.50	Medopharm - Malur Plant	India
24	Methyldopa 250mg, coated	3,000	3	1000 tablets	40.00	0.04	120.00	Medicamen - Bhiwadi	India
25	Metronidazole 250mg	125,000	125	1000 tablets	5.45	0.01	681.13	Nanjing Baijingyu - General	China
29	Phenoxymethylpenicillin 250mg	63,000	63	1000 tablets	14.50	0.01	913.50	Medicamen - Bhiwadi	India
34	Ampicillin 1g, as Sodium	14,000	280	50 vials	5.95	0.12	1,666.00	Reyoung Pharmaceutical, workshop 305	China
37	Ciprofloxacin 2mg/ml, 100ml	200	200	1 bottle	0.36	0.36	72.00	Fresenius Kabi - Pune site	India
49	Insulin Soluble HM 40 IU/ml, 10ml	500	500	1 vial	3.41	3.41	1,706.25	Novo Nordisk, Bagsvaerd	Denmark
50	Insulin Isophane NPH HM 40 IU/ml, 10ml	500	500	1 vial	7.27	7.27	3,635.00	Novo Nordisk, Bagsvaerd	Denmark
51	Insulin Isophane NPH HM 100 IU/ml, 10ml	280	280	1 vial	6.49	6.49	1,816.67	Novo Nordisk, Bagsvaerd	Denmark
57	Oxytocin 10 IU/ml, 1ml	83,200	832	100 ampoules	6.02	0.06	5,008.64	Gland - Pally Plant	India
59	Pentazocine 30mg/ml, 1ml	1,500	150	10 ampoules	7.27	0.73	1,090.50	Fresenius Kabi - Bodene	South Africa
60	Phenobarbital Sodium 100mg/ml, 2ml	500	5	100 ampoules	36.79	0.37	183.93	Wholesaler in Europe	
95	Lopinavir 200mg + Ritonavir 50mg	22,200	185	120 tablets	42.17	0.35	7,801.21	Aurobindo - Unit-III, Block IV	India
96	Levonorgestrel 0.75mg	370	185	2 tablets	4.38	2.19	809.38	Cipla Verna Indl. Estate, Unit V-VIII	India
100	Lamivudine 150mg +	1,980	33	60 tablets	10.62	0.18	350.62	Aurobindo - Unit-III,	India

	Zidovudine 300mg							Block IV	
103	Lamivudine 150mg + Zidovudine 300mg	8,220	137	60 tablets	10.63	0.18	1,455.63	Aurobindo - Unit-III, Block IV	India
106	Cotrimoxazole 240mg/5ml, 100ml	14,513	14513	1 bottle	0.39	0.39	5,680.39	Medicamen - Bhiwadi	India
108	Test kit, Syphilis, RPR, 250 tests	11,000	44	1 kit = 250 tests	17.19	0.07	756.25	Tulip Diagnostics Pvt. Ltd. - Verna, Goa	India
109	Test kit, Syphilis, TP-HA, 100 tests	1,100	11	1 kit = 100 tests	132.53	1.33	1,457.83	Tulip Diagnostics Pvt. Ltd. - Verna, Goa	India
110	Test kit, HIV 1+2 (Determine), 100 tests without chase buffer	11,000	110	1 kit = 100 tests	45.00	0.45	4,950.00	Inverness Medical Japan- Chiba plant	Japan
111	Test kit, HIV 1+2 (DoubleCheck Gold), 100 tests, Rapid test	400	4	1 kit = 100 tests	173.33	1.73	693.33	Inverness Medical Japan- Chiba plant	Japan
112	Test kit, HIV 1+2 (Uni-Gold), 20 tests Rapid test	220	11	1 kit = 20 tests	54.51	2.73	599.57	Trinity Biotech PLC	Ireland
113	Test kit, Hepatitis B (ELISA), 96 tests	9,600	100	1 kit = 96 tests	96.19	1.00	9,619.00	Tulip Diagnostics Pvt. Ltd. - Verna, Goa	India
							Product Total	\$59,401.02	

Shipment G. Products for Air shipment CIP (Incoterms 2000) to DEPOT PHARMACEUTIQUE BDOM BUKAVU:

AIR SHIPMENT CIP (INCOTERMS 2000) TO DEPOT PHARMACEUTIQUE BDOM BUKAVU									
Item No.	Item Description	Total Qty	No. of Packs	Pack Size	Pack Price	Unit Price	Total Value USD	Manufacturer	Origin
3	Aluminium Hydroxide 120mg + Magnesium Trisilicate 250mg	60,000	60	1000 tablets	\$3.31	\$0.00	\$198.75	Fourrts	India
5	Amoxicillin 500mg	131,000	131	1000 capsules	27.88	0.03	3,651.63	CSPC Zhongnuo Pharma Workshop 204	China
10	Cotrimoxazole 480mg	350,000	350	1000 tablets	9.50	0.01	3,325.00	Guilin Pharma - Workshop 2	China
14	Doxycycline 100mg, as Hyclate	49,000	49	1000 tablets	10.33	0.01	506.32	Nanjing Baijingyu - General	China
23	Mebendazole, 100mg, Tab, 1000, Vrac	174,000	174	1000 tablets	3.75	0.00	652.50	Medopharm - Malur Plant	India
24	Methyldopa 250mg, coated	3,000	3	1000 tablets	40.00	0.04	120.00	Medicamen - Bhiwadi	India
25	Metronidazole 250mg	125,000	125	1000 tablets	5.45	0.01	681.13	Nanjing Baijingyu - General	China
29	Phenoxymethylpenicillin 250mg	63,000	63	1000 tablets	14.50	0.01	913.50	Medicamen - Bhiwadi	India
34	Ampicillin 1g, as Sodium	14,000	280	50 vials	5.95	0.12	1,666.00	Reyoung Pharmaceutical, workshop 305	China
37	Ciprofloxacin 2mg/ml, 100ml	200	200	1 bottle	0.36	0.36	72.00	Fresenius Kabi - Pune site	India
49	Insulin Soluble HM 40 IU/ml, 10ml	500	500	1 vial	3.41	3.41	1,706.25	Novo Nordisk, Bagsvaerd	Denmark
50	Insulin Isophane NPH HM 40 IU/ml, 10ml	500	500	1 vial	7.27	7.27	3,635.00	Novo Nordisk, Bagsvaerd	Denmark
51	Insulin Isophane NPH HM 100 IU/ml, 10ml	280	280	1 vial	6.49	6.49	1,816.67	Novo Nordisk, Bagsvaerd	Denmark
57	Oxytocin 10 IU/ml, 1ml	83,200	832	100 ampoules	6.02	0.06	5,008.64	Gland - Pally Plant	India
59	Pentazocine 30mg/ml, 1ml	1,500	150	10 ampoules	7.27	0.73	1,090.50	Fresenius Kabi - Bodene	South Africa
60	Phenobarbital Sodium 100mg/ml, 2ml	500	5	100 ampoules	36.79	0.37	183.93	Wholesaler in Europe	
95	Lopinavir 200mg + Ritonavir 50mg	22,200	185	120 tablets	42.17	0.35	7,801.21	Aurobindo - Unit-III, Block IV	India
96	Levonorgestrel 0.75mg	370	185	2 tablets	4.38	2.19	809.38	Cipla Verna Indl. Estate, Unit V-VIII	India

100	Lamivudine 150mg + Zidovudine 300mg	1,980	33	60 tablets	10.62	0.18	350.62	Aurobindo - Unit-III, Block IV	India
103	Lamivudine 150mg + Zidovudine 300mg	8,220	137	60 tablets	10.63	0.18	1,455.63	Aurobindo - Unit-III, Block IV	India
106	Cotrimoxazole 240mg/5ml, 100ml	14,513	14513	1 bottle	0.39	0.39	5,680.39	Medicamen - Bhiwadi	India
108	Test kit, Syphilis, RPR, 250 tests	11,000	44	1 kit = 250 tests	17.19	0.07	756.25	Tulip Diagnostics Pvt. Ltd. - Verna, Goa	India
109	Test kit, Syphilis, TP-HA, 100 tests	1,100	11	1 kit = 100 tests	132.53	1.33	1,457.83	Tulip Diagnostics Pvt. Ltd. - Verna, Goa	India
110	Test kit, HIV 1+2 (Determine), 100 tests without chase buffer	11,000	110	1 kit = 100 tests	45.00	0.45	4,950.00	Inverness Medical Japan- Chiba plant	Japan
111	Test kit, HIV 1+2 (DoubleCheck Gold), 100 tests, Rapid test	400	4	1 kit = 100 tests	173.33	1.73	693.33	Inverness Medical Japan- Chiba plant	Japan
112	Test kit, HIV 1+2 (Uni-Gold), 20 tests Rapid test	220	11	1 kit = 20 tests	54.51	2.73	599.57	Trinity Biotech PLC	Ireland
113	Test kit, Hepatitis B (ELISA), 96 tests	9,600	100	1 kit = 96 tests	96.19	1.00	9,619.00	Tulip Diagnostics Pvt. Ltd. - Verna, Goa	India
							Product Total	\$59,401.02	

Shipment H. Products for Air shipment CIP (Incoterms 2000) to DEPOT CENTRAL MEDICO-PHARMACEUTIQUE 8è CEPAC BUKAVU:

AIR SHIPMENT CIP (INCOTERMS 2000) TO DEPOT CENTRAL MEDICO-PHARMACEUTIQUE 8è CEPAC BUKAVU									
Item No.	Item Description	Total Qty	No. of Packs	Pack Size	Pack Price	Unit Price	Total Value USD	Manufacturer	Origin
3	Aluminium Hydroxide 120mg + Magnesium Trisilicate 250mg	60,000	60	1000 tablets	\$3.31	\$0.00	\$198.75	Fourrts	India
5	Amoxicillin 500mg	130,000	130	1000 capsules	27.88	0.03	3,623.75	CSPC Zhongnuo Pharma Workshop 204	China
10	Cotrimoxazole 480mg	351,000	351	1000 tablets	9.50	0.01	3,334.50	Guilin Pharma - Workshop 2	China
14	Doxycycline 100mg, as Hyclate	49,000	49	1000 tablets	10.33	0.01	506.32	Nanjing Baijingyu - General	China
23	Mebendazole, 100mg, Tab, 1000, Vrac	173,000	173	1000 tablets	3.75	0.00	648.75	Medopharm - Malur Plant	India
24	Methyldopa 250mg, coated	3,000	3	1000 tablets	40.00	0.04	120.00	Medicamen - Bhiwadi	India
25	Metronidazole 250mg	125,000	125	1000 tablets	5.45	0.01	681.13	Nanjing Baijingyu - General	China
29	Phenoxyethylpenicillin 250mg	63,000	63	1000 tablets	14.50	0.01	913.50	Medicamen - Bhiwadi	India
34	Ampicillin 1g, as Sodium	14,050	281	50 vials	5.95	0.12	1,671.95	Reyoung Pharmaceutical, workshop 305	China
37	Ciprofloxacin 2mg/ml, 100ml	200	200	1 bottle	0.36	0.36	72.00	Fresenius Kabi - Pune site	India
49	Insulin Soluble HM 40 IU/ml, 10ml	500	500	1 vial	3.41	3.41	1,706.25	Novo Nordisk, Bagsvaerd	Denmark
50	Insulin Isophane NPH HM 40 IU/ml, 10ml	500	500	1 vial	7.27	7.27	3,635.00	Novo Nordisk, Bagsvaerd	Denmark
51	Insulin Isophane NPH HM 100 IU/ml, 10ml	280	280	1 vial	6.49	6.49	1,816.67	Novo Nordisk, Bagsvaerd	Denmark
57	Oxytocin 10 IU/ml, 1ml	83,300	833	100 ampoules	6.02	0.06	5,014.66	Gland - Pally Plant	India
59	Pentazocine 30mg/ml, 1ml	1,500	150	10 ampoules	7.27	0.73	1,090.50	Fresenius Kabi - Bodene	South Africa
60	Phenobarbital Sodium 100mg/ml, 2ml	500	5	100 ampoules	36.79	0.37	183.93	Wholesaler in Europe	
95	Lopinavir 200mg + Ritonavir 50mg	22,200	185	120 tablets	42.17	0.35	7,801.21	Aurobindo - Unit-III, Block IV	India
96	Levonorgestrel 0.75mg	370	185	2 tablets	4.38	2.19	809.38	Cipla Verna Indl.	India

								Estate, Unit V-VIII	
100	Lamivudine 150mg + Zidovudine 300mg	1,980	33	60 tablets	10.62	0.18	350.62	Aurobindo - Unit-III, Block IV	India
103	Lamivudine 150mg + Zidovudine 300mg	8,220	137	60 tablets	10.63	0.18	1,455.63	Aurobindo - Unit-III, Block IV	India
106	Cotrimoxazole 240mg/5ml, 100ml	14,513	14513	1 bottle	0.39	0.39	5,680.39	Medicamen - Bhiwadi	India
108	Test kit, Syphilis, RPR, 250 tests	11,000	44	1 kit = 250 tests	17.19	0.07	756.25	Tulip Diagnostics Pvt. Ltd. - Verna, Goa	India
109	Test kit, Syphilis, TP-HA, 100 tests	1,100	11	1 kit = 100 tests	132.53	1.33	1,457.83	Tulip Diagnostics Pvt. Ltd. - Verna, Goa	India
110	Test kit, HIV 1+2 (Determine), 100 tests without chase buffer	11,000	110	1 kit = 100 tests	45.00	0.45	4,950.00	Inverness Medical Japan- Chiba plant	Japan
111	Test kit, HIV 1+2 (DoubleCheck Gold), 100 tests, Rapid test	400	4	1 kit = 100 tests	173.33	1.73	693.33	Inverness Medical Japan- Chiba plant	Japan
112	Test kit, HIV 1+2 (Uni-Gold), 20 tests Rapid test	220	11	1 kit = 20 tests	54.51	2.73	599.57	Trinity Biotech PLC	Ireland
113	Test kit, Hepatitis B (ELISA), 96 tests	9,696	101	1 kit = 96 tests	96.19	1.00	9,715.19	Tulip Diagnostics Pvt. Ltd. - Verna, Goa	India
					Product Total		\$59,487.06		

Shipment I. Products for Air shipment CIP (Incoterms 2000) to MSH, KINSHASA:

AIR SHIPMENT CIP (INCOTERMS 2000) TO MSH, KINSHASA									
Item No.	Item Description	Total Qty	No. of Packs	Pack Size	Pack Price	Unit Price	Total Value USD	Manufacturer	Origin
95	Lopinavir 200mg + Ritonavir 50mg	177,600	1480	120 tablets	\$42.17	\$0.35	\$62,409.68	Aurobindo - Unit-III, Block IV	India
100	Lamivudine 150mg + Zidovudine 300mg	16,020	\$ 267.00	60 tablets	10.62	0.18	2,836.87	Aurobindo - Unit-III, Block IV	India
103	Lamivudine 150mg + Zidovudine 300mg	65,820	1097	60 tablets	10.63	0.18	11,655.63	Aurobindo - Unit-III, Block IV	India
106	Cotrimoxazole 240mg/5ml, 100ml	116,100	116100	1 bottle	0.39	0.39	45,441.54	Medicamen - Bhiwadi	India
108	Test kit, Syphilis, RPR, 250 tests	88,120	352.48	1 kit = 250 tests	17.19	0.07	6,058.25	Tulip Diagnostics Pvt. Ltd. - Verna, Goa	India
109	Test kit, Syphilis, TP-HA, 100 tests	8,800	88	1 kit = 100 tests	132.53	1.33	11,662.65	Tulip Diagnostics Pvt. Ltd. - Verna, Goa	India
110	Test kit, HIV 1+2 (Determine), 100 tests without chase buffer	88,300	883	1 kit = 100 tests	45.00	0.45	39,735.00	InTec PRODUCTS, Xiamen	China
111	Test kit, HIV 1+2 (DoubleCheck Gold), 100 tests, Rapid test	3,500	35	1 kit = 100 tests	173.33	1.73	6,066.67	Inverness Medical Japan- Chiba plant	Japan
112	Test kit, HIV 1+2 (Uni-Gold), 20 tests Rapid test	3,500	175	1 kit = 20 tests	10.90	0.55	1,907.73	Trinity Biotech PLC	Ireland
113	Test kit, Hepatitis B (ELISA), 96 tests	77,088	803	1 kit = 96 tests	96.19	1.00	77,240.57	Human	Germany
							Product Total	\$265,014.59	

III. List of medicines and medical supplies found in Task Order 107 issued to IDA Foundation

Shipment A. Products for Surface Shipment CIP (Incoterms 2000) to CDR CEDIMEK KAMINA:

SURFACE SHIPMENT CIP (INCOTERMS 2000) TO CDR CEDIMEK KAMINA									
Item No.	Item Description	Total Qty	No. of Packs	Pack Size	Pack Price	Unit Price	Total Value USD	Manufacturer	Origin
1	Acetylsalicylic Acid , 500mg, Tab, 1000, Vrac	138,000	138	1000 TAB	\$3.25	\$0.00	\$448.50	Tianjin Huajin Pharm. Co. Ltd	CHINA
2	Acide Folique, 5mg, Tab, 1000, Vrac (Folic Acid)	15,000	15	1000 TAB	2.02	0.00	30.30	Medopharm Malur Factory	INDIA
7	Cloxacilline 250mg, caps, 1000, Vrac	30,000	30	1000 CAP	17.30	0.02	519.00	Medopharm Guduvanchery	INDIA
9	Cimétidine 200 mg, Ces, 1000, Vrac (Cimetidine)	10,000	20	500 TAB	3.28	0.01	65.60	Micro Labs Hosur	INDIA
11	Diazepam, 5mg, Tab, 1000, Vrac	15,000	15	1000 TAB	4.76	0.00	71.40	Meditab (for Cipla) at Daman	INDIA
13	Digoxine, 0.25mg, Tab, 100, Vrac (Digoxin)	980	35	28 TAB BL	2.09	0.07	73.15	Alpharma (Actavis)	UNITED KINGDOM
15	Enalapril ce 2,5mg, Tab, 1000, Vrac	10,000	100	100 TAB BL	0.68	0.01	68.00	Medopharm Malur Factory	INDIA
17	Erythromycine, 250mg, Tab, 1000, Vrac	10,000	10	1000 TAB	34.24	0.03	342.40	Medopharm Malur Factory	INDIA
18	Fer sulfate+Acide Folique, 200mg+0,25mg, Tab, 1000, Vrac (Ferrous Sulfate + Folic Acid)	633,000	633	1000 TAB	2.38	0.00	1506.54	Bio Nova Pharmaceuticals Pvt.	INDIA
19	Furosemide, 40mg, Tab, 1000, Vrac	47,000	47	1000 TAB	3.63	0.00	170.61	Medopharm	INDIA
20	Glibenclamide, 5mg, Tab, 1000, Vrac	10,000	10	1000 TAB	2.91	0.00	29.10	Micro Labs Hosur	INDIA
21	Griseofulvine, 500mg, Tab, 1000, Vrac (Griseofulvin)	4,000	4	1000 TAB	52.31	0.05	209.24	Micro Labs Hosur	INDIA
22	Hyoscine bulybromide, 10mg, Tab, 1000, Vrac	68,000	68	1000 TAB	23.18	0.02	1576.24	Medopharm Malur Factory	INDIA
26	Nystatine, 500.000 UI, Tab, 100, Vrac (Nystatin)	25,000	250	100 TAB	7.27	0.07	1817.50	Cipla Patalganga	INDIA
28	Phenobarbital, 100mg, Tab, 1000, Vrac	3,000	3	1000 TAB	8.17	0.01	24.51	Medopharm Malur Factory	INDIA

32	Zinc sulphate 20mg, Tab, 100, Vrac	103,700	1037	100 TAB BL	2.11	0.02	2188.07	KBI	GERMANY
35	Atropine, 1mg/ml, 1ml, Amp, Unité	1,500	15	100 AMP	8.20	0.08	123.00	Gland Pharma ltd Pally Factory	INDIA
36	Chloramphenicol sodium succinate, 1g, Vial, Unité	2,000	40	50 VLS	17.03	0.34	681.20	Macleods Pharm Ltd Daman Plant	INDIA
38	Dexamethasone sodium phosphate, 4mg/ml, 1ml, Amp, Unité	1,000	10	100 AMP	8.84	0.09	88.40	Gland Pharma ltd Pally Factory	INDIA
41	Digoxin 250mcg/ml, 2ml, Amp, Unité	500	5	100 AMP	8.71	0.09	43.55	Gland Pharma ltd Pally Factory	INDIA
42	Eau pour injection, 10ml, Vial, Unité (Water for Injection)	79,250	1585	50 AMP	1.71	0.06	2710.35	Marck Biosciences Ltd.	INDIA
44	Epinéphrine (Adrenaline), 1mg/ml, 1ml, Amp, Unité	400	4	100 AMP	47.13	0.47	188.52	Laboratoire Renaudin	FRANCE
45	Furosemide, 10mg/ml, 2ml, Amp, Unité	3,000	30	100 AMP	6.97	0.07	209.10	Gland Pharma ltd Pally Factory	INDIA
46	Gentamycin, 40mg/ml, 2ml, Amp, Unité	15,000	150	100 AMP	8.71	0.09	1306.50	Gland Pharma ltd Pally Factory	INDIA
47	Hydrocortisone 100mg (as sodium succinate) inj	8,550	171	50 VLS	19.00	0.38	3249.00	Macleods Pharm Ltd Daman Plant	INDIA
52	Ketamine, 50mg/ml, 10ml, Vial, Unité	525	21	25 VLS	19.63	0.79	412.23	Rotexmedica Gmbh	GERMANY
53	Lidocaïne chlorhydrate, 2%, 20 ml, Vial, Unité (Magnesium Sulfate)	1,040	104	10 VLS	9.13	0.91	949.52	Gland Pharma ltd Pally Factory	INDIA
54	Lidocaïne chlorhydrate+dextrose, 5%+7,5%/2 ml, Amp, Unité	200	2	100 AMP	6.96	0.07	13.92	Gland Pharma ltd Pally Factory	INDIA
55	Métoclopramide chlorhydrate, 5mg/ml, 2ml, Amp, Unité	3,000	30	100 AMP	6.82	0.07	204.60	Gland Pharma ltd Pally Factory	INDIA
58	Penicillin Benzathine, 2,4MUI, Vial, Unité	40,650	813	50 VLS	8.26	0.17	6715.38	NCPC North Best Co Ltd	CHINA
62	Salbutamol, 0,5mg/ml, 1ml, Amp, Unité	1,500	15	100 AMP	6.80	0.07	102.00	Gland Pharma ltd Pally Factory	INDIA
63	Sulfate de Magnésium, 500mg, 10ml, Amp, Unité Magnesium Sulfate	200	20	10 VLS	8.66	0.87	173.20	Gland Pharma ltd Pally Factory	INDIA
66	Dichloroisocyanurate de sodium (Na DCC) 1.67(ecq. 1g	45,000	225	200 TAB	9.38	0.05	2110.50	Medentech Ltd.	IRELAND

	CI)									
71	Chlorure de sodium, 0.9%, 500ml, Perfusion, Unité (Sodium Chloride)	4,500	225	20 BTL	7.01	0.35	1577.25	Albert David Ghaziabad	INDIA	
72	Dextrose (Glucose), 5%, 500ml, Perfusion, Unité	5,000	250	20 BTL	7.01	0.35	1752.50	Albert David Ghaziabad	INDIA	
73	Dextrose (Glucose), 50%, 50ml,	760	38	20 VLS	16.34	0.82	620.92	B Braun Melsungen	GERMANY	
74	Ringer lactate (Solution de Hartmann), 500ml, Perfusion, Unité	3,000	150	20 BTL	7.13	0.36	1069.50	Albert David Ghaziabad	INDIA	
79	Seringue, u.u., Luer, 5ml, avec aiguille G21	249,600	2496	100 PCE	4.35	0.04	10857.60	Becton Dickenson CTRA	SPAIN	
80	Seringues a insuline 40 UI	2,000	20	100 PCE	8.56	0.09	171.20	B Braun Melsungen	GERMANY	
81	Seringues a insuline 100 UI	500	5	100 PCE	8.56	0.09	42.80	B Braun Melsungen	GERMANY	
83	Coton hydrophile, rouleau, 500g	2,000	80	25 rol	49.72	1.99	3977.60	Taizhou Xinkang Medical	CHINA	
84	Sparadrap, Oxyde de Zinc, non perforé, 5cm*5m	8,500	2125	4 ROL	2.37	0.59	5036.25	Changzhou Hualian Health	CHINA	
87	Sonde vésicale, Foley, 2 voies, ballonnet, CH14, stérile, Unité	380	38	10 PCE	4.12	0.41	156.56	Uro Technologies	MALAYSIA	
88	Sonde vésicale, Foley, 2 voies, ballonnet, CH16, stérile, Unité	380	38	10 PCE	4.12	0.41	156.56	Uro Technologies	MALAYSIA	
90	Aiguille à Ailette (épicranienne), u.u., 21G (0.8*19mm), vert, Unité	1,500	15	100 PCE	5.87	0.06	88.05	Tianjin Hanaco Medical Co, Ltd	CHINA	
91	Aiguille à Ailette (épicranienne), u.u., 23G (0.6*19mm), ..., Unité	3,000	30	100 PCE	5.87	0.06	176.10	Tianjin Hanaco Medical Co, Ltd	CHINA	
92	Gants chirurgicaux, latex, u.u., non poudrés, stériles, Taille 7½, Paire	18,000	45	8X50 PR	85.88	0.21	3864.60	H.B.M. USA Co., Inc.	CHINA	
93	Gants d'examen, latex, u.u., non poudrés, non stériles, Taille Moyenne (7½), 100	72,000	36	20 x100PCE	88.37	0.04	3181.32	TG Medical SDN BHD	MALAYSIA	
				Product Total			\$61,149.94			

Shipment B. Products for SURFACE shipment CIP (Incoterms 2000) to DEPOT PHARMACEUTIQUE CDMEK KOLWEZI:

SURFACE SHIPMENT CIP (INCOTERMS 2000) TO DEPOT PHARMACEUTIQUE CDMEK KOLWEZI									
Item No.	Item Description	Total Qty	No. of Packs	Pack Size	Pack Price	Unit Price	Total Value USD	Manufacturer	Origin
1	Acetylsalicylic Acid , 500mg, Tab, 1000, Vrac	138,000	138	1000 TAB	\$3.25	\$0.00	\$448.50	Tianjin Huajin Pharm. Co.Ltd	CHINA
2	Acide Folique, 5mg, Tab, 1000, Vrac (Folic Acid)	15,000	15	1000 TAB	2.02	0.00	30.30	Medopharm Malur Factory	INDIA
7	Cloxacilline 250mg, caps, 1000, Vrac	30,000	30	1000 CAP	17.30	0.02	519.00	Medopharm Guduvanchery	INDIA
9	Cimétidine 200 mg, Ces, 1000, Vrac (Cimetidine)	10,000	20	500 TAB	3.28	0.01	65.60	Micro Labs Hosur	INDIA
11	Diazepam, 5mg, Tab, 1000, Vrac	15,000	15	1000 TAB	4.76	0.00	71.40	Meditab (for Cipla) at Daman	INDIA
13	Digoxine, 0.25mg, Tab, 100, Vrac (Digoxin)	1,008	36	28 TAB BL	2.09	0.07	75.24	Alpharma (Actavis)	UNITED KINGDOM
15	Enalapril ce 2,5mg, Tab, 1000, Vrac	10,000	100	100 TAB BL	0.68	0.01	68.00	Medopharm Malur Factory	INDIA
17	Erythromycine, 250mg, Tab, 1000, Vrac	10,000	10	1000 TAB	34.24	0.03	342.40	Medopharm Malur Factory	INDIA
18	Fer sulfate+Acide Folique, 200mg+0,25mg, Tab, 1000, Vrac (Ferrous Sulfate + Folic Acid)	633,000	633	1000 TAB	2.38	0.00	1506.54	Bio Nova Pharmaceuticals Pvt.	INDIA
19	Furosemide, 40mg, Tab, 1000, Vrac	47,000	47	1000 TAB	3.63	0.00	170.61	Medopharm	INDIA
20	Glibenclamide, 5mg, Tab, 1000, Vrac	10,000	10	1000 TAB	2.91	0.00	29.10	Micro Labs Hosur	INDIA
21	Griseofulvine, 500mg, Tab, 1000, Vrac (Griseofulvin)	4,000	4	1000 TAB	52.31	0.05	209.24	Micro Labs Hosur	INDIA
22	Hyoscine bulybromide, 10mg, Tab, 1000, Vrac	68,000	68	1000 TAB	23.18	0.02	1576.24	Medopharm Malur Factory	INDIA
26	Nystatine, 500.000 UI, Tab, 100, Vrac (Nystatin)	25,000	250	100 TAB	7.27	0.07	1817.50	Cipla Patalganga	INDIA
28	Phenobarbital, 100mg, Tab, 1000, Vrac	3,000	3	1000 TAB	8.17	0.01	24.51	Medopharm Malur Factory	INDIA
32	Zinc sulphate 20mg, Tab, 100, Vrac	103,700	1037	100 TAB BL	2.11	0.02	2188.07	KBI	GERMANY

35	Atropine, 1mg/ml, 1ml, Amp, Unité	1,500	15	100 AMP	8.20	0.08	123.00	Gland Pharma ltd Pally Factory	INDIA
36	Chloramphenicol sodium succinate, 1g, Vial, Unité	2,000	40	50 VLS	17.03	0.34	681.20	Macleods Pharm Ltd Daman Plant	INDIA
38	Dexamethasone sodium phosphate, 4mg/ml, 1ml, Amp, Unité	1,000	10	100 AMP	8.84	0.09	88.40	Gland Pharma ltd Pally Factory	INDIA
41	Digoxin 250mcg/ml, 2ml, Amp, Unité	500	5	100 AMP	8.71	0.09	43.55	Gland Pharma ltd Pally Factory	INDIA
42	Eau pour injection, 10ml, Vial, Unité (Water for Injection)	79,250	1585	50 AMP	1.71	0.06	2710.35	Marck Biosciences Ltd.	INDIA
44	Epinephrine (Adrenaline), 1mg/ml, 1ml, Amp, Unité	400	4	100 AMP	47.13	0.47	188.52	Laboratoire Renaudin	FRANCE
45	Furosemide, 10mg/ml, 2ml, Amp, Unité	3,000	30	100 AMP	6.97	0.07	209.10	Gland Pharma ltd Pally Factory	INDIA
46	Gentamycin, 40mg/ml, 2ml, Amp, Unité	15,000	150	100 AMP	8.71	0.09	1306.50	Gland Pharma ltd Pally Factory	INDIA
47	Hydrocortisone 100mg (as sodium succinate) inj	8,550	171	50 VLS	19.00	0.38	3249.00	Macleods Pharm Ltd Daman Plant	INDIA
52	Ketamine, 50mg/ml, 10ml, Vial, Unité	525	21	25 VLS	19.63	0.79	412.23	Rotexmedica Gmbh	GERMANY
53	Lidocaine chlorhydrate, 2%, 20 ml, Vial, Unité (Magnesium Sulfate)	1,040	104	10 VLS	9.13	0.91	949.52	Gland Pharma ltd Pally Factory	INDIA
54	Lidocaine chlorhydrate+dextrose, 5%+7,5%/2 ml, Amp, Unité	200	2	100 AMP	6.96	0.07	13.92	Gland Pharma ltd Pally Factory	INDIA
55	Métoclopramide chlorhydrate, 5mg/ml, 2ml, Amp, Unité	3,000	30	100 AMP	6.82	0.07	204.60	Gland Pharma ltd Pally Factory	INDIA
58	Penicillin Benzathine, 2,4MUI, Vial, Unité	40,650	813	50 VLS	8.26	0.17	6715.38	NCPC North Best Co Ltd	CHINA
62	Salbutamol, 0,5mg/ml, 1ml, Amp, Unité	1,500	15	100 AMP	6.80	0.07	102.00	Gland Pharma ltd Pally Factory	INDIA
63	Sulfate de Magnésium, 500mg, 10ml, Amp, Unité Magnesium Sulfate	200	20	10 VLS	8.66	0.87	173.20	Gland Pharma ltd Pally Factory	INDIA
66	Dichloroisocyanurate de sodium (Na DCC) 1.67(eq. 1g Cl)	45,000	225	200 TAB	9.38	0.05	2110.50	Medentech Ltd.	IRELAND

71	Chlorure de sodium, 0.9%, 500ml, Perfusion, Unité (Sodium Chloride)	4,500	225	20 BTL	7.01	0.35	1577.25	Albert David Ghaziabad	INDIA
72	Dextrose (Glucose), 5%, 500ml, Perfusion, Unité	5,000	250	20 BTL	7.01	0.35	1752.50	Albert David Ghaziabad	INDIA
73	Dextrose (Glucose), 50%, 50ml,	760	38	20 VLS	16.34	0.82	620.92	B Braun Melsungen	GERMANY
74	Ringer lactate (Solution de Hartmann), 500ml, Perfusion, Unité	3,000	150	20 BTL	7.13	0.36	1069.50	Albert David Ghaziabad	INDIA
79	Seringue, u.u., Luer, 5ml, avec aiguille G21	249,700	2497	100 PCE	4.35	0.04	10861.95	Becton Dickenson CTRA	SPAIN
80	Seringues a insuline 40 UI	2,100	21	100 PCE	8.56	0.09	179.76	B Braun Melsungen	GERMANY
81	Seringues a insuline 100 UI	500	5	100 PCE	8.56	0.09	42.80	B Braun Melsungen	GERMANY
83	Coton hydrophile, rouleau, 500g	2,000	80	25 rol	49.72	1.99	3977.60	Taizhou Xinkang Medical	CHINA
84	Sparadrap, Oxyde de Zinc, non perforé, 5cm*5m	8,500	2125	4 ROL	2.37	0.59	5036.25	Changzhou Hualian Health	CHINA
87	Sonde vésicale, Foley, 2 voies, ballonnet, CH14, stérile, Unité	380	38	10 PCE	4.12	0.41	156.56	Uro Technologies	MALAYSIA
88	Sonde vésicale, Foley, 2 voies, ballonnet, CH16, stérile, Unité	380	38	10 PCE	4.12	0.41	156.56	Uro Technologies	MALAYSIA
90	Aiguille à Ailette (épicranienne), u.u., 21G (0.8*19mm), vert, Unité	1,500	15	100 PCE	5.87	0.06	88.05	Tianjin Hanaco Medical Co, Ltd	CHINA
91	Aiguille à Ailette (épicranienne), u.u., 23G (0.6*19mm), ..., Unité	3,000	30	100 PCE	5.87	0.06	176.10	Tianjin Hanaco Medical Co, Ltd	CHINA
92	Gants chirurgicaux, latex, u.u., non poudrés, stériles, Taille 7½, Paire	18,000	45	8X50 PR	85.88	0.21	3864.60	H.B.M. USA Co., Inc.	CHINA
93	Gants d'examen, latex, u.u., non poudrés, non stériles, Taille Moyenne (7½), 100	70,000	35	20 x100PCE	88.37	0.04	3092.95	TG Medical SDN BHD	MALAYSIA
							Product Total	\$61,076.57	

Shipment C. Products for SURFACE shipment CIP (Incoterms 2000) to CDR CADIMEK KANANGA:

SURFACE SHIPMENT CIP (INCOTERMS 2000) TO CDR CADIMEK KANANGA									
Item No.	Item Description	Total Qty	No. of Packs	Pack Size	Pack Price	Unit Price	Total Value USD	Manufacturer	Origin
1	Acetylsalicylic Acid , 500mg, Tab, 1000, Vrac	138,000	138	1000 TAB	\$3.25	\$0.00	\$448.50	Tianjin Huajin Pharm. Co.Ltd	CHINA
2	Acide Folique, 5mg, Tab, 1000, Vrac (Folic Acid)	15,000	15	1000 TAB	2.02	0.00	30.30	Medopharm Malur Factory	INDIA
7	Cloxacilline 250mg, caps, 1000, Vrac	30,000	30	1000 CAP	17.30	0.02	519.00	Medopharm Guduvanchery	INDIA
9	Cimétidine 200 mg, Ces, 1000, Vrac (Cimetidine)	10,000	20	500 TAB	3.28	0.01	65.60	Micro Labs Hosur	INDIA
11	Diazepam, 5mg, Tab, 1000, Vrac	15,000	15	1000 TAB	4.76	0.00	71.40	Meditab (for Cipla) at Daman	INDIA
13	Digoxine, 0.25mg, Tab, 100, Vrac (Digoxin)	1,008	36	28 TAB BL	2.09	0.07	75.24	Alpharma (Actavis)	UNITED KINGDOM
15	Enalapril ce 2,5mg, Tab, 1000, Vrac	10,000	100	100 TAB BL	0.68	0.01	68.00	Medopharm Malur Factory	INDIA
17	Erythromycine, 250mg, Tab, 1000, Vrac	10,000	10	1000 TAB	34.24	0.03	342.40	Medopharm Malur Factory	INDIA
18	Fer sulfate+Acide Folique, 200mg+0,25mg, Tab, 1000, Vrac (Ferrous Sulfate + Folic Acid)	633,000	633	1000 TAB	2.38	0.00	1506.54	Bio Nova Pharmaceuticals Pvt.	INDIA
19	Furoseamide, 40mg, Tab, 1000, Vrac	47,000	47	1000 TAB	3.63	0.00	170.61	Medopharm	INDIA
20	Glibenclamide, 5mg, Tab, 1000, Vrac	10,000	10	1000 TAB	2.91	0.00	29.10	Micro Labs Hosur	INDIA
21	Griseofulvine, 500mg, Tab, 1000, Vrac (Griseofulvin)	4,000	4	1000 TAB	52.31	0.05	209.24	Micro Labs Hosur	INDIA
22	Hyoscine bulybromide, 10mg, Tab, 1000, Vrac	69,000	69	1000 TAB	23.18	0.02	1599.42	Medopharm Malur Factory	INDIA
26	Nystatine, 500.000 UI, Tab, 100, Vrac (Nystatin)	25,000	250	100 TAB	7.27	0.07	1817.50	Cipla Patalganga	INDIA
28	Phenobarbital, 100mg, Tab, 1000, Vrac	3,000	3	1000 TAB	8.17	0.01	24.51	Medopharm Malur Factory	INDIA
32	Zinc sulphate 20mg, Tab, 100, Vrac	103,700	1037	100 TAB BL	2.11	0.02	2188.07	KBI	GERMANY

35	Atropine, 1mg/ml, 1ml, Amp, Unité	1,500	15	100 AMP	8.20	0.08	123.00	Gland Pharma ltd Pally Factory	INDIA
36	Chloramphenicol sodium succinate, 1g, Vial, Unité	2,000	40	50 VLS	17.03	0.34	681.20	Macleods Pharm Ltd Daman Plant	INDIA
38	Dexamethasone sodium phosphate, 4mg/ml, 1ml, Amp, Unité	1,000	10	100 AMP	8.84	0.09	88.40	Gland Pharma ltd Pally Factory	INDIA
41	Digoxin 250mcg/ml, 2ml, Amp, Unité	500	5	100 AMP	8.71	0.09	43.55	Gland Pharma ltd Pally Factory	INDIA
42	Eau pour injection, 10ml, Vial, Unité (Water for Injection)	79,250	1585	50 AMP	1.71	0.06	2710.35	Marck Biosciences Ltd.	INDIA
44	Epinéphrine (Adrenaline), 1mg/ml, 1ml, Amp, Unité	400	4	100 AMP	47.13	0.47	188.52	Laboratoire Renaudin	FRANCE
45	Furosemide, 10mg/ml, 2ml, Amp, Unité	3,000	30	100 AMP	6.97	0.07	209.10	Gland Pharma ltd Pally Factory	INDIA
46	Gentamycin, 40mg/ml, 2ml, Amp, Unité	15,000	150	100 AMP	8.71	0.09	1306.50	Gland Pharma ltd Pally Factory	INDIA
47	Hydrocortisone 100mg (as sodium succinate) inj	8,550	171	50 VLS	19.00	0.38	3249.00	Macleods Pharm Ltd Daman Plant	INDIA
52	Ketamine, 50mg/ml, 10ml, Vial, Unité	525	21	25 VLS	19.63	0.79	412.23	Rotexmedica Gmbh	GERMANY
53	Lidocaïne chlorhydrate, 2%, 20 ml, Vial, Unité (Magnesium Sulfate)	1,040	104	10 VLS	9.13	0.91	949.52	Gland Pharma ltd Pally Factory	INDIA
54	Lidocaïne chlorhydrate+dextrose, 5%+7,5%/2 ml, Amp, Unité	300	3	100 AMP	6.96	0.07	20.88	Gland Pharma ltd Pally Factory	INDIA
55	Métoclopramide chlorhydrate, 5mg/ml, 2ml, Amp, Unité	3,000	30	100 AMP	6.82	0.07	204.60	Gland Pharma ltd Pally Factory	INDIA
58	Penicillin Benzathine, 2,4MUI, Vial, Unité	40,650	813	50 VLS	8.26	0.17	6715.38	NCPC North Best Co Ltd	CHINA
62	Salbutamol, 0,5mg/ml, 1ml, Amp, Unité	1,500	15	100 AMP	6.80	0.07	102.00	Gland Pharma ltd Pally Factory	INDIA
63	Sulfate de Magnésium, 500mg, 10ml, Amp, Unité Magnesium Sulfate	200	20	10 VLS	8.66	0.87	173.20	Gland Pharma ltd Pally Factory	INDIA
66	Dichloroisocyanurate de sodium (Na DCC) 1.67(eq. 1g Cl)	45,000	225	200 TAB	9.38	0.05	2110.50	Medentech Ltd.	IRELAND

71	Chlorure de sodium, 0.9%, 500ml, Perfusion, Unité (Sodium Chloride)	4,500	225	20 BTL	7.01	0.35	1577.25	Albert David Ghaziabad	INDIA
72	Dextrose (Glucose), 5%, 500ml, Perfusion, Unité	5,000	250	20 BTL	7.01	0.35	1752.50	Albert David Ghaziabad	INDIA
73	Dextrose (Glucose), 50%, 50ml,	760	38	20 VLS	16.34	0.82	620.92	B Braun Melsungen	GERMANY
74	Ringer lactate (Solution de Hartmann), 500ml, Perfusion, Unité	3,000	150	20 BTL	7.13	0.36	1069.50	Albert David Ghaziabad	INDIA
79	Seringue, u.u., Luer, 5ml, avec aiguille G21	249,700	2497	100 PCE	4.35	0.04	10861.95	Becton Dickenson CTRA	SPAIN
80	Seringues a insuline 40 UI	2,100	21	100 PCE	8.56	0.09	179.76	B Braun Melsungen	GERMANY
81	Seringues a insuline 100 UI	500	5	100 PCE	8.56	0.09	42.80	B Braun Melsungen	GERMANY
83	Coton hydrophile, rouleau, 500g	2,000	80	25 rol	49.72	1.99	3977.60	Taizhou Xinkang Medical	CHINA
84	Sparadrap, Oxyde de Zinc, non perforé, 5cm*5m	8,500	2125	4 ROL	2.37	0.59	5036.25	Changzhou Hualian Health	CHINA
87	Sonde vésicale, Foley, 2 voies, ballonnet, CH14, stérile, Unité	380	38	10 PCE	4.12	0.41	156.56	Uro Technologies	MALAYSIA
88	Sonde vésicale, Foley, 2 voies, ballonnet, CH16, stérile, Unité	380	38	10 PCE	4.12	0.41	156.56	Uro Technologies	MALAYSIA
90	Aiguille à Ailette (épicranienne), u.u., 21G (0.8*19mm), vert, Unité	1,500	15	100 PCE	5.87	0.06	88.05	Tianjin Hanaco Medical Co, Ltd	CHINA
91	Aiguille à Ailette (épicranienne), u.u., 23G (0.6*19mm), ..., Unité	3,000	30	100 PCE	5.87	0.06	176.10	Tianjin Hanaco Medical Co, Ltd	CHINA
92	Gants chirurgicaux, latex, u.u., non poudrés, stériles, Taille 7½, Paire	18,000	45	8X50 PR	85.88	0.21	3864.60	H.B.M. USA Co., Inc.	CHINA
93	Gants d'examen, latex, u.u., non poudrés, non stériles, Taille Moyenne (7½), 100	70,000	35	20 x100PCE	88.37	0.04	3092.95	TG Medical SDN BHD	MALAYSIA
							Product Total	\$61,106.71	

Shipment D. Products for SURFACE shipment CIP (Incoterms 2000) to CDR CADMEKO MBUJIMAYI:

SURFACE SHIPMENT CIP (INCOTERMS 2000) TO CDR CADMEKO MBUJIMAYI									
Item No.	Item Description	Total Qty	No. of Packs	Pack Size	Pack Price	Unit Price	Total Value USD	Manufacturer	Origin
1	Acetylsalicylic Acid , 500mg, Tab, 1000, Vrac	138,000	138	1000 TAB	\$3.25	\$0.00	\$448.50	Tianjin Huajin Pharm. Co.Ltd	CHINA
2	Acide Folique, 5mg, Tab, 1000, Vrac (Folic Acid)	15,000	15	1000 TAB	2.02	0.00	30.30	Medopharm Malur Factory	INDIA
7	Cloxacilline 250mg, caps, 1000, Vrac	30,000	30	1000 CAP	17.30	0.02	519.00	Medopharm Guduvanchery	INDIA
9	Cimétidine 200 mg, Ces, 1000, Vrac (Cimetidine)	10,000	20	500 TAB	3.28	0.01	65.60	Micro Labs Hosur	INDIA
11	Diazepam, 5mg, Tab, 1000, Vrac	15,000	15	1000 TAB	4.76	0.00	71.40	Meditab (for Cipla) at Daman	INDIA
13	Digoxine, 0.25mg, Tab, 100, Vrac (Digoxin)	1,008	36	28 TAB BL	2.09	0.07	75.24	Alpharma (Actavis)	UNITED KINGDOM
15	Enalapril ce 2,5mg, Tab, 1000, Vrac	10,000	100	100 TAB BL	0.68	0.01	68.00	Medopharm Malur Factory	INDIA
17	Erythromycine, 250mg, Tab, 1000, Vrac	10,000	10	1000 TAB	34.24	0.03	342.40	Medopharm Malur Factory	INDIA
18	Fer sulfate+Acide Folique, 200mg+0,25mg, Tab, 1000, Vrac (Ferrous Sulfate + Folic Acid)	632,000	632	1000 TAB	2.38	0.00	1504.16	Bio Nova Pharmaceuticals Pvt.	INDIA
19	Furosemide, 40mg, Tab, 1000, Vrac	46,000	46	1000 TAB	3.63	0.00	166.98	Medopharm	INDIA
20	Glibenclamide, 5mg, Tab, 1000, Vrac	10,000	10	1000 TAB	2.91	0.00	29.10	Micro Labs Hosur	INDIA
21	Griseofulvine, 500mg, Tab, 1000, Vrac (Griseofulvin)	4,000	4	1000 TAB	52.31	0.05	209.24	Micro Labs Hosur	INDIA
22	Hyoscine bulybromide, 10mg, Tab, 1000, Vrac	69,000	69	1000 TAB	23.18	0.02	1599.42	Medopharm Malur Factory	INDIA
26	Nystatine, 500.000 UI, Tab, 100, Vrac (Nystatin)	24,900	249	100 TAB	7.27	0.07	1810.23	Cipla Patalganga	INDIA
28	Phenobarbital, 100mg, Tab, 1000, Vrac	3,000	3	1000 TAB	8.17	0.01	24.51	Medopharm Malur Factory	INDIA
32	Zinc sulphate 20mg, Tab, 100, Vrac	103,600	1036	100 TAB BL	2.11	0.02	2185.96	KBI	GERMANY

35	Atropine, 1mg/ml, 1ml, Amp, Unité	1,500	15	100 AMP	8.20	0.08	123.00	Gland Pharma ltd Pally Factory	INDIA
36	Chloramphenicol sodium succinate, 1g, Vial, Unité	2,000	40	50 VLS	17.03	0.34	681.20	Macleods Pharm Ltd Daman Plant	INDIA
38	Dexamethasone sodium phosphate, 4mg/ml, 1ml, Amp, Unité	1,000	10	100 AMP	8.84	0.09	88.40	Gland Pharma ltd Pally Factory	INDIA
41	Digoxin 250mcg/ml, 2ml, Amp, Unité	500	5	100 AMP	8.71	0.09	43.55	Gland Pharma ltd Pally Factory	INDIA
42	Eau pour injection, 10ml, Vial, Unité (Water for Injection)	79,200	1584	50 AMP	1.71	0.06	2708.64	Marck Biosciences Ltd.	INDIA
44	Epinephrine (Adrenaline), 1mg/ml, 1ml, Amp, Unité	300	3	100 AMP	47.13	0.47	141.39	Laboratoire Renaudin	FRANCE
45	Furosemide, 10mg/ml, 2ml, Amp, Unité	3,000	30	100 AMP	6.97	0.07	209.10	Gland Pharma ltd Pally Factory	INDIA
46	Gentamycin, 40mg/ml, 2ml, Amp, Unité	15,000	150	100 AMP	8.71	0.09	1306.50	Gland Pharma ltd Pally Factory	INDIA
47	Hydrocortisone 100mg (as sodium succinate) inj	8,550	171	50 VLS	19.00	0.38	3249.00	Macleods Pharm Ltd Daman Plant	INDIA
52	Ketamine, 50mg/ml, 10ml, Vial, Unité	525	21	25 VLS	19.63	0.79	412.23	Rotexmedica Gmbh	GERMANY
53	Lidocaine chlorhydrate, 2%, 20 ml, Vial, Unité (Magnesium Sulfate)	1,030	103	10 VLS	9.13	0.91	940.39	Gland Pharma ltd Pally Factory	INDIA
54	Lidocaine chlorhydrate+dextrose, 5%+7.5%/2 ml, Amp, Unité	300	3	100 AMP	6.96	0.07	20.88	Gland Pharma ltd Pally Factory	INDIA
55	Métoclopramide chlorhydrate, 5mg/ml, 2ml, Amp, Unité	3,000	30	100 AMP	6.82	0.07	204.60	Gland Pharma ltd Pally Factory	INDIA
58	Penicillin Benzathine, 2,4MUI, Vial, Unité	40,600	812	50 VLS	8.26	0.17	6707.12	NCPC North Best Co Ltd	CHINA
62	Salbutamol, 0,5mg/ml, 1ml, Amp, Unité	1,500	15	100 AMP	6.80	0.07	102.00	Gland Pharma ltd Pally Factory	INDIA
63	Sulfate de Magnésium, 500mg, 10ml, Amp, Unité Magnesium Sulfate	200	20	10 VLS	8.66	0.87	173.20	Gland Pharma ltd Pally Factory	INDIA
66	Dichloroisocyanurate de sodium (Na DCC) 1.67(eq. 1g Cl)	45,000	225	200 TAB	9.38	0.05	2110.50	Medentech Ltd.	IRELAND

71	Chlorure de sodium, 0.9%, 500ml, Perfusion, Unité (Sodium Chloride)	4,500	225	20 BTL	7.01	0.35	1577.25	Albert David Ghaziabad	INDIA
72	Dextrose (Glucose), 5%, 500ml, Perfusion, Unité	5,000	250	20 BTL	7.01	0.35	1752.50	Albert David Ghaziabad	INDIA
73	Dextrose (Glucose), 50%, 50ml,	740	37	20 VLS	16.34	0.82	604.58	B Braun Melsungen	GERMANY
74	Ringer lactate (Solution de Hartmann), 500ml, Perfusion, Unité	3,000	150	20 BTL	7.13	0.36	1069.50	Albert David Ghaziabad	INDIA
79	Seringue, u.u., Luer, 5ml, avec aiguille G21	249,600	2496	100 PCE	4.35	0.04	10857.60	Becton Dickenson CTRA	SPAIN
80	Seringues a insuline 40 UI	2,000	20	100 PCE	8.56	0.09	171.20	B Braun Melsungen	GERMANY
81	Seringues a insuline 100 UI	500	5	100 PCE	8.56	0.09	42.80	B Braun Melsungen	GERMANY
83	Coton hydrophile, rouleau, 500g	2,000	80	25 rol	49.72	1.99	3977.60	Taizhou Xinkang Medical	CHINA
84	Sparadrap, Oxyde de Zinc, non perforé, 5cm*5m	8,500	2125	4 ROL	2.37	0.59	5036.25	Changzhou Hualian Health	CHINA
87	Sonde vésicale, Foley, 2 voies, ballonnet, CH14, stérile, Unité	370	37	10 PCE	4.12	0.41	152.44	Uro Technologies	MALAYSIA
88	Sonde vésicale, Foley, 2 voies, ballonnet, CH16, stérile, Unité	370	37	10 PCE	4.12	0.41	152.44	Uro Technologies	MALAYSIA
90	Aiguille à Ailette (épicranienne), u.u., 21G (0.8*19mm), vert, Unité	1,500	15	100 PCE	5.87	0.06	88.05	Tianjin Hanaco Medical Co, Ltd	CHINA
91	Aiguille à Ailette (épicranienne), u.u., 23G (0.6*19mm), ..., Unité	3,000	30	100 PCE	5.87	0.06	176.10	Tianjin Hanaco Medical Co, Ltd	CHINA
92	Gants chirurgicaux, latex, u.u., non poudrés, stériles, Taille 7½, Paire	17,600	44	8X50 PR	85.88	0.21	3778.72	H.B.M. USA Co., Inc.	CHINA
93	Gants d'examen, latex, u.u., non poudrés, non stériles, Taille Moyenne (7½), 100	72,000	36	20 x100PCE	88.37	0.04	3181.32	TG Medical SDN BHD	MALAYSIA
							Product Total	\$60,990.09	

Shipment E. Products for SURFACE shipment CIP (Incoterms 2000) to DEPOT PHARMACEUTIQUE FODESA:

SURFACE SHIPMENT CIP (INCOTERMS 2000) TO DEPOT PHARMACEUTIQUE FODESA									
Item No.	Item Description	Total Qty	No. of Packs	Pack Size	Pack Price	Unit Price	Total Value USD	Manufacturer	Origin
1	Acetylsalicylic Acid , 500mg, Tab, 1000, Vrac	138,000	138	1000 TAB	\$3.25	\$0.00	\$448.50	Tianjin Huajin Pharm. Co.Ltd	CHINA
2	Acide Folique, 5mg, Tab, 1000, Vrac (Folic Acid)	15,000	15	1000 TAB	2.02	0.00	30.30	Medopharm Malur Factory	INDIA
7	Cloxacilline 250mg, caps, 1000, Vrac	30,000	30	1000 CAP	17.30	0.02	519.00	Medopharm Guduvanchery	INDIA
9	Cimétidine 200 mg, Ces, 1000, Vrac (Cimetidine)	10,000	20	500 TAB	3.28	0.01	65.60	Micro Labs Hosur	INDIA
11	Diazepam, 5mg, Tab, 1000, Vrac	15,000	15	1000 TAB	4.76	0.00	71.40	Meditab (for Cipla) at Daman	INDIA
13	Digoxine, 0.25mg, Tab, 100, Vrac (Digoxin)	980	35	28 TAB BL	2.09	0.07	73.15	Alpharma (Actavis)	UNITED KINGDOM
15	Enalapril ce 2,5mg, Tab, 1000, Vrac	10,000	100	100 TAB BL	0.68	0.01	68.00	Medopharm Malur Factory	INDIA
17	Erythromycine, 250mg, Tab, 1000, Vrac	10,000	10	1000 TAB	34.24	0.03	342.40	Medopharm Malur Factory	INDIA
18	Fer sulfate+Acide Folique, 200mg+0,25mg, Tab, 1000, Vrac (Ferrous Sulfate + Folic Acid)	632,000	632	1000 TAB	2.38	0.00	1504.16	Bio Nova Pharmaceuticals Pvt.	INDIA
19	Furosemide, 40mg, Tab, 1000, Vrac	46,000	46	1000 TAB	3.63	0.00	166.98	Medopharm	INDIA
20	Glibenclamide, 5mg, Tab, 1000, Vrac	10,000	10	1000 TAB	2.91	0.00	29.10	Micro Labs Hosur	INDIA
21	Griseofulvine, 500mg, Tab, 1000, Vrac (Griseofulvin)	5,000	5	1000 TAB	52.31	0.05	261.55	Micro Labs Hosur	INDIA
22	Hyoscine bulybromide, 10mg, Tab, 1000, Vrac	69,000	69	1000 TAB	23.18	0.02	1599.42	Medopharm Malur Factory	INDIA
26	Nystatine, 500.000 UI, Tab, 100, Vrac (Nystatin)	24,900	249	100 TAB	7.27	0.07	1810.23	Cipla Patalganga	INDIA
28	Phenobarbital, 100mg, Tab, 1000, Vrac	3,000	3	1000 TAB	8.17	0.01	24.51	Medopharm Malur Factory	INDIA
32	Zinc sulphate 20mg, Tab, 100, Vrac	103,700	1037	100 TAB BL	2.11	0.02	2188.07	KBI	GERMANY

35	Atropine, 1mg/ml, 1ml, Amp, Unité	1,500	15	100 AMP	8.20	0.08	123.00	Gland Pharma ltd Pally Factory	INDIA
36	Chloramphenicol sodium succinate, 1g, Vial, Unité	2,000	40	50 VLS	17.03	0.34	681.20	Macleods Pharm Ltd Daman Plant	INDIA
38	Dexamethasone sodium phosphate, 4mg/ml, 1ml, Amp, Unité	1,000	10	100 AMP	8.84	0.09	88.40	Gland Pharma ltd Pally Factory	INDIA
41	Digoxin 250mcg/ml, 2ml, Amp, Unité	500	5	100 AMP	8.71	0.09	43.55	Gland Pharma ltd Pally Factory	INDIA
42	Eau pour injection, 10ml, Vial, Unité (Water for Injection)	79,200	1584	50 AMP	1.71	0.06	2708.64	Marck Biosciences Ltd.	INDIA
44	Epinephrine (Adrenaline), 1mg/ml, 1ml, Amp, Unité	300	3	100 AMP	47.13	0.47	141.39	Laboratoire Renaudin	FRANCE
45	Furosemide, 10mg/ml, 2ml, Amp, Unité	3,000	30	100 AMP	6.97	0.07	209.10	Gland Pharma ltd Pally Factory	INDIA
46	Gentamycin, 40mg/ml, 2ml, Amp, Unité	15,000	150	100 AMP	8.71	0.09	1306.50	Gland Pharma ltd Pally Factory	INDIA
47	Hydrocortisone 100mg (as sodium succinate) inj	8,550	171	50 VLS	19.00	0.38	3249.00	Macleods Pharm Ltd Daman Plant	INDIA
52	Ketamine, 50mg/ml, 10ml, Vial, Unité	525	21	25 VLS	19.63	0.79	412.23	Rotexmedica Gmbh	GERMANY
53	Lidocaïne chlorhydrate, 2%, 20 ml, Vial, Unité (Magnesium Sulfate)	1,030	103	10 VLS	9.13	0.91	940.39	Gland Pharma ltd Pally Factory	INDIA
54	Lidocaïne chlorhydrate+dextrose, 5%+7,5%/2 ml, Amp, Unité	300	3	100 AMP	6.96	0.07	20.88	Gland Pharma ltd Pally Factory	INDIA
55	Métoclopramide chlorhydrate, 5mg/ml, 2ml, Amp, Unité	3,000	30	100 AMP	6.82	0.07	204.60	Gland Pharma ltd Pally Factory	INDIA
58	Penicillin Benzathine, 2,4MUI, Vial, Unité	40,600	812	50 VLS	8.26	0.17	6707.12	NCPC North Best Co Ltd	CHINA
62	Salbutamol, 0,5mg/ml, 1ml, Amp, Unité	1,500	15	100 AMP	6.80	0.07	102.00	Gland Pharma ltd Pally Factory	INDIA
63	Sulfate de Magnésium, 500mg, 10ml, Amp, Unité Magnesium Sulfate	200	20	10 VLS	8.66	0.87	173.20	Gland Pharma ltd Pally Factory	INDIA
66	Dichloroisocyanurate de sodium (Na DCC) 1.67(eq. 1g Cl)	45,000	225	200 TAB	9.38	0.05	2110.50	Medentech Ltd.	IRELAND

71	Chlorure de sodium, 0.9%, 500ml, Perfusion, Unité (Sodium Chloride)	4,500	225	20 BTL	7.01	0.35	1577.25	Albert David Ghaziabad	INDIA
72	Dextrose (Glucose), 5%, 500ml, Perfusion, Unité	5,000	250	20 BTL	7.01	0.35	1752.50	Albert David Ghaziabad	INDIA
73	Dextrose (Glucose), 50%, 50ml,	740	37	20 VLS	16.34	0.82	604.58	B Braun Melsungen	GERMANY
74	Ringer lactate (Solution de Hartmann), 500ml, Perfusion, Unité	3,000	150	20 BTL	7.13	0.36	1069.50	Albert David Ghaziabad	INDIA
79	Seringue, u.u., Luer, 5ml, avec aiguille G21	249,600	2496	100 PCE	4.35	0.04	10857.60	Becton Dickenson CTRA	SPAIN
80	Seringues a insuline 40 UI	2,000	20	100 PCE	8.56	0.09	171.20	B Braun Melsungen	GERMANY
81	Seringues a insuline 100 UI	500	5	100 PCE	8.56	0.09	42.80	B Braun Melsungen	GERMANY
83	Coton hydrophile, rouleau, 500g	2,000	80	25 rol	49.72	1.99	3977.60	Taizhou Xinkang Medical	CHINA
84	Sparadrap, Oxyde de Zinc, non perforé, 5cm*5m	8,500	2125	4 ROL	2.37	0.59	5036.25	Changzhou Hualian Health	CHINA
87	Sonde vésicale, Foley, 2 voies, ballonnet, CH14, stérile, Unité	370	37	10 PCE	4.12	0.41	152.44	Uro Technologies	MALAYSIA
88	Sonde vésicale, Foley, 2 voies, ballonnet, CH16, stérile, Unité	370	37	10 PCE	4.12	0.41	152.44	Uro Technologies	MALAYSIA
90	Aiguille à Ailette (épicranienne), u.u., 21G (0.8*19mm), vert, Unité	1,500	15	100 PCE	5.87	0.06	88.05	Tianjin Hanaco Medical Co, Ltd	CHINA
91	Aiguille à Ailette (épicranienne), u.u., 23G (0.6*19mm), ..., Unité	3,000	30	100 PCE	5.87	0.06	176.10	Tianjin Hanaco Medical Co, Ltd	CHINA
92	Gants chirurgicaux, latex, u.u., non poudrés, stériles, Taille 7½, Paire	17,600	44	8X50 PR	85.88	0.21	3778.72	H.B.M. USA Co., Inc.	CHINA
93	Gants d'examen, latex, u.u., non poudrés, non stériles, Taille Moyenne (7½), 100	70,000	35	20 x100PCE	88.37	0.04	3092.95	TG Medical SDN BHD	MALAYSIA
							Product Total	\$60,954.05	

Shipment F. Products for SURFACE shipment CIP (Incoterms 2000) to APAMESK ASBL:

SURFACE SHIPMENT CIP (INCOTERMS 2000) TO APAMESK ASBL									
Item No.	Item Description	Total Qty	No. of Packs	Pack Size	Pack Price	Unit Price	Total Value USD	Manufacturer	Origin
1	Acetylsalicylic Acid , 500mg, Tab, 1000, Vrac	138,000	138	1000 TAB	\$3.25	\$0.00	\$448.50	Tianjin Huajin Pharm. Co.Ltd	CHINA
2	Acide Folique, 5mg, Tab, 1000, Vrac (Folic Acid)	15,000	15	1000 TAB	2.02	0.00	30.30	Medopharm Malur Factory	INDIA
7	Cloxacilline 250mg, caps, 1000, Vrac	30,000	30	1000 CAP	17.30	0.02	519.00	Medopharm Guduvanchery	INDIA
9	Cimétidine 200 mg, Ces, 1000, Vrac (Cimetidine)	10,000	20	500 TAB	3.28	0.01	65.60	Micro Labs Hosur	INDIA
11	Diazepam, 5mg, Tab, 1000, Vrac	15,000	15	1000 TAB	4.76	0.00	71.40	Meditab (for Cipla) at Daman	INDIA
13	Digoxine, 0.25mg, Tab, 100, Vrac (Digoxin)	1,008	36	28 TAB BL	2.09	0.07	75.24	Alpharma (Actavis)	UNITED KINGDOM
15	Enalapril ce 2,5mg, Tab, 1000, Vrac	10,000	100	100 TAB BL	0.68	0.01	68.00	Medopharm Malur Factory	INDIA
17	Erythromycine, 250mg, Tab, 1000, Vrac	10,000	10	1000 TAB	34.24	0.03	342.40	Medopharm Malur Factory	INDIA
18	Fer sulfate+Acide Folique, 200mg+0,25mg, Tab, 1000, Vrac (Ferrous Sulfate + Folic Acid)	632,000	632	1000 TAB	2.38	0.00	1504.16	Bio Nova Pharmaceuticals Pvt.	INDIA
19	Furosemide, 40mg, Tab, 1000, Vrac	46,000	46	1000 TAB	3.63	0.00	166.98	Medopharm	INDIA
20	Glibenclamide, 5mg, Tab, 1000, Vrac	10,000	10	1000 TAB	2.91	0.00	29.10	Micro Labs Hosur	INDIA
21	Griseofulvine, 500mg, Tab, 1000, Vrac (Griseofulvin)	5,000	5	1000 TAB	52.31	0.05	261.55	Micro Labs Hosur	INDIA
22	Hyoscine bulybromide, 10mg, Tab, 1000, Vrac	69,000	69	1000 TAB	23.18	0.02	1599.42	Medopharm Malur Factory	INDIA
26	Nystatine, 500.000 UI, Tab, 100, Vrac (Nystatin)	24,900	249	100 TAB	7.27	0.07	1810.23	Cipla Patalganga	INDIA
28	Phenobarbital, 100mg, Tab, 1000, Vrac	3,000	3	1000 TAB	8.17	0.01	24.51	Medopharm Malur Factory	INDIA
32	Zinc sulphate 20mg, Tab, 100, Vrac	103,700	1037	100 TAB BL	2.11	0.02	2188.07	KBI	GERMANY

35	Atropine, 1mg/ml, 1ml, Amp, Unité	1,500	15	100 AMP	8.20	0.08	123.00	Gland Pharma ltd Pally Factory	INDIA
36	Chloramphenicol sodium succinate, 1g, Vial, Unité	2,000	40	50 VLS	17.03	0.34	681.20	Macleods Pharm Ltd Daman Plant	INDIA
38	Dexamethasone sodium phosphate, 4mg/ml, 1ml, Amp, Unité	1,000	10	100 AMP	8.84	0.09	88.40	Gland Pharma ltd Pally Factory	INDIA
41	Digoxin 250mcg/ml, 2ml, Amp, Unité	500	5	100 AMP	8.71	0.09	43.55	Gland Pharma ltd Pally Factory	INDIA
42	Eau pour injection, 10ml, Vial, Unité (Water for Injection)	79,200	1584	50 AMP	1.71	0.06	2708.64	Marck Biosciences Ltd.	INDIA
44	Epinephrine (Adrenaline), 1mg/ml, 1ml, Amp, Unité	300	3	100 AMP	47.13	0.47	141.39	Laboratoire Renaudin	FRANCE
45	Furosemide, 10mg/ml, 2ml, Amp, Unité	3,000	30	100 AMP	6.97	0.07	209.10	Gland Pharma ltd Pally Factory	INDIA
46	Gentamycin, 40mg/ml, 2ml, Amp, Unité	15,000	150	100 AMP	8.71	0.09	1306.50	Gland Pharma ltd Pally Factory	INDIA
47	Hydrocortisone 100mg (as sodium succinate) inj	8,550	171	50 VLS	19.00	0.38	3249.00	Macleods Pharm Ltd Daman Plant	INDIA
52	Ketamine, 50mg/ml, 10ml, Vial, Unité	525	21	25 VLS	19.63	0.79	412.23	Rotexmedica Gmbh	GERMANY
53	Lidocaine chlorhydrate, 2%, 20 ml, Vial, Unité (Magnesium Sulfate)	1,040	104	10 VLS	9.13	0.91	949.52	Gland Pharma ltd Pally Factory	INDIA
54	Lidocaine chlorhydrate+dextrose, 5%+7,5%/2 ml, Amp, Unité	300	3	100 AMP	6.96	0.07	20.88	Gland Pharma ltd Pally Factory	INDIA
55	Métoclopramide chlorhydrate, 5mg/ml, 2ml, Amp, Unité	3,000	30	100 AMP	6.82	0.07	204.60	Gland Pharma ltd Pally Factory	INDIA
58	Penicillin Benzathine, 2,4MUI, Vial, Unité	40,600	812	50 VLS	8.26	0.17	6707.12	NCPC North Best Co Ltd	CHINA
62	Salbutamol, 0,5mg/ml, 1ml, Amp, Unité	1,500	15	100 AMP	6.80	0.07	102.00	Gland Pharma ltd Pally Factory	INDIA
63	Sulfate de Magnésium, 500mg, 10ml, Amp, Unité Magnesium Sulfate	200	20	10 VLS	8.66	0.87	173.20	Gland Pharma ltd Pally Factory	INDIA
66	Dichloroisocyanurate de sodium (Na DCC) 1.67(eq. 1g Cl)	45,000	225	200 TAB	9.38	0.05	2110.50	Medentech Ltd.	IRELAND

71	Chlorure de sodium, 0.9%, 500ml, Perfusion, Unité (Sodium Chloride)	4,500	225	20 BTL	7.01	0.35	1577.25	Albert David Ghaziabad	INDIA
72	Dextrose (Glucose), 5%, 500ml, Perfusion, Unité	5,000	250	20 BTL	7.01	0.35	1752.50	Albert David Ghaziabad	INDIA
73	Dextrose (Glucose), 50%, 50ml,	740	37	20 VLS	16.34	0.82	604.58	B Braun Melsungen	GERMANY
74	Ringer lactate (Solution de Hartmann), 500ml, Perfusion, Unité	3,000	150	20 BTL	7.13	0.36	1069.50	Albert David Ghaziabad	INDIA
79	Seringue, u.u., Luer, 5ml, avec aiguille G21	249,600	2496	100 PCE	4.35	0.04	10857.60	Becton Dickenson CTRA	SPAIN
80	Seringues a insuline 40 UI	2,000	20	100 PCE	8.56	0.09	171.20	B Braun Melsungen	GERMANY
81	Seringues a insuline 100 UI	500	5	100 PCE	8.56	0.09	42.80	B Braun Melsungen	GERMANY
83	Coton hydrophile, rouleau, 500g	2,000	80	25 rol	49.72	1.99	3977.60	Taizhou Xinkang Medical	CHINA
84	Sparadrap, Oxyde de Zinc, non perforé, 5cm*5m	8,500	2125	4 ROL	2.37	0.59	5036.25	Changzhou Hualian Health	CHINA
87	Sonde vésicale, Foley, 2 voies, ballonnet, CH14, stérile, Unité	370	37	10 PCE	4.12	0.41	152.44	Uro Technologies	MALAYSIA
88	Sonde vésicale, Foley, 2 voies, ballonnet, CH16, stérile, Unité	370	37	10 PCE	4.12	0.41	152.44	Uro Technologies	MALAYSIA
90	Aiguille à Ailette (épicranienne), u.u., 21G (0.8*19mm), vert, Unité	1,500	15	100 PCE	5.87	0.06	88.05	Tianjin Hanaco Medical Co, Ltd	CHINA
91	Aiguille à Ailette (épicranienne), u.u., 23G (0.6*19mm), ..., Unité	3,000	30	100 PCE	5.87	0.06	176.10	Tianjin Hanaco Medical Co, Ltd	CHINA
92	Gants chirurgicaux, latex, u.u., non poudrés, stériles, Taille 7½, Paire	17,600	44	8X50 PR	85.88	0.21	3778.72	H.B.M. USA Co., Inc.	CHINA
93	Gants d'examen, latex, u.u., non poudrés, non stériles, Taille Moyenne (7½), 100	72,000	36	20 x100PCE	88.37	0.04	3181.32	TG Medical SDN BHD	MALAYSIA
							Product Total	\$61,053.64	

Shipment G. Products for SURFACE shipment CIP (Incoterms 2000) to DEPOT PHARMACEUTIQUE BDOM BUKAVU:

SURFACE SHIPMENT CIP (INCOTERMS 2000) TO DEPOT PHARMACEUTIQUE BDOM BUKAVU									
Item No.	Item Description	Total Qty	No. of Packs	Pack Size	Pack Price	Unit Price	Total Value USD	Manufacturer	Origin
1	Acetylsalicylic Acid , 500mg, Tab, 1000, Vrac	138,000	138	1000 TAB	\$3.25	\$0.00	\$448.50	Tianjin Huajin Pharm. Co.Ltd	CHINA
2	Acide Folique, 5mg, Tab, 1000, Vrac (Folic Acid)	15,000	15	1000 TAB	2.02	0.00	30.30	Medopharm Malur Factory	INDIA
7	Cloxacilline 250mg, caps, 1000, Vrac	30,000	30	1000 CAP	17.30	0.02	519.00	Medopharm Guduvanchery	INDIA
9	Cimétidine 200 mg, Ces, 1000, Vrac (Cimetidine)	10,000	20	500 TAB	3.28	0.01	65.60	Micro Labs Hosur	INDIA
11	Diazepam, 5mg, Tab, 1000, Vrac	15,000	15	1000 TAB	4.76	0.00	71.40	Meditab (for Cipla) at Daman	INDIA
13	Digoxine, 0.25mg, Tab, 100, Vrac (Digoxin)	1,008	36	28 TAB BL	2.09	0.07	75.24	Alpharma (Actavis)	UNITED KINGDOM
15	Enalapril ce 2,5mg, Tab, 1000, Vrac	10,000	100	100 TAB BL	0.68	0.01	68.00	Medopharm Malur Factory	INDIA
17	Erythromycine, 250mg, Tab, 1000, Vrac	10,000	10	1000 TAB	34.24	0.03	342.40	Medopharm Malur Factory	INDIA
18	Fer sulfate+Acide Folique, 200mg+0,25mg, Tab, 1000, Vrac (Ferrous Sulfate + Folic Acid)	631,000	631	1000 TAB	2.38	0.00	1501.78	Bio Nova Pharmaceuticals Pvt.	INDIA
19	Furosemide, 40mg, Tab, 1000, Vrac	47,000	47	1000 TAB	3.63	0.00	170.61	Medopharm	INDIA
20	Glibenclamide, 5mg, Tab, 1000, Vrac	10,000	10	1000 TAB	2.91	0.00	29.10	Micro Labs Hosur	INDIA
21	Griseofulvine, 500mg, Tab, 1000, Vrac (Griseofulvin)	5,000	5	1000 TAB	52.31	0.05	261.55	Micro Labs Hosur	INDIA
22	Hyoscine bulybromide, 10mg, Tab, 1000, Vrac	69,000	69	1000 TAB	23.18	0.02	1599.42	Medopharm Malur Factory	INDIA
26	Nystatine, 500.000 UI, Tab, 100, Vrac (Nystatin)	24,900	249	100 TAB	7.27	0.07	1810.23	Cipla Patalganga	INDIA
28	Phenobarbital, 100mg, Tab, 1000, Vrac	3,000	3	1000 TAB	8.17	0.01	24.51	Medopharm Malur Factory	INDIA

32	Zinc sulphate 20mg, Tab, 100, Vrac	103,700	1037	100 TAB BL	2.11	0.02	2188.07	KBI	GERMANY
35	Atropine, 1mg/ml, 1ml, Amp, Unité	1,500	15	100 AMP	8.20	0.08	123.00	Gland Pharma ltd Pally Factory	INDIA
36	Chloramphenicol sodium succinate, 1g, Vial, Unité	2,000	40	50 VLS	17.03	0.34	681.20	Macleods Pharm Ltd Daman Plant	INDIA
38	Dexamethasone sodium phosphate, 4mg/ml, 1ml, Amp, Unité	1,000	10	100 AMP	8.84	0.09	88.40	Gland Pharma ltd Pally Factory	INDIA
41	Digoxin 250mcg/ml, 2ml, Amp, Unité	500	5	100 AMP	8.71	0.09	43.55	Gland Pharma ltd Pally Factory	INDIA
42	Eau pour injection, 10ml, Vial, Unité (Water for Injection)	79,200	1584	50 AMP	1.71	0.06	2708.64	Marck Biosciences Ltd.	INDIA
44	Epinéphrine (Adrenaline), 1mg/ml, 1ml, Amp, Unité	300	3	100 AMP	47.13	0.47	141.39	Laboratoire Renaudin	FRANCE
45	Furosemide, 10mg/ml, 2ml, Amp, Unité	3,000	30	100 AMP	6.97	0.07	209.10	Gland Pharma ltd Pally Factory	INDIA
46	Gentamycin, 40mg/ml, 2ml, Amp, Unité	15,000	150	100 AMP	8.71	0.09	1306.50	Gland Pharma ltd Pally Factory	INDIA
47	Hydrocortisone 100mg (as sodium succinate) inj	8,550	171	50 VLS	19.00	0.38	3249.00	Macleods Pharm Ltd Daman Plant	INDIA
52	Ketamine, 50mg/ml, 10ml, Vial, Unité	525	21	25 VLS	19.63	0.79	412.23	Rotexmedica Gmbh	GERMANY
53	Lidocaïne chlorhydrate, 2%, 20 ml, Vial, Unité (Magnesium Sulfate)	1,040	104	10 VLS	9.13	0.91	949.52	Gland Pharma ltd Pally Factory	INDIA
54	Lidocaïne chlorhydrate+dextrose, 5%+7,5%/2 ml, Amp, Unité	200	2	100 AMP	6.96	0.07	13.92	Gland Pharma ltd Pally Factory	INDIA
55	Métoclopramide chlorhydrate, 5mg/ml, 2ml, Amp, Unité	3,000	30	100 AMP	6.82	0.07	204.60	Gland Pharma ltd Pally Factory	INDIA
58	Penicillin Benzathine, 2,4MUI, Vial, Unité	40,600	812	50 VLS	8.26	0.17	6707.12	NCPC North Best Co Ltd	CHINA
62	Salbutamol, 0,5mg/ml, 1ml, Amp, Unité	1,500	15	100 AMP	6.80	0.07	102.00	Gland Pharma ltd Pally Factory	INDIA
63	Sulfate de Magnésium, 500mg, 10ml, Amp, Unité Magnesium Sulfate	200	20	10 VLS	8.66	0.87	173.20	Gland Pharma ltd Pally Factory	INDIA
66	Dichloroisocyanurate de	45,000	225	200 TAB	9.38	0.05	2110.50	Medentech Ltd.	IRELAND

	sodium (Na DCC) 1.67(eq. 1g Cl)									
71	Chlorure de sodium, 0.9%, 500ml, Perfusion, Unité (Sodium Chloride)	4,500	225	20 BTL	7.01	0.35	1577.25	Albert David Ghaziabad	INDIA	
72	Dextrose (Glucose), 5%, 500ml, Perfusion, Unité	5,000	250	20 BTL	7.01	0.35	1752.50	Albert David Ghaziabad	INDIA	
73	Dextrose (Glucose), 50%, 50ml,	740	37	20 VLS	16.34	0.82	604.58	B Braun Melsungen	GERMANY	
74	Ringer lactate (Solution de Hartmann), 500ml, Perfusion, Unité	3,000	150	20 BTL	7.13	0.36	1069.50	Albert David Ghaziabad	INDIA	
79	Seringue, u.u., Luer, 5ml, avec aiguille G21	249,600	2496	100 PCE	4.35	0.04	10857.60	Becton Dickenson CTRA	SPAIN	
80	Seringues a insuline 40 UI	2,000	20	100 PCE	8.56	0.09	171.20	B Braun Melsungen	GERMANY	
81	Seringues a insuline 100 UI	500	5	100 PCE	8.56	0.09	42.80	B Braun Melsungen	GERMANY	
83	Coton hydrophile, rouleau, 500g	2,000	80	25 rol	49.72	1.99	3977.60	Taizhou Xinkang Medical	CHINA	
84	Sparadrap, Oxyde de Zinc, non perforé, 5cm*5m	8,500	2125	4 ROL	2.37	0.59	5036.25	Changzhou Hualian Health	CHINA	
87	Sonde vésicale, Foley, 2 voies, ballonnet, CH14, stérile, Unité	370	37	10 PCE	4.12	0.41	152.44	Uro Technologies	MALAYSIA	
88	Sonde vésicale, Foley, 2 voies, ballonnet, CH16, stérile, Unité	370	37	10 PCE	4.12	0.41	152.44	Uro Technologies	MALAYSIA	
90	Aiguille à Ailette (épicranienne), u.u., 21G (0.8*19mm), vert, Unité	1,500	15	100 PCE	5.87	0.06	88.05	Tianjin Hanaco Medical Co, Ltd	CHINA	
91	Aiguille à Ailette (épicranienne), u.u., 23G (0.6*19mm), ..., Unité	3,000	30	100 PCE	5.87	0.06	176.10	Tianjin Hanaco Medical Co, Ltd	CHINA	
92	Gants chirurgicaux, latex, u.u., non poudrés, stériles, Taille 7½, Paire	17,600	44	8X50 PR	85.88	0.21	3778.72	H.B.M. USA Co., Inc.	CHINA	
93	Gants d'examen, latex, u.u., non poudrés, non stériles, Taille Moyenne (7½), 100	72,000	36	20 x100PCE	88.37	0.04	3181.32	TG Medical SDN BHD	MALAYSIA	
					Product Total		\$61,047.93			

Shipment H. Products for SURFACE shipment CIP (Incoterms 2000) to DEPOT CENTRAL MEDICO-PHARMACEUTIQUE 8è CEPAC BUKAVU:

SURFACE SHIPMENT CIP (INCOTERMS 2000) TO DEPOT CENTRAL MEDICO-PHARMACEUTIQUE 8è CEPAC BUKAVU									
Item No.	Item Description	Total Qty	No. of Packs	Pack Size	Pack Price	Unit Price	Total Value USD	Manufacturer	Origin
1	Acetylsalicylic Acid , 500mg, Tab, 1000, Vrac	138,000	138	1000 TAB	\$3.25	\$0.00	\$448.50	Tianjin Huajin Pharm. Co.Ltd	CHINA
2	Acide Folique, 5mg, Tab, 1000, Vrac (Folic Acid)	15,000	15	1000 TAB	2.02	0.00	30.30	Medopharm Malur Factory	INDIA
7	Cloxacilline 250mg, caps, 1000, Vrac	30,000	30	1000 CAP	17.30	0.02	519.00	Medopharm Guduvanchery	INDIA
9	Cimétidine 200 mg, Ces, 1000, Vrac (Cimetidine)	10,000	20	500 TAB	3.28	0.01	65.60	Micro Labs Hosur	INDIA
11	Diazepam, 5mg, Tab, 1000, Vrac	15,000	15	1000 TAB	4.76	0.00	71.40	Meditab (for Cipla) at Daman	INDIA
13	Digoxine, 0.25mg, Tab, 100, Vrac (Digoxin)	1,008	36	28 TAB BL	2.09	0.07	75.24	Alpharma (Actavis)	UNITED KINGDOM
15	Enalapril ce 2,5mg, Tab, 1000, Vrac	10,000	100	100 TAB BL	0.68	0.01	68.00	Medopharm Malur Factory	INDIA
17	Erythromycine, 250mg, Tab, 1000, Vrac	10,000	10	1000 TAB	34.24	0.03	342.40	Medopharm Malur Factory	INDIA
18	Fer sulfate+Acide Folique, 200mg+0,25mg, Tab, 1000, Vrac (Ferrous Sulfate + Folic Acid)	631,000	631	1000 TAB	2.38	0.00	1501.78	Bio Nova Pharmaceuticals Pvt.	INDIA
19	Furosemeide, 40mg, Tab, 1000, Vrac	47,000	47	1000 TAB	3.63	0.00	170.61	Medopharm	INDIA
20	Glibenclamide, 5mg, Tab, 1000, Vrac	10,000	10	1000 TAB	2.91	0.00	29.10	Micro Labs Hosur	INDIA
21	Griseofulvine, 500mg, Tab, 1000, Vrac (Griseofulvin)	5,000	5	1000 TAB	52.31	0.05	261.55	Micro Labs Hosur	INDIA
22	Hyoscine bulybromide, 10mg, Tab, 1000, Vrac	69,000	69	1000 TAB	23.18	0.02	1599.42	Medopharm Malur Factory	INDIA
26	Nystatine, 500.000 UI, Tab, 100, Vrac (Nystatin)	24,800	248	100 TAB	7.27	0.07	1802.96	Cipla Patalganga	INDIA
28	Phenobarbital, 100mg, Tab, 1000, Vrac	3,000	3	1000 TAB	8.17	0.01	24.51	Medopharm Malur Factory	INDIA

32	Zinc sulphate 20mg, Tab, 100, Vrac	103,700	1037	100 TAB BL	2.11	0.02	2188.07	KBI	GERMANY
35	Atropine, 1mg/ml, 1ml, Amp, Unité	1,500	15	100 AMP	8.20	0.08	123.00	Gland Pharma ltd Pally Factory	INDIA
36	Chloramphenicol sodium succinate, 1g, Vial, Unité	2,000	40	50 VLS	17.03	0.34	681.20	Macleods Pharm Ltd Daman Plant	INDIA
38	Dexamethasone sodium phosphate, 4mg/ml, 1ml, Amp, Unité	1,000	10	100 AMP	8.84	0.09	88.40	Gland Pharma ltd Pally Factory	INDIA
41	Digoxin 250mcg/ml, 2ml, Amp, Unité	500	5	100 AMP	8.71	0.09	43.55	Gland Pharma ltd Pally Factory	INDIA
42	Eau pour injection, 10ml, Vial, Unité (Water for Injection)	79,200	1584	50 AMP	1.71	0.06	2708.64	Marck Biosciences Ltd.	INDIA
44	Epinephrine (Adrenaline), 1mg/ml, 1ml, Amp, Unité	400	4	100 AMP	47.13	0.47	188.52	Laboratoire Renaudin	FRANCE
45	Furosemide, 10mg/ml, 2ml, Amp, Unité	3,000	30	100 AMP	6.97	0.07	209.10	Gland Pharma ltd Pally Factory	INDIA
46	Gentamycin, 40mg/ml, 2ml, Amp, Unité	15,000	150	100 AMP	8.71	0.09	1306.50	Gland Pharma ltd Pally Factory	INDIA
47	Hydrocortisone 100mg (as sodium succinate) inj	8,550	171	50 VLS	19.00	0.38	3249.00	Macleods Pharm Ltd Daman Plant	INDIA
52	Ketamine, 50mg/ml, 10ml, Vial, Unité	525	21	25 VLS	19.63	0.79	412.23	Rotexmedica Gmbh	GERMANY
53	Lidocaïne chlorhydrate, 2%, 20 ml, Vial, Unité (Magnesium Sulfate)	1,040	104	10 VLS	9.13	0.91	949.52	Gland Pharma ltd Pally Factory	INDIA
54	Lidocaïne chlorhydrate+dextrose, 5%+7,5%/2 ml, Amp, Unité	200	2	100 AMP	6.96	0.07	13.92	Gland Pharma ltd Pally Factory	INDIA
55	Métoclopramide chlorhydrate, 5mg/ml, 2ml, Amp, Unité	3,000	30	100 AMP	6.82	0.07	204.60	Gland Pharma ltd Pally Factory	INDIA
58	Penicillin Benzathine, 2,4MUI, Vial, Unité	40,650	813	50 VLS	8.26	0.17	6715.38	NCPC North Best Co Ltd	CHINA
62	Salbutamol, 0,5mg/ml, 1ml, Amp, Unité	1,500	15	100 AMP	6.80	0.07	102.00	Gland Pharma ltd Pally Factory	INDIA
63	Sulfate de Magnésium, 500mg, 10ml, Amp, Unité Magnesium Sulfate	200	20	10 VLS	8.66	0.87	173.20	Gland Pharma ltd Pally Factory	INDIA
66	Dichloroisocyanurate de	45,000	225	200 TAB	9.38	0.05	2110.50	Medentech Ltd.	IRELAND

	sodium (Na DCC) 1.67(eq. 1g Cl)									
71	Chlorure de sodium, 0.9%, 500ml, Perfusion, Unité (Sodium Chloride)	4,500	225	20 BTL	7.01	0.35	1577.25	Albert David Ghaziabad	INDIA	
72	Dextrose (Glucose), 5%, 500ml, Perfusion, Unité	5,000	250	20 BTL	7.01	0.35	1752.50	Albert David Ghaziabad	INDIA	
73	Dextrose (Glucose), 50%, 50ml,	760	38	20 VLS	16.34	0.82	620.92	B Braun Melsungen	GERMANY	
74	Ringer lactate (Solution de Hartmann), 500ml, Perfusion, Unité	3,000	150	20 BTL	7.13	0.36	1069.50	Albert David Ghaziabad	INDIA	
79	Seringue, u.u., Luer, 5ml, avec aiguille G21	249,600	2496	100 PCE	4.35	0.04	10857.60	Becton Dickenson CTRA	SPAIN	
80	Seringues a insuline 40 UI	2,000	20	100 PCE	8.56	0.09	171.20	B Braun Melsungen	GERMANY	
81	Seringues a insuline 100 UI	500	5	100 PCE	8.56	0.09	42.80	B Braun Melsungen	GERMANY	
83	Coton hydrophile, rouleau, 500g	2,000	80	25 rol	49.72	1.99	3977.60	Taizhou Xinkang Medical	CHINA	
84	Sparadrap, Oxyde de Zinc, non perforé, 5cm*5m	8,500	2125	4 ROL	2.37	0.59	5036.25	Changzhou Hualian Health	CHINA	
87	Sonde vésicale, Foley, 2 voies, ballonnet, CH14, stérile, Unité	380	38	10 PCE	4.12	0.41	156.56	Uro Technologies	MALAYSIA	
88	Sonde vésicale, Foley, 2 voies, ballonnet, CH16, stérile, Unité	380	38	10 PCE	4.12	0.41	156.56	Uro Technologies	MALAYSIA	
90	Aiguille à Ailette (épicranienne), u.u., 21G (0.8*19mm), vert, Unité	1,500	15	100 PCE	5.87	0.06	88.05	Tianjin Hanaco Medical Co, Ltd	CHINA	
91	Aiguille à Ailette (épicranienne), u.u., 23G (0.6*19mm), ..., Unité	3,000	30	100 PCE	5.87	0.06	176.10	Tianjin Hanaco Medical Co, Ltd	CHINA	
92	Gants chirurgicaux, latex, u.u., non poudrés, stériles, Taille 7½, Paire	18,000	45	8X50 PR	85.88	0.21	3864.60	H.B.M. USA Co., Inc.	CHINA	
93	Gants d'examen, latex, u.u., non poudrés, non stériles, Taille Moyenne (7½), 100	72,000	36	20 x100PCE	88.37	0.04	3181.32	TG Medical SDN BHD	MALAYSIA	
							Product Total	\$61,206.51		

IV. List of medicines and medical supplies found in Task Order 107 issued to MissionPharma A/S

Shipment A. Products for SURFACE Shipment CIP (Incoterms 2000) to CDR CEDIMEK KAMINA:

SURFACE SHIPMENT CIP (INCOTERMS 2000) TO CDR CEDIMEK KAMINA									
Item No.	Item Description	Total Qty	No. of Packs	Pack Size	Pack Price	Unit Price	Total Value USD	Manufacturer	Origin
3	Aluminium Hydroxide 120mg + Magnesium Trisilicate 250mg	137,000	137	1000 tablets	3.31	0.0033	453.81	Fourrts	India
4	Amoxicillin 250mg/5ml, 100ml	4,500	4500	1 bottle	0.53	0.53	2390.85	Medicamen - Bhiwadi	India
5	Amoxicillin 500mg	304,000	304	1000 capsules	27.88	0.03	8474.00	CSPC Zhongnuo Pharma Workshop 204	China
6	Chlorphenamine Maleate 4mg	198,000	198	1000 tablets	1.73	0.00	343.13	Medicamen - Bhiwadi	India
8	Ciprofloxacin 500mg, film-coated	326,100	3261	100 tablets	3.44	0.03	11209.69	Nanjing Baijingyu - General	China
10	Cotrimoxazole 480mg	814,000	814	1000 tablets	9.50	0.01	7733.00	Guilin Pharma - Workshop 2	China
12	Diclofenac Sodium 50mg, enteric coated	198,000	198	1000 tablets	3.44	0.00	681.12	Medicamen - Bhiwadi	India
14	Doxycycline 100mg, as Hyclate	114,000	114	1000 tablets	10.33	0.01	1177.96	Nanjing Baijingyu - General	China
16	Erythromycin 125mg/5ml, 100ml as Ethyl Succinate	2,000	2000	1 bottle	0.69	0.69	1375.00	Medicamen - Bhiwadi	India
23	Mebendazole, 100mg, Tab, 1000, Vrac	405,000	405	1000 tablets	3.75	0.00	1518.75	Medopharm - Malur Plant	India
24	Methyl dopa 250mg, coated	7,000	7	1000 tablets	40.00	0.04	280.00	Medicamen - Bhiwadi	India
25	Metronidazole 250mg	290,000	290	1000 tablets	5.45	0.01	1580.21	Nanjing Baijingyu - General	China
27	Paracetamol 500mg	1,184,000	1184	1000 tablets	5.00	0.01	5920.00	Medicamen - Bhiwadi	India
29	Phenoxymethylpenicillin 250mg	144,000	144	1000 tablets	14.50	0.01	2088.00	Medicamen - Bhiwadi	India
30	Prednisolone 5mg	208,000	208	1000 tablets	7.75	0.01	1612.00	Medicamen - Bhiwadi	India

31	Oral Rehydration Salts 20.5g,WHO mod	127,800	1278	100 sachets	6.99	0.07	8933.22	Medicamen - Bhiwadi	India
33	Lysine Acetylsalicylate 1.8g eq. to 1g ASA	6,000	120	50 vials	20.25	0.41	2430.00	Reyoung Pharmaceutical, workshop 304	China
34	Ampicillin 1g, as Sodium	32,650	653	50 vials	5.95	0.12	3885.35	Reyoung Pharmaceutical, workshop 305	China
37	Ciprofloxacin 2mg/ml, 100ml	1,800	1800	1 bottle	0.36	0.36	648.00	Fresenius Kabi - Pune site	India
40	Diclofenac Sodium 25mg/ml, 3ml	13,000	130	100 ampoules	5.42	0.05	704.82	Gland - Pally Plant	India
43	Ephedrine HCl 30mg/ml, 1ml	1,000	100	10 ampoules	5.96	0.60	596.25	Lab. Aguettant, Unité de Chantecaille	France
48	Hyoscine Butylbromide 20mg/ml, 1ml	10,500	105	100 ampoules	9.94	0.10	1043.68	Gland - Pally Plant	India
56	Metronidazole 125mg/5ml, 100ml, as Benzoate	4,500	4500	1 bottle	0.34	0.34	1518.75	Medicamen - Bhiwadi	India
61	Vitamin K1 10mg/ml, 1ml (Phytomenadione)	20,800	208	100 ampoules	29.97	0.30	6234.45	Rotexmedica GmbH	Germany
64	Tetracycline HCl 1%, 5g, eye ointment	9,375	9375	1 tube	0.10	0.10	937.50	Nanjing Baijingyu - Ointment, Creams,	China
65	Chlorhexidine 1.5% + Cetrimide 15%, 1L	300	300	1 bottle	3.06	3.06	918.75	Sirmaxo Chemicals - Palghar plant	India
67	Povidone Iodine 10%, 200ml	1,000	1000	1 bottle	0.83	0.83	825.00	Sirmaxo Chemicals - Palghar plant	India
68	Benzyl Benzoate 25%, 1L, application	625	625	1 bottle	3.00	3.00	1875.00	Sirmaxo Chemicals - Palghar plant	India
69	Nystatin 100.000 IU, pessaries	68,300	683	100 vagitories	1.56	0.02	1067.19	Medicamen - Bhiwadi	India
70	Salbutamol 100mcg/dose, 200 doses CFC free	1,000	1000	1 inhaler	1.19	1.19	1187.50	Jewim Pharmaceutical, Taian High tech. Workshop 1 Steroids	China
82	Gauze bandage 5cm x 5m, BP17, individually packaged, self-edged	16,875	16875	1 roll	0.10	0.10	1687.50	Shaoxing Fuqing Health - Shaoxing	China

85	Polyamide 2/0, 75cm w/needle-monofil 3/8circl,35mm-tapercut	11,760	980	12 pieces	1.46	0.12	1433.25	Shanghai Pudong Jinhuan Medical Co., Ltd	China
86	Polyglycolic Acid 2/0, 75cm w/needle 1/2 circle, RB, 30mm	11,760	980	12 pieces	9.15	0.76	8963.38	Shanghai Pudong Jinhuan Medical Co., Ltd	China
89	Catheter Foley, CH 20	375	375	1 piece	0.35	0.35	130.01	Zhanjiang Star Enterprise - Jinchuan Rd.	China
					Product Total		\$91,857.12		

Shipment B. Products for SURFACE shipment CIP (Incoterms 2000) to DEPOT PHARMACEUTIQUE CDMEK KOLWEZI:

SURFACE SHIPMENT CIP (INCOTERMS 2000) TO DEPOT PHARMACEUTIQUE CDMEK KOLWEZI									
Item No.	Item Description	Total Qty	No. of Packs	Pack Size	Pack Price	Unit Price	Total Value USD	Manufacturer	Origin
3	Aluminium Hydroxide 120mg + Magnesium Trisilicate 250mg	137,000	137	1000 tablets	3.31	0.0033	453.81	Fourrts	India
4	Amoxicillin 250mg/5ml, 100ml	4,500	4500	1 bottle	0.53	0.53	2390.85	Medicamen - Bhiwadi	India
5	Amoxicillin 500mg	304,000	304	1000 capsules	27.88	0.03	8474.00	CSPC Zhongnuo Pharma Workshop 204	China
6	Chlorphenamine Maleate 4mg	198,000	198	1000 tablets	1.73	0.00	343.13	Medicamen - Bhiwadi	India
8	Ciprofloxacin 500mg, film-coated	326,100	3261	100 tablets	3.44	0.03	11209.69	Nanjing Baijingyu - General	China
10	Cotrimoxazole 480mg	815,000	815	1000 tablets	9.50	0.01	7742.50	Guilin Pharma - Workshop 2	China
12	Diclofenac Sodium 50mg, enteric coated	198,000	198	1000 tablets	3.44	0.00	681.12	Medicamen - Bhiwadi	India
14	Doxycycline 100mg, as Hyclate	114,000	114	1000 tablets	10.33	0.01	1177.96	Nanjing Baijingyu - General	China
16	Erythromycin 125mg/5ml, 100ml as Ethyl Succinate	2,000	2000	1 bottle	0.69	0.69	1375.00	Medicamen - Bhiwadi	India
23	Mebendazole, 100mg, Tab, 1000, Vrac	404,000	404	1000 tablets	3.75	0.00	1515.00	Medopharm - Malur Plant	India
24	Methyldopa 250mg, coated	7,000	7	1000 tablets	40.00	0.04	280.00	Medicamen - Bhiwadi	India
25	Metronidazole 250mg	290,000	290	1000 tablets	5.45	0.01	1580.21	Nanjing Baijingyu - General	China
27	Paracetamol 500mg	1,185,000	1185	1000 tablets	5.00	0.01	5925.00	Medicamen - Bhiwadi	India
29	Phenoxymethylpenicillin 250mg	144,000	144	1000 tablets	14.50	0.01	2088.00	Medicamen - Bhiwadi	India
30	Prednisolone 5mg	208,000	208	1000 tablets	7.75	0.01	1612.00	Medicamen - Bhiwadi	India
31	Oral Rehydration Salts 20.5g,WHO mod	127,800	1278	100 sachets	6.99	0.07	8933.22	Medicamen - Bhiwadi	India
33	Lysine Acetylsalicylate 1.8g eq. to 1g ASA	6,000	120	50 vials	20.25	0.41	2430.00	Reyoung Pharmaceutical, workshop 304	China
34	Ampicillin 1g, as Sodium	32,650	653	50 vials	5.95	0.12	3885.35	Reyoung Pharmaceutical, workshop 305	China

37	Ciprofloxacin 2mg/ml, 100ml	1,800	1800	1 bottle	0.36	0.36	648.00	Fresenius Kabi - Pune site	India
40	Diclofenac Sodium 25mg/ml, 3ml	13,000	130	100 ampoules	5.42	0.05	704.82	Gland - Pally Plant	India
43	Ephedrine HCl 30mg/ml, 1ml	1,000	100	10 ampoules	5.96	0.60	596.25	Lab. Aguetant, Unité de Chantecaille	France
48	Hyoscine Butylbromide 20mg/ml, 1ml	10,600	106	100 ampoules	9.94	0.10	1053.62	Gland - Pally Plant	India
56	Metronidazole 125mg/5ml, 100ml, as Benzoate	4,500	4500	1 bottle	0.34	0.34	1518.75	Medicamen - Bhiwadi	India
61	Vitamin K1 10mg/ml, 1ml (Phytomenadione)	20,800	208	100 ampoules	29.97	0.30	6234.45	Rotexmedica GmbH	Germany
64	Tetracycline HCl 1%, 5g, eye ointment	9,375	9375	1 tube	0.10	0.10	937.50	Nanjing Baijingyu - Ointmen, Creams,	China
65	Chlorhexidine 1.5% + Cetrimide 15%, 1L	300	300	1 bottle	3.06	3.06	918.75	Sirmaxo Chemicals - Palghar plant	India
67	Povidone Iodine 10%, 200ml	1,000	1000	1 bottle	0.83	0.83	825.00	Sirmaxo Chemicals - Palghar plant	India
68	Benzyl Benzoate 25%, 1L, application	625	625	1 bottle	3.00	3.00	1875.00	Sirmaxo Chemicals - Palghar plant	India
69	Nystatin 100.000 IU, pessaries	68,300	683	100 vagitories	1.56	0.02	1067.19	Medicamen - Bhiwadi	India
70	Salbutamol 100mcg/dose, 200 doses CFC free	1,000	1000	1 inhaler	1.19	1.19	1187.50	Jewim Pharmaceutical, Taian High tech. Workshop 1 Steroids	China
82	Gauze bandage 5cm x 5m, BP17, individually packaged, self-edged	16,875	16875	1 roll	0.10	0.10	1687.50	Shaoxing Fuqing Health - Shaoxing	China
85	Polyamide 2/0, 75cm w/needle-monofil 3/8circl,35mm-tapercut	11,760	980	12 pieces	1.46	0.12	1433.25	Shanghai Pudong Jinhuan Medical Co., Ltd	China
86	Polyglycolic Acid 2/0, 75cm w/needle 1/2 circle, RB, 30mm	11,760	980	12 pieces	9.15	0.76	8963.38	Shanghai Pudong Jinhuan Medical Co., Ltd	China
89	Catheter Foley, CH 20	375	375	1 piece	0.35	0.35	130.01	Zhanjiang Star Enterprise - Jinchuan Rd.	China
							Product Total	\$91,877.81	

Shipment C. Products for SURFACE shipment CIP (Incoterms 2000) to CDR CADIMEK KANANGA:

SURFACE SHIPMENT CIP (INCOTERMS 2000) TO CDR CADIMEK KANANGA									
Item No.	Item Description	Total Qty	No. of Packs	Pack Size	Pack Price	Unit Price	Total Value USD	Manufacturer	Origin
3	Aluminium Hydroxide 120mg + Magnesium Trisilicate 250mg	138,000	138	1000 tablets	3.31	0.0033	457.13	Fourrts	India
4	Amoxicillin 250mg/5ml, 100ml	4,500	4500	1 bottle	0.53	0.53	2390.85	Medicamen - Bhiwadi	India
5	Amoxicillin 500mg	304,000	304	1000 capsules	27.88	0.03	8474.00	CSPC Zhongnuo Pharma Workshop 204	China
6	Chlorphenamine Maleate 4mg	198,000	198	1000 tablets	1.73	0.00	343.13	Medicamen - Bhiwadi	India
8	Ciprofloxacin 500mg, film-coated	326,100	3261	100 tablets	3.44	0.03	11209.69	Nanjing Baijingyu - General	China
10	Cotrimoxazole 480mg	815,000	815	1000 tablets	9.50	0.01	7742.50	Guilin Pharma - Workshop 2	China
12	Diclofenac Sodium 50mg, enteric coated	198,000	198	1000 tablets	3.44	0.00	681.12	Medicamen - Bhiwadi	India
14	Doxycycline 100mg, as Hyclate	114,000	114	1000 tablets	10.33	0.01	1177.96	Nanjing Baijingyu - General	China
16	Erythromycin 125mg/5ml, 100ml as Ethyl Succinate	2,000	2000	1 bottle	0.69	0.69	1375.00	Medicamen - Bhiwadi	India
23	Mebendazole, 100mg, Tab, 1000, Vrac	404,000	404	1000 tablets	3.75	0.00	1515.00	Medopharm - Malur Plant	India
24	Methyldopa 250mg, coated	7,000	7	1000 tablets	40.00	0.04	280.00	Medicamen - Bhiwadi	India
25	Metronidazole 250mg	290,000	290	1000 tablets	5.45	0.01	1580.21	Nanjing Baijingyu - General	China
27	Paracetamol 500mg	1,185,000	1185	1000 tablets	5.00	0.01	5925.00	Medicamen - Bhiwadi	India
29	Phenoxymethylpenicillin 250mg	144,000	144	1000 tablets	14.50	0.01	2088.00	Medicamen - Bhiwadi	India
30	Prednisolone 5mg	208,000	208	1000 tablets	7.75	0.01	1612.00	Medicamen - Bhiwadi	India
31	Oral Rehydration Salts 20.5g,WHO mod	127,800	1278	100 sachets	6.99	0.07	8933.22	Medicamen - Bhiwadi	India
33	Lysine Acetylsalicylate 1.8g eq. to 1g ASA	6,000	120	50 vials	20.25	0.41	2430.00	Reyoung Pharmaceutical, workshop 304	China
34	Ampicillin 1g, as Sodium	32,650	653	50 vials	5.95	0.12	3885.35	Reyoung Pharmaceutical, workshop 305	China

37	Ciprofloxacin 2mg/ml, 100ml	1,800	1800	1 bottle	0.36	0.36	648.00	Fresenius Kabi - Pune site	India
40	Diclofenac Sodium 25mg/ml, 3ml	13,000	130	100 ampoules	5.42	0.05	704.82	Gland - Pally Plant	India
43	Ephedrine HCl 30mg/ml, 1ml	1,000	100	10 ampoules	5.96	0.60	596.25	Lab. Aguettant, Unité de Chantecaille	France
48	Hyoscine Butylbromide 20mg/ml, 1ml	10,400	104	100 ampoules	9.94	0.10	1033.74	Gland - Pally Plant	India
56	Metronidazole 125mg/5ml, 100ml, as Benzoate	4,500	4500	1 bottle	0.34	0.34	1518.75	Medicamen - Bhiwadi	India
61	Vitamin K1 10mg/ml, 1ml (Phytomenadione)	20,800	208	100 ampoules	29.97	0.30	6234.45	Rotexmedica GmbH	Germany
64	Tetracycline HCl 1%, 5g, eye ointment	9,375	9375	1 tube	0.10	0.10	937.50	Nanjing Baijingyu - Ointmen, Creams,	China
65	Chlorhexidine 1.5% + Cetrimide 15%, 1L	300	300	1 bottle	3.06	3.06	918.75	Sirmaxo Chemicals - Palghar plant	India
67	Povidone Iodine 10%, 200ml	1,000	1000	1 bottle	0.83	0.83	825.00	Sirmaxo Chemicals - Palghar plant	India
68	Benzyl Benzoate 25%, 1L, application	625	625	1 bottle	3.00	3.00	1875.00	Sirmaxo Chemicals - Palghar plant	India
69	Nystatin 100.000 IU, pessaries	68,300	683	100 vagitories	1.56	0.02	1067.19	Medicamen - Bhiwadi	India
70	Salbutamol 100mcg/dose, 200 doses CFC free	1,000	1000	1 inhaler	1.19	1.19	1187.50	Jewim Pharmaceutical, Taian High tech. Workshop 1 Steroids	China
82	Gauze bandage 5cm x 5m, BP17, individually packaged, self-edged	16,875	16875	1 roll	0.10	0.10	1687.50	Shaoxing Fuqing Health - Shaoxing	China
85	Polyamide 2/0, 75cm w/needle-monofil 3/8circl,35mm-tapercut	11,760	980	12 pieces	1.46	0.12	1433.25	Shanghai Pudong Jinhuan Medical Co., Ltd	China
86	Polyglycolic Acid 2/0, 75cm w/needle 1/2 circle, RB, 30mm	11,760	980	12 pieces	9.15	0.76	8963.38	Shanghai Pudong Jinhuan Medical Co., Ltd	China
89	Catheter Foley, CH 20	375	375	1 piece	0.35	0.35	130.01	Zhanjiang Star Enterprise - Jinchuan Rd.	China
							Product Total	\$91,861.24	

Shipment D. Products for SURFACE shipment CIP (Incoterms 2000) to CDR CADMEKO MBUJIMAYI:

SURFACE SHIPMENT CIP (INCOTERMS 2000) TO CDR CADMEKO MBUJIMAYI									
Item No.	Item Description	Total Qty	No. of Packs	Pack Size	Pack Price	Unit Price	Total Value USD	Manufacturer	Origin
3	Aluminium Hydroxide 120mg + Magnesium Trisilicate 250mg	138,000	138	1000 tablets	3.31	0.0033	457.13	Fourrts	India
4	Amoxycillin 250mg/5ml, 100ml	4,500	4500	1 bottle	0.53	0.53	2390.85	Medicamen - Bhiwadi	India
5	Amoxycillin 500mg	304,000	304	1000 capsules	27.88	0.03	8474.00	CSPC Zhongnuo Pharma Workshop 204	China
6	Chlorphenamine Maleate 4mg	197,000	197	1000 tablets	1.73	0.00	341.40	Medicamen - Bhiwadi	India
8	Ciprofloxacin 500mg, film-coated	326,000	3260	100 tablets	3.44	0.03	11206.25	Nanjing Baijingyu - General	China
10	Cotrimoxazole 480mg	814,000	814	1000 tablets	9.50	0.01	7733.00	Guilin Pharma - Workshop 2	China
12	Diclofenac Sodium 50mg, enteric coated	197,000	197	1000 tablets	3.44	0.00	677.68	Medicamen - Bhiwadi	India
14	Doxycycline 100mg, as Hyclate	114,000	114	1000 tablets	10.33	0.01	1177.96	Nanjing Baijingyu - General	China
16	Erythromycin 125mg/5ml, 100ml as Ethyl Succinate	2,000	2000	1 bottle	0.69	0.69	1375.00	Medicamen - Bhiwadi	India
23	Mebendazole, 100mg, Tab, 1000, Vrac	403,000	403	1000 tablets	3.75	0.00	1511.25	Medopharm - Malur Plant	India
24	Methyl dopa 250mg, coated	7,000	7	1000 tablets	40.00	0.04	280.00	Medicamen - Bhiwadi	India
25	Metronidazole 250mg	290,000	290	1000 tablets	5.45	0.01	1580.21	Nanjing Baijingyu - General	China
27	Paracetamol 500mg	1,184,000	1184	1000 tablets	5.00	0.01	5920.00	Medicamen - Bhiwadi	India
29	Phenoxymethylpenicillin 250mg	145,000	145	1000 tablets	14.50	0.01	2102.50	Medicamen - Bhiwadi	India
30	Prednisolone 5mg	207,000	207	1000 tablets	7.75	0.01	1604.25	Medicamen - Bhiwadi	India
31	Oral Rehydration Salts 20.5g,WHO mod	127,800	1278	100 sachets	6.99	0.07	8933.22	Medicamen - Bhiwadi	India
33	Lysine Acetylsalicylate 1.8g eq. to 1g ASA	6,000	120	50 vials	20.25	0.41	2430.00	Reyoung Pharmaceutical, workshop 304	China
34	Ampicillin 1g, as Sodium	32,600	652	50 vials	5.95	0.12	3879.40	Reyoung Pharmaceutical,	China

								workshop 305	
37	Ciprofloxacin 2mg/ml, 100ml	1,800	1800	1 bottle	0.36	0.36	648.00	Fresenius Kabi - Pune site	India
40	Diclofenac Sodium 25mg/ml, 3ml	12,800	128	100 ampoules	5.42	0.05	693.98	Gland - Pally Plant	India
43	Ephedrine HCl 30mg/ml, 1ml	1,000	100	10 ampoules	5.96	0.60	596.25	Lab. Aguetant, Unité de Chantecaille	France
48	Hyoscine Butylbromide 20mg/ml, 1ml	10,300	103	100 ampoules	9.94	0.10	1023.80	Gland - Pally Plant	India
56	Metronidazole 125mg/5ml, 100ml, as Benzoate	4,500	4500	1 bottle	0.34	0.34	1518.75	Medicamen - Bhiwadi	India
61	Vitamin K1 10mg/ml, 1ml (Phytomenadione)	20,700	207	100 ampoules	29.97	0.30	6204.47	Rotexmedica GmbH	Germany
64	Tetracycline HCl 1%, 5g, eye ointment	9,375	9375	1 tube	0.10	0.10	937.50	Nanjing Baijingyu - Ointment, Creams,	China
65	Chlorhexidine 1.5% + Cetrimide 15%, 1L	300	300	1 bottle	3.06	3.06	918.75	Sirmaxo Chemicals - Palghar plant	India
67	Povidone Iodine 10%, 200ml	1,000	1000	1 bottle	0.83	0.83	825.00	Sirmaxo Chemicals - Palghar plant	India
68	Benzyl Benzoate 25%, 1L, application	625	625	1 bottle	3.00	3.00	1875.00	Sirmaxo Chemicals - Palghar plant	India
69	Nystatin 100.000 IU, pessaries	68,200	682	100 vagitories	1.56	0.02	1065.63	Medicamen - Bhiwadi	India
70	Salbutamol 100mcg/dose, 200 doses CFC free	1,000	1000	1 inhaler	1.19	1.19	1187.50	Jewim Pharmaceutical, Taian High tech. Workshop 1 Steroids	China
82	Gauze bandage 5cm x 5m, BP17, individually packaged, self-edged	16,875	16875	1 roll	0.10	0.10	1687.50	Shaoxing Fuqing Health - Shaoxing	China
85	Polyamide 2/0, 75cm w/needle-monofil 3/8circl,35mm-tapercut	11,748	979	12 pieces	1.46	0.12	1431.79	Shanghai Pudong Jinhuan Medical Co., Ltd	China
86	Polyglycolic Acid 2/0, 75cm w/needle 1/2 circle, RB, 30mm	11,748	979	12 pieces	9.15	0.76	8954.23	Shanghai Pudong Jinhuan Medical Co., Ltd	China
89	Catheter Foley, CH 20	375	375	1 piece	0.35	0.35	130.01	Zhanjiang Star Enterprise - Jinchuan Rd.	China
							Product Total	\$91,772.25	

Shipment E. Products for SURFACE shipment CIP (Incoterms 2000) to DEPOT PHARMACEUTIQUE FODESA:

SURFACE SHIPMENT CIP (INCOTERMS 2000) TO DEPOT PHARMACEUTIQUE FODESA									
Item No.	Item Description	Total Qty	No. of Packs	Pack Size	Pack Price	Unit Price	Total Value USD	Manufacturer	Origin
3	Aluminium Hydroxide 120mg + Magnesium Trisilicate 250mg	138,000	138	1000 tablets	3.31	0.0033	457.13	Fourrts	India
4	Amoxycillin 250mg/5ml, 100ml	4,500	4500	1 bottle	0.53	0.53	2390.85	Medicamen - Bhiwadi	India
5	Amoxycillin 500mg	304,000	304	1000 capsules	27.88	0.03	8474.00	CSPC Zhongnuo Pharma Workshop 204	China
6	Chlorphenamine Maleate 4mg	197,000	197	1000 tablets	1.73	0.00	341.40	Medicamen - Bhiwadi	India
8	Ciprofloxacin 500mg, film-coated	326,000	3260	100 tablets	3.44	0.03	11206.25	Nanjing Baijingyu - General	China
10	Cotrimoxazole 480mg	814,000	814	1000 tablets	9.50	0.01	7733.00	Gulin Pharma - Workshop 2	China
12	Diclofenac Sodium 50mg, enteric coated	197,000	197	1000 tablets	3.44	0.00	677.68	Medicamen - Bhiwadi	India
14	Doxycycline 100mg, as Hyclate	114,000	114	1000 tablets	10.33	0.01	1177.96	Nanjing Baijingyu - General	China
16	Erythromycin 125mg/5ml, 100ml as Ethyl Succinate	2,000	2000	1 bottle	0.69	0.69	1375.00	Medicamen - Bhiwadi	India
23	Mebendazole, 100mg, Tab, 1000, Vrac	403,000	403	1000 tablets	3.75	0.00	1511.25	Medopharm - Malur Plant	India
24	Methyldopa 250mg, coated	7,000	7	1000 tablets	40.00	0.04	280.00	Medicamen - Bhiwadi	India
25	Metronidazole 250mg	290,000	290	1000 tablets	5.45	0.01	1580.21	Nanjing Baijingyu - General	China
27	Paracetamol 500mg	1,184,000	1184	1000 tablets	5.00	0.01	5920.00	Medicamen - Bhiwadi	India
29	Phenoxymethylpenicillin 250mg	145,000	145	1000 tablets	14.50	0.01	2102.50	Medicamen - Bhiwadi	India
30	Prednisolone 5mg	207,000	207	1000 tablets	7.75	0.01	1604.25	Medicamen - Bhiwadi	India
31	Oral Rehydration Salts 20.5g,WHO mod	127,800	1278	100 sachets	6.99	0.07	8933.22	Medicamen - Bhiwadi	India
33	Lysine Acetylsalicylate 1.8g eq. to 1g ASA	6,000	120	50 vials	20.25	0.41	2430.00	Reyoung Pharmaceutical, workshop 304	China
34	Ampicillin 1g, as Sodium	32,600	652	50 vials	5.95	0.12	3879.40	Reyoung Pharmaceutical, workshop 305	China

37	Ciprofloxacin 2mg/ml, 100ml	1,800	1800	1 bottle	0.36	0.36	648.00	Fresenius Kabi - Pune site	India
40	Diclofenac Sodium 25mg/ml, 3ml	12,800	128	100 ampoules	5.42	0.05	693.98	Gland - Pally Plant	India
43	Ephedrine HCl 30mg/ml, 1ml	1,000	100	10 ampoules	5.96	0.60	596.25	Lab. Aguettant, Unité de Chantecaille	France
48	Hyoscine Butylbromide 20mg/ml, 1ml	10,300	103	100 ampoules	9.94	0.10	1023.80	Gland - Pally Plant	India
56	Metronidazole 125mg/5ml, 100ml, as Benzoate	4,500	4500	1 bottle	0.34	0.34	1518.75	Medicamen - Bhiwadi	India
61	Vitamin K1 10mg/ml, 1ml (Phytomenadione)	20,700	207	100 ampoules	29.97	0.30	6204.47	Rotexmedica GmbH	Germany
64	Tetracycline HCl 1%, 5g, eye ointment	9,375	9375	1 tube	0.10	0.10	937.50	Nanjing Baijingyu - Ointment, Creams,	China
65	Chlorhexidine 1.5% + Cetrimide 15%, 1L	300	300	1 bottle	3.06	3.06	918.75	Sirmaxo Chemicals - Palghar plant	India
67	Povidone Iodine 10%, 200ml	1,000	1000	1 bottle	0.83	0.83	825.00	Sirmaxo Chemicals - Palghar plant	India
68	Benzyl Benzoate 25%, 1L, application	625	625	1 bottle	3.00	3.00	1875.00	Sirmaxo Chemicals - Palghar plant	India
69	Nystatin 100.000 IU, pessaries	68,200	682	100 vagitories	1.56	0.02	1065.63	Medicamen - Bhiwadi	India
70	Salbutamol 100mcg/dose, 200 doses CFC free	1,000	1000	1 inhaler	1.19	1.19	1187.50	Jewim Pharmaceutical, Taian High tech. Workshop 1 Steroids	China
82	Gauze bandage 5cm x 5m, BP17, individually packaged, self-edged	16,875	16875	1 roll	0.10	0.10	1687.50	Shaoxing Fuqing Health - Shaoxing	China
85	Polyamide 2/0, 75cm w/needle-monofil 3/8circl,35mm-tapercut	11,748	979	12 pieces	1.46	0.12	1431.79	Shanghai Pudong Jinhuan Medical Co., Ltd	China
86	Polyglycolic Acid 2/0, 75cm w/needle 1/2 circle, RB, 30mm	11,748	979	12 pieces	9.15	0.76	8954.23	Shanghai Pudong Jinhuan Medical Co., Ltd	China
89	Catheter Foley, CH 20	375	375	1 piece	0.35	0.35	130.01	Zhanjiang Star Enterprise - Jinchuan Rd.	China
							Product Total	\$91,772.25	

Shipment F. Products for SURFACE shipment CIP (Incoterms 2000) to APAMESK ASBL:

SURFACE SHIPMENT CIP (INCOTERMS 2000) TO APAMESK ASBL									
Item No.	Item Description	Total Qty	No. of Packs	Pack Size	Pack Price	Unit Price	Total Value USD	Manufacturer	Origin
3	Aluminium Hydroxide 120mg + Magnesium Trisilicate 250mg	138,000	138	1000 tablets	3.31	0.00	457.13	Fourrts	India
4	Amoxycillin 250mg/5ml, 100ml	4,500	4500	1 bottle	0.53	0.53	2390.85	Medicamen - Bhiwadi	India
5	Amoxycillin 500mg	304,000	304	1000 capsules	27.88	0.03	8474.00	CSPC Zhongnuo Pharma Workshop 204	China
6	Chlorphenamine Maleate 4mg	197,000	197	1000 tablets	1.73	0.00	341.40	Medicamen - Bhiwadi	India
8	Ciprofloxacin 500mg, film-coated	326,000	3260	100 tablets	3.44	0.03	11206.25	Nanjing Baijingyu - General	China
10	Cotrimoxazole 480mg	814,000	814	1000 tablets	9.50	0.01	7733.00	Guilin Pharma - Workshop 2	China
12	Diclofenac Sodium 50mg, enteric coated	197,000	197	1000 tablets	3.44	0.00	677.68	Medicamen - Bhiwadi	India
14	Doxycycline 100mg, as Hyclate	114,000	114	1000 tablets	10.33	0.01	1177.96	Nanjing Baijingyu - General	China
16	Erythromycin 125mg/5ml, 100ml as Ethyl Succinate	2,000	2000	1 bottle	0.69	0.69	1375.00	Medicamen - Bhiwadi	India
23	Mebendazole, 100mg, Tab, 1000, Vrac	403,000	403	1000 tablets	3.75	0.00	1511.25	Medopharm - Malur Plant	India
24	Methyldopa 250mg, coated	7,000	7	1000 tablets	40.00	0.04	280.00	Medicamen - Bhiwadi	India
25	Metronidazole 250mg	290,000	290	1000 tablets	5.45	0.01	1580.21	Nanjing Baijingyu - General	China
27	Paracetamol 500mg	1,184,000	1184	1000 tablets	5.00	0.01	5920.00	Medicamen - Bhiwadi	India
29	Phenoxymethylpenicillin 250mg	145,000	145	1000 tablets	14.50	0.01	2102.50	Medicamen - Bhiwadi	India
30	Prednisolone 5mg	207,000	207	1000 tablets	7.75	0.01	1604.25	Medicamen - Bhiwadi	India
31	Oral Rehydration Salts 20.5g,WHO mod	127,800	1278	100 sachets	6.99	0.07	8933.22	Medicamen - Bhiwadi	India
33	Lysine Acetylsalicylate 1.8g eq. to 1g ASA	6,000	120	50 vials	20.25	0.41	2430.00	Reyoung Pharmaceutical, workshop 304	China
34	Ampicillin 1g, as Sodium	32,600	652	50 vials	5.95	0.12	3879.40	Reyoung Pharmaceutical,	China

								workshop 305	
37	Ciprofloxacin 2mg/ml, 100ml	1,800	1800	1 bottle	0.36	0.36	648.00	Fresenius Kabi - Pune site	India
40	Diclofenac Sodium 25mg/ml, 3ml	12,800	128	100 ampoules	5.42	0.05	693.98	Gland - Pally Plant	India
43	Ephedrine HCl 30mg/ml, 1ml	1,000	100	10 ampoules	5.96	0.60	596.25	Lab. Aguetant, Unité de Chantecaille	France
48	Hyoscine Butylbromide 20mg/ml, 1ml	10,300	103	100 ampoules	9.94	0.10	1023.80	Gland - Pally Plant	India
56	Metronidazole 125mg/5ml, 100ml, as Benzoate	4,500	4500	1 bottle	0.34	0.34	1518.75	Medicamen - Bhiwadi	India
61	Vitamin K1 10mg/ml, 1ml (Phytomenadione)	20,700	207	100 ampoules	29.97	0.30	6204.47	Rotexmedica GmbH	Germany
64	Tetracycline HCl 1%, 5g, eye ointment	9,375	9375	1 tube	0.10	0.10	937.50	Nanjing Baijingyu - Ointmen, Creams,	China
65	Chlorhexidine 1.5% + Cetrime 15%, 1L	300	300	1 bottle	3.06	3.06	918.75	Sirmaxo Chemicals - Palghar plant	India
67	Povidone Iodine 10%, 200ml	1,000	1000	1 bottle	0.83	0.83	825.00	Sirmaxo Chemicals - Palghar plant	India
68	Benzyl Benzoate 25%, 1L, application	625	625	1 bottle	3.00	3.00	1875.00	Sirmaxo Chemicals - Palghar plant	India
69	Nystatin 100.000 IU, pessaries	68,200	682	100 vagitories	1.56	0.02	1065.63	Medicamen - Bhiwadi	India
70	Salbutamol 100mcg/dose, 200 doses CFC free	1,000	1000	1 inhaler	1.19	1.19	1187.50	Jewim Pharmaceutical, Taian High tech. Workshop 1 Steroids	China
82	Gauze bandage 5cm x 5m, BP17, individually packaged, self-edged	16,875	16875	1 roll	0.10	0.10	1687.50	Shaoxing Fuqing Health - Shaoxing	China
85	Polyamide 2/0, 75cm w/needle-monofil 3/8circl,35mm-tapercut	11,748	979	12 pieces	1.46	0.12	1431.79	Shanghai Pudong Jinhuan Medical Co., Ltd	China
86	Polyglycolic Acid 2/0, 75cm w/needle 1/2 circle, RB, 30mm	11,748	979	12 pieces	9.15	0.76	8954.23	Shanghai Pudong Jinhuan Medical Co., Ltd	China
89	Catheter Foley, CH 20	375	375	1 piece	0.35	0.35	130.01	Zhanjiang Star Enterprise - Jinchuan Rd.	China
							Product Total	\$91,772.25	

Shipment G. Products for SURFACE shipment CIP (Incoterms 2000) to DEPOT PHARMACEUTIQUE BDOM BUKAVU:

SURFACE SHIPMENT CIP (INCOTERMS 2000) TO DEPOT PHARMACEUTIQUE BDOM BUKAVU									
Item No.	Item Description	Total Qty	No. of Packs	Pack Size	Pack Price	Unit Price	Total Value USD	Manufacturer	Origin
3	Aluminium Hydroxide 120mg + Magnesium Trisilicate 250mg	138,000	138	1000 tablets	3.31	0.0033	457.13	Fourrts	India
4	Amoxicillin 250mg/5ml, 100ml	4,500	4500	1 bottle	0.53	0.53	2390.85	Medicamen - Bhiwadi	India
5	Amoxicillin 500mg	304,000	304	1000 capsules	27.88	0.03	8474.00	CSPC Zhongnuo Pharma Workshop 204	China
6	Chlorphenamine Maleate 4mg	197,000	197	1000 tablets	1.73	0.00	341.40	Medicamen - Bhiwadi	India
8	Ciprofloxacin 500mg, film-coated	326,100	3261	100 tablets	3.44	0.03	11209.69	Nanjing Baijingyu - General	China
10	Cotrimoxazole 480mg	814,000	814	1000 tablets	9.50	0.01	7733.00	Guilin Pharma - Workshop 2	China
12	Diclofenac Sodium 50mg, enteric coated	197,000	197	1000 tablets	3.44	0.00	677.68	Medicamen - Bhiwadi	India
14	Doxycycline 100mg, as Hyclate	114,000	114	1000 tablets	10.33	0.01	1177.96	Nanjing Baijingyu - General	China
16	Erythromycin 125mg/5ml, 100ml as Ethyl Succinate	2,000	2000	1 bottle	0.69	0.69	1375.00	Medicamen - Bhiwadi	India
23	Mebendazole, 100mg, Tab, 1000, Vrac	403,000	403	1000 tablets	3.75	0.00	1511.25	Medopharm - Malur Plant	India
24	Methyldopa 250mg, coated	7,000	7	1000 tablets	40.00	0.04	280.00	Medicamen - Bhiwadi	India
25	Metronidazole 250mg	290,000	290	1000 tablets	5.45	0.01	1580.21	Nanjing Baijingyu - General	China
27	Paracetamol 500mg	1,184,000	1184	1000 tablets	5.00	0.01	5920.00	Medicamen - Bhiwadi	India
29	Phenoxymethylpenicillin 250mg	145,000	145	1000 tablets	14.50	0.01	2102.50	Medicamen - Bhiwadi	India
30	Prednisolone 5mg	207,000	207	1000 tablets	7.75	0.01	1604.25	Medicamen - Bhiwadi	India
31	Oral Rehydration Salts 20.5g,WHO mod	127,800	1278	100 sachets	6.99	0.07	8933.22	Medicamen - Bhiwadi	India
33	Lysine Acetylsalicylate 1.8g eq. to 1g ASA	6,000	120	50 vials	20.25	0.41	2430.00	Reyoung Pharmaceutical, workshop 304	China
34	Ampicillin 1g, as Sodium	32,600	652	50 vials	5.95	0.12	3879.40	Reyoung Pharmaceutical, workshop 305	China

37	Ciprofloxacin 2mg/ml, 100ml	1,800	1800	1 bottle	0.36	0.36	648.00	Fresenius Kabi - Pune site	India
40	Diclofenac Sodium 25mg/ml, 3ml	12,800	128	100 ampoules	5.42	0.05	693.98	Gland - Pally Plant	India
43	Ephedrine HCl 30mg/ml, 1ml	1,000	100	10 ampoules	5.96	0.60	596.25	Lab. Aguettant, Unité de Chantecaille	France
48	Hyoscine Butylbromide 20mg/ml, 1ml	10,300	103	100 ampoules	9.94	0.10	1023.80	Gland - Pally Plant	India
56	Metronidazole 125mg/5ml, 100ml, as Benzoate	4,500	4500	1 bottle	0.34	0.34	1518.75	Medicamen - Bhiwadi	India
61	Vitamin K1 10mg/ml, 1ml (Phytomenadione)	20,700	207	100 ampoules	29.97	0.30	6204.47	Rotexmedica GmbH	Germany
64	Tetracycline HCl 1%, 5g, eye ointment	9,375	9375	1 tube	0.10	0.10	937.50	Nanjing Baijingyu - Ointment, Creams,	China
65	Chlorhexidine 1.5% + Cetrimide 15%, 1L	300	300	1 bottle	3.06	3.06	918.75	Sirmaxo Chemicals - Palghar plant	India
67	Povidone Iodine 10%, 200ml	1,000	1000	1 bottle	0.83	0.83	825.00	Sirmaxo Chemicals - Palghar plant	India
68	Benzyl Benzoate 25%, 1L, application	625	625	1 bottle	3.00	3.00	1875.00	Sirmaxo Chemicals - Palghar plant	India
69	Nystatin 100.000 IU, pessaries	68,100	681	100 vagitories	1.56	0.02	1064.06	Medicamen - Bhiwadi	India
70	Salbutamol 100mcg/dose, 200 doses CFC free	1,000	1000	1 inhaler	1.19	1.19	1187.50	Jewim Pharmaceutical, Taian High tech. Workshop 1 Steroids	China
82	Gauze bandage 5cm x 5m, BP17, individually packaged, self-edged	16,875	16875	1 roll	0.10	0.10	1687.50	Shaoxing Fuqing Health - Shaoxing	China
85	Polyamide 2/0, 75cm w/needle-monofil 3/8circl,35mm-tapercut	11,748	979	12 pieces	1.46	0.12	1431.79	Shanghai Pudong Jinhuan Medical Co., Ltd	China
86	Polyglycolic Acid 2/0, 75cm w/needle 1/2 circle, RB, 30mm	11,748	979	12 pieces	9.15	0.76	8954.23	Shanghai Pudong Jinhuan Medical Co., Ltd	China
89	Catheter Foley, CH 20	375	375	1 piece	0.35	0.35	130.01	Zhanjiang Star Enterprise - Jinchuan Rd.	China
							Product Total	\$91,774.13	

Shipment H. Products for SURFACE shipment CIP (Incoterms 2000) to DEPOT CENTRAL MEDICO-PHARMACEUTIQUE 8è CEPAC BUKAVU:

SURFACE SHIPMENT CIP (INCOTERMS 2000) TO DEPOT CENTRAL MEDICO-PHARMACEUTIQUE 8è CEPAC BUKAVU									
Item No.	Item Description	Total Qty	No. of Packs	Pack Size	Pack Price	Unit Price	Total Value USD	Manufacturer	Origin
3	Aluminium Hydroxide 120mg + Magnesium Trisilicate 250mg	137,000	137	1000 tablets	3.31	0.0033	453.81	Fourrts	India
4	Amoxicillin 250mg/5ml, 100ml	4,500	4500	1 bottle	0.53	0.53	2390.85	Medicamen - Bhiwadi	India
5	Amoxicillin 500mg	303,000	303	1000 capsules	27.88	0.03	8446.13	CSPC Zhongnuo Pharma Workshop 204	China
6	Chlorphenamine Maleate 4mg	197,000	197	1000 tablets	1.73	0.00	341.40	Medicamen - Bhiwadi	India
8	Ciprofloxacin 500mg, film-coated	326,100	3261	100 tablets	3.44	0.03	11209.69	Nanjing Baijingyu - General	China
10	Cotrimoxazole 480mg	814,000	814	1000 tablets	9.50	0.01	7733.00	Guilin Pharma - Workshop 2	China
12	Diclofenac Sodium 50mg, enteric coated	197,000	197	1000 tablets	3.44	0.00	677.68	Medicamen - Bhiwadi	India
14	Doxycycline 100mg, as Hyclate	114,000	114	1000 tablets	10.33	0.01	1177.96	Nanjing Baijingyu - General	China
16	Erythromycin 125mg/5ml, 100ml as Ethyl Succinate	2,000	2000	1 bottle	0.69	0.69	1375.00	Medicamen - Bhiwadi	India
23	Mebendazole, 100mg, Tab, 1000, Vrac	403,000	403	1000 tablets	3.75	0.00	1511.25	Medopharm - Malur Plant	India
24	Methyldopa 250mg, coated	7,000	7	1000 tablets	40.00	0.04	280.00	Medicamen - Bhiwadi	India
25	Metronidazole 250mg	290,000	290	1000 tablets	5.45	0.01	1580.21	Nanjing Baijingyu - General	China
27	Paracetamol 500mg	1,184,000	1184	1000 tablets	5.00	0.01	5920.00	Medicamen - Bhiwadi	India
29	Phenoxymethylpenicillin 250mg	144,000	144	1000 tablets	14.50	0.01	2088.00	Medicamen - Bhiwadi	India
30	Prednisolone 5mg	207,000	207	1000 tablets	7.75	0.01	1604.25	Medicamen - Bhiwadi	India
31	Oral Rehydration Salts 20.5g,WHO mod	127,800	1278	100 sachets	6.99	0.07	8933.22	Medicamen - Bhiwadi	India
33	Lysine Acetylsalicylate 1.8g eq. to 1g ASA	6,000	120	50 vials	20.25	0.41	2430.00	Reyoung Pharmaceutical, workshop 304	China
34	Ampicillin 1g, as Sodium	32,600	652	50 vials	5.95	0.12	3879.40	Reyoung	China

								Pharmaceutical, workshop 305	
37	Ciprofloxacin 2mg/ml, 100ml	1,800	1800	1 bottle	0.36	0.36	648.00	Fresenius Kabi - Pune site	India
40	Diclofenac Sodium 25mg/ml, 3ml	12,800	128	100 ampoules	5.42	0.05	693.98	Gland - Pally Plant	India
43	Ephedrine HCl 30mg/ml, 1ml	1,000	100	10 ampoules	5.96	0.60	596.25	Lab. Aguetant, Unité de Chantecaille	France
48	Hyoscine Butylbromide 20mg/ml, 1ml	10,300	103	100 ampoules	9.94	0.10	1023.80	Gland - Pally Plant	India
56	Metronidazole 125mg/5ml, 100ml, as Benzoate	4,500	4500	1 bottle	0.34	0.34	1518.75	Medicamen - Bhiwadi	India
61	Vitamin K1 10mg/ml, 1ml (Phytomenadione)	20,800	208	100 ampoules	29.97	0.30	6234.45	Rotexmedica GmbH	Germany
64	Tetracycline HCl 1%, 5g, eye ointment	9,375	9375	1 tube	0.10	0.10	937.50	Nanjing Baijingyu - Ointment, Creams,	China
65	Chlorhexidine 1.5% + Cetrimide 15%, 1L	300	300	1 bottle	3.06	3.06	918.75	Sirmaxo Chemicals - Palghar plant	India
67	Povidone Iodine 10%, 200ml	1,000	1000	1 bottle	0.83	0.83	825.00	Sirmaxo Chemicals - Palghar plant	India
68	Benzyl Benzoate 25%, 1L, application	625	625	1 bottle	3.00	3.00	1875.00	Sirmaxo Chemicals - Palghar plant	India
69	Nystatin 100.000 IU, pessaries	68,100	681	100 vagitories	1.56	0.02	1064.06	Medicamen - Bhiwadi	India
70	Salbutamol 100mcg/dose, 200 doses CFC free	1,000	1000	1 inhaler	1.19	1.19	1187.50	Jewim Pharmaceutical, Taian High tech. Workshop 1 Steroids	China
82	Gauze bandage 5cm x 5m, BP17, individually packaged, self-edged	16,875	16875	1 roll	0.10	0.10	1687.50	Shaoxing Fuqing Health - Shaoxing	China
85	Polyamide 2/0, 75cm w/needle-monofil 3/8circl,35mm-tapercut	11,736	978	12 pieces	1.46	0.12	1430.33	Shanghai Pudong Jinhuan Medical Co., Ltd	China
86	Polyglycolic Acid 2/0, 75cm w/needle 1/2 circle, RB, 30mm	11,736	978	12 pieces	9.15	0.76	8945.09	Shanghai Pudong Jinhuan Medical Co., Ltd	China
89	Catheter Foley, CH 20	375	375	1 piece	0.35	0.35	130.01	Zhanjiang Star Enterprise - Jinchuan Rd.	China

				Product Total	\$91,747.81		
--	--	--	--	---------------	--------------------	--	--

ANNEX 4: INTERNATIONAL TRAVEL AND SHORT-TERM ASSISTANCE PLAN (ATTACHED AS EXCEL FILE)

**ANNEX 5: INVENTORY OF EXISTING AND NEEDED SMALL MEDICAL EQUIPMENT FOR PROVISION OF MPA AND CPA-PLUS IN HEALTH ZONES
(ATTACHED AS EXCEL FILE)**

ANNEX 6: MANAGEMENT TOOLS REQUESTED BY HEALTH ZONES (ATTACHED AS EXCEL FILE)

**ANNEX 7: FAMILY PLANNING COMMODITIES RECEIVED FROM USAID AND DISTRIBUTED TO SUPPORTED HEALTH ZONES (ATTACHED AS EXCEL
FILE)**

ANNEX 8: WASH ASSESSMENT FORMS (ATTACHED AS EXCEL FILE)

ANNEX 9: IHP ACCRUALS REPORT (ATTACHED AS EXCEL FILE)

ANNEX 10: DRC IHP SF425 JAN-MAR 2011 (ATTACHED AS PDF FILE)

Annex 4 - Integrated Health Project (IHP) Year 1 International Travel and STTA Plan Oct 2010-Sept 2011

#	TECHNICAL AREA	SUGGESTED PERSON	ORG	Travel dates	INDICATIVE SCOPE OF WORK	Origin/destination	length of	PLANNED TIMEFRAME	
						to	days	From	To
STTA/PROJECT MANAGEMENT AND MONITORING									
Quarter 1 Oct-Dec 2010									
1	Project Management	Kristin Cooney	MSH	Nov 17-Dec 09, 2010	Start up the Integrated Health Project and assist the project transition from the Axxes Project and Leadership, Management, and Sustainability program to the Integrated Health Project, including meetings with USAID and project partners and stakeholders.	Boston	23		
2	Workplanning	Jean Kagubare	MSH	Nov 28-Dec 4, 2010	Support of the start-up phase and development of the workplan for the IHP project.	Boston	7		
3	Workplanning and Communication plan	Ryan Crow	OSC	Nov 28-Dec 8, 2010	Contribute to the development of the workplan and the strategic communications plan. He will also work with the Senior Staffing Specialist to recruit local communications staff.	DC	11		
4	Start-up operations	Christele Joseph-Pressat	MSH	Nov 28-Dec 14, 2010	Start up the DRC IHP project and assist in development of the workplan.	Boston	17		
5	Project start up	Larry Michel	MSH	Nov 20-Nov 24, 2010	Start up the DRC IHP program, including meetings with USAID and project partners and stakeholders.	Boston	5		
6	Recruitment	Tori Caldwell	MSH	Nov 20-Dec 4, 2010	Complete local staff recruitment for the Integrated Health Project, including training a new Human Resources Manager.	Boston	15		

7	COMU	Kate Onyejekwe	MSH	Nov 17-Dec 4, 2010	Orient the Finance and Administration Specialist and set up the Kinshasa office.	Boston	18		
8	Operations/Finance	Steve Morgan	MSH	Dec 08-Dec 22, 2010	Provide coverage for the Director of Finance and operations.	Boston	12		
Quarter 2 Jan-Mar 2011									
9	Team Orientation Workshop	John Pollock	MSH	Jan 01- Jan 15, 2011	Conduct team orientation Workshop/ Role & Clarification workshop.	Boston	15		
10	Recruitment	Felix Austine	MSH	Jan 04 - Feb 02, 2011	Continue the recruitment of new staff.	Nigeria	30		
11	Program Support	Gordana Ivkovic-Grujic	IRC	January 13-April 1, 2011	Support operational start-up of IHP project.	Serbia / Kinshasa return	78		
12	WASH	Hassan Coulibaly	IRC	Jan 20-Jan 30, 2011	Support development of IHP WASH strategy.	Nairobi / Kinshasa return	11		
13	M&E	Juan-Carlos Alegre	MSH	Feb 02 - Feb 12, 2011	Provide assistance in monitoring and evaluation	Boston	11		
14	Security	John McKenney	MSH	Feb 5 - Feb 19, 2011	Strengthen security systems and processes in Kinshasa and regions and advise on travel security	Boston	15		
15	BCC Assessment	Andrei Sinioukov	OSC	Feb 14-March 4, 2011	Conduct baseline KAP assessments for IHP target zones	Tanzania	19		
16	BCC Assessment	Waverly Rennie	OSC	Feb 14-March 4, 2011	Conduct baseline KAP assessments for IHP target zones.	Tanzania	19		

17	Recruitment	Tori Caldwell	MSH	Feb 18 - March 6, 2011	To finalize local staff recruitment for the Integrated Health Project and offer additional orientation for the new Human Resources Manager.	Boston	20		
18	Program Support	Suleiman Abdiel	IRC	February 15-May 15, 2011	Supporting operational start-up of IHP project at field level	Tanzania / Kinshasa return	90		
19	Public Health	Camilo Valderama	IRC	Feb 18-February 28, 2011	Support IRC IHP start-up, review integration of Community-Driven Reconstruction approaches into IHP strategy	Pakistan / Kinshasa return	11		
20	Project Management	Kristin Cooney	MSH	March 06- March 19, 2011	To provide technical support and guidance /reporting assistance.	Boston	14		
21	Gender / GBV	Ashley Wolfington	IRC	March 15-March 30, 2011	Support development of IHP Gender / GBV strategy.	New York / Kinshasa return	16		
22	WASH	Hassan Coulibaly	IRC	March 21-March 30, 2011	Support development of IHP WASH strategy.	Nairobi / Kinshasa return	10		
23	BCC Assessment and Technical Assistance	Waverly Rennie	OSC	March 28-April 2, 2011	Provide support to communications and KAP assessments for IHP target zones.	Tanzania	9		

New trip since last STTA plan but concurrence was already requested and received

Quarter 3 Apr-Jun 2011

24	SNIS	Nkossi Dambita	MSH	Apr 1 - Apr 16, 2011	Support PROSANI to strengthen MoH Système National de Information de la Santé (SNIS).	Maryland	16			New trip since last STTA plan but concurrence was already requested and received
25	PBF	Jean Kagubare	MSH	April 4-13, 2011	To support an internal PBF workshop (with USAID and other implementing agencies funded by USAID) and design the IHP PBF approach.	Boston	10			
26	Accounting and Finance	Donna Coulibaly	MSH	April 4 - April 17, 2011	Navigator and Quickbooks, review and strengthen Financial Systems; Support Payroll outsourcing	Nigeria	14			replaced Uder Antoine
27	Contract and Grant Management	Peter Mahoney	MSH	April 4 - April 15, 2011	Contracts/Grants Management; PBF contracting system; contractor/grantee monitoring system.	Boston	14			
28	Training and Technical Assistance	TBD	OSC	April 18-September 30, 2011	Communications Capacity Building, Design and implement health communications campaigns.	New York	125			Dates changing
29	Program Support	Gordana Ivkovic-Grujic	IRC	April 10-June 10, 2011	Supporting operational start-up of IHP project.	Serbia / Kinshasa return	61			
30	M&E	Juan-Carlos Alegre	MSH	May 15-20, 2011.	Monitoring and evaluation; baseline study.	Arlington	7			
31	MNCH Activity Planning and Technical Assistance	Ciro Franco	MSH	May 10-May 26, 2011	Train MNCH advisor; strengthen planning on maternal health interventions; strengthening community care sites (CCM).	Arlington	16			
32	Communications Planning and Technical Assistance	Elizabeth Walsh	MSH	May 22-June 8, 2011	Implement IHP communications plan, including building staff capacity to develop success stories.	Cambridge	21			

33	Community Mobilization	Susana Galdos	Consultant	May 25-Jun 10, 2011	Conduct on-the-job training for eight IHP community mobilization specialists and develop assessment tools for CODESAs.	Peru	15		
34	PBF	Cedric Ndizeye	MSH	June 8-21, 2011	Develop and test PBF curriculum with high performing trainers.	Rwanda	14		
35	Newborn Health Activity Planning and Technical Assistance	Indira Narayanan	MSH	Jun 10-Jun 26, 2011	Train MNH advisor; strengthen planning on newborn health interventions.	Arlington	16		
36	Nutrition Activity Planning and Technical Assistance	TBD	MSH	Jun 20-Jul 1, 2011	Train nutrition advisor; strengthen planning on nutrition interventions.	TBD	16		
37	Information Systems	Rabin Khadgi	MSH	June 01-June 14, 2011	Review IT systems and options for optimal IT Support to Kinshasa and other regions and orient the IT manager.	Boston	14		
Quarter 4 Jul-Sep 2011									
38	Project Management and Technical Assistance	Kristin Cooney	MSH	July 10-23, 2011	To provide technical support and guidance /reporting.	Boston	16		
39	Operations and workplanning for Year II	Christele Joseph-Pressat	MSH	Sep 01-Sep 15, 2011	Work with finance/admin team on budgeting workplan produced during workplanning workshop.	Boston	16		
40	Operations, workplanning Year II, and technical support	Carey Johnson	MSH	Sep 01-Sep 15, 2011	Provide technical support during workplanning workshop; visit project sites.	Boston	16		

Previously approved but name changed

Previously approved but dates shifted from July

Previously approved but dates shifted from July; replaces Ashley Stephens for this visit

41	Workplanning Year 2 and Technical Assistance	Jean Kagubare	MSH	Sep 01-Sep 15, 2011	Provide technical support during workplanning workshop; visit project sites related to PBF	Boston	16		
42	Project Management and Technical Assistance; Workplanning Year 2	Kristin Cooney	MSH	Sep 01-Sep 15, 2011	Provide technical support during workplanning workshop; visit project sites.	Boston	16		
43	Workplanning Year 2 and M&E Technical Assistance	Juan Carlos Alegre	MSH	Sep 01-Sep 15, 2011	Provide technical support during workplanning workshop; Training of M&E staff; visit project sites related to M&E system.	Arlington	16		
44	Commodity Security Technical Assistance	Tom Layloff	MSH	Sep 4-Sep 16, 2011	Provide technical assistance on quality assurance for essential medicines.	Arlington	12		
45	Commodity Security Technical Assistance	Ned Helzer	MSH	Sep 4-Sep 16, 2011	Provide technical assistance on quality assurance for essential medicines, procurement, and distribution.	Arlington	12		
INTERNATIONAL TRAVEL IHP LOCAL STAFF AND PARTNERS									
Quarter 1 Oct-Dec 2010									
N/A									
Quarter 2 Jan-Mar 2011									
46	WHO Training	Narcisse Naia	MSH	March 1-March 4, 2011	Immunization Program Managers meeting for Central Africa	Kinshasa/Gabon	4		

Previously approved but dates shifted from July

45

47	WASH	Simeon Kenfack	IRC	April-11	Travel to post for WASH Advisor	TBD	-			Previously approved but dates and name changed
48	Gender / GBV	TBD	IRC	May-11	Travel to post for Gender / GBV Advisor	TBD	-			Previously approved but dates changed
49	HMIS	SNIS Representative	MOH	May 2 - 20, 2011	Travel to / from Measure Evaluation CESAG Seminar on Improving HMIS	Kinshasa/Dakar	18			
50	Regional Workshop on Pneumonia and Diarrhea	Gilbert Andrianandrasana	MSH	May 23-May 28, 2011	Attend WHO/UNICEF Regional Workshop on Pneumonia and Diarrhea	Kinshasa/Ouagadougou	6			
51	Public Health	DCOP	IRC	May 28-June 6, 2011	Travel to / from IRC Global Health Conference - DCOP	Kinshasa/Bangkok	10			
52	WASH	Simeon Kenfack	IRC	May 28-June 3, 2011	Travel to / from IRC Global Health Conference - WASH Advisor	Kinshasa/Bangkok	7			Previously approved but name changed
53	USAID training	Finance Manager	MSH	June 20 -June 24, 2011	USAID/CDC Regulations & Policies - Financial Management of USAID/CDC Awards	South Africa (Pretoria)	6			
54	USAID training	Contracts&Compliance Manager	MSH	June 20 -June 24, 2011	USAID/CDC Regulations & Policies - Financial Management of USAID/CDC Awards	South Africa (Pretoria)	6			
55	USAID training	Finance and Administration Specialist	MSH	June 20 -June 24, 2011	USAID/CDC Regulations & Policies - Financial Management of USAID/CDC Awards	South Africa (Pretoria)	6			

Quarter 4 Jul-Sep 2011

56	USAID/East Africa FP Meeting	Severin Bushiri Mutepeke	MSH	Jul 25-Jul 29, 2011	Attend USAID/East Africa FP meeting and serve as ongoing contact for action plans developed at meeting	Nairobi / Kinshasa return	6		
57	USAID/East Africa FP Meeting	Pauline Kasuni	MSH	Jul 25-Jul 29, 2011	Attend USAID/East Africa FP meeting and serve as ongoing contact for action plans developed at meeting	Nairobi / Kinshasa return	6		
58	USAID training	Ousmane Faye	MSH	Sept 26 -Sept 30, 2011	USAID/CDC Regulations & Policies - Financial Management of USAID/CDC Awards	Nairobi / Kinshasa return	6		
59	Gender / GBV	TBD	IRC	September 19-September 23, 2011	Travel to / from IRC Global Women's Protection and Empowerment Conference Gender / GBV Advisor	TBD	5		
60	Public Health	TBD	IRC	September 12-September 23, 2011	Travel to / from IRC Global Health Conference	Kinshasa / Bangkok	11		

New trips requiring approval are indicated in pink (these trips have been added since the 02/08/2011 version of the STTA plan submitted with the IHP workplan for USAID approval)

No	Designation	Qte	Tshumbe			Kole			Luiza			Mwene Ditu			Kamina		Bukavu		Uvira		Kolwezi		Total CS (100%)	Total proposition (1/3 CS)	PU	Cout total (100 %)	Cout total proposition (1/3 CS)				
			Nbre de CS	Besoins exprimés par Bureau	Proposition (1/3 CS)	Nbre de CS	Besoins exprimés par Bureau	Proposition (1/3 CS)	Nbre de CS	Besoins exprimés par Bureau	Proposition (1/3 CS)	Nbre de CS	Besoins exprimés par Bureau	Proposition (1/3 CS)	Nbre de CS	Proposition (1/3 CS)															
			156			55			183			191			207			408			104			105			1409				
1	Balance Salter avec 3 culottes,	1	156	251	52	55	141	18	183	151	61	191		64	207	69	408	136	104	35	105	35	1409	470	\$ 50.00	\$ 70,450.00	\$ 23,483				
2	Bassin réniforme,	1	156	332	52	55	423	18	183	502	61	191	164	64	207	69	408	136	104	35	105	35	1409	470	\$ 88.64	\$ 124,894.46	\$ 41,631				
3	Blouse manches courtes, infirmiers	5	780		260	275		92	915		305	955		318	1035	345	2040	680	520	173	525	175	7045	2348	\$ 15.00	\$ 105,675.00	\$ 35,225				
4	Bocal en inox,	3	468		156	165		55	549		183	573		191	621	207	1224	408	312	104	315	105	4227	1409	\$ 25.00	\$ 105,675.00	\$ 35,225				
5	Boite à pansement,	1	156	278	52	55		18	183	665	61	191	218	64	207	69	408	136	104	35	105	35	1409	470	\$ 104.00	\$ 146,536.00	\$ 48,845				
6	Bouillotte,	2	312		104	110		37	366		122	382		127	414	138	6272	272	88	69	0	70	2818	939	\$ 8.00	\$ 22,544.00	\$ 7,515				
7	Hemoglobinomètre de Sahli,	1	156	0	52	55	141	18	183	169	61	191	186	64	207	69	408	136	104	35	105	35	1409	470	\$ 60.00	\$ 84,540.00	\$ 28,180				
8	Mètre ruban,	2	312	242	104	110	282	37	366	329	122	382	209	127	414	138	6272	272	88	69	0	70	2818	939	\$ 1.00	\$ 2,818.00	\$ 939				
9	Pèse bébé,	1	156	260	52	55	141	18	183	165	61	191	88	64	207	69	408	136	104	35	105	35	1409	470	\$ 167.67	\$ 236,242.66	\$ 78,748				
10	Balance pèse personne	1	156	157	52	55	141	18	183	122	61	191	215	64	207	69	408	136	104	35	105	35	1409	470	\$ 107.73	\$ 151,794.81	\$ 50,598				
11	Pince porte tampons,	1	156		52	55		18	183		61	191		64	207	69	408	136	104	35	105	35	1409	470	\$ 6.20	\$ 8,735.80	\$ 2,912				
12	Poire nouveau-ne	2	312		104	110		37	366		122	382		127	414	138	6272	272	88	69	0	70	2818	939	\$ 2.00	\$ 5,636.00	\$ 1,879				
13	Plateau,	1	156	166	52	55	282	18	183	342	61	191	123	64	207	69	408	136	104	35	105	35	1409	470	\$ 6.20	\$ 8,735.80	\$ 2,912				
14	Spéculum vaginal (boîte),	1	156		52	55	282	18	183	341	61	191	37	64	207	69	408	136	104	35	105	35	1409	470	\$ 125.00	\$ 176,125.00	\$ 58,708				
15	Stéthoscope obstétrical,	2	312	224	104	110	141	37	366	155	122	382		127	414	138	6272	272	88	69	0	70	2818	939	\$ 6.20	\$ 17,471.60	\$ 5,824				
16	Stéthoscope (double membrane),	2	312	148	104	110		37	366	152	122	382	234	127	414	138	6272	272	88	69	0	70	2818	939	\$ 10.00	\$ 28,180.00	\$ 9,393				
17	Ballon embout	2	312		104	110		37	366		122	382		127	414	138	6272	272	88	69	0	70	2818	939	\$ 10.00	\$ 28,180.00	\$ 9,393				
18	Sonde nasogastrique N°8	5	780		260	275		92	915		305	955		318	1035	345	2040	680	520	173	525	175	7045	2348	\$ 0.41	\$ 2,888.45	\$ 963				
19	Sonde nasogastrique N°9	5	780		260	275		92	915		305	955		318	1035	345	2040	680	520	173	525	175	7045	2348	\$ 0.41	\$ 2,888.45	\$ 963				
20	Sonde nasogastrique N°10	5	780		260	275		92	915		305	955		318	1035	345	2040	680	520	173	525	175	7045	1804	\$ 0.41	\$ 2,888.45	\$ 740				
21	Tambour,	1	156	314	52	55	282	18	183	328	61	191	87	64	207	69	408	136	104	35	105	35	1409	470	\$ 10.00	\$ 14,090.00	\$ 4,697				
22	Tensiometre,	1	156	148	52	55	282	18	183	196	61	191	211	64	207	69	408	136	104	35	105	35	1409	470	\$ 50.00	\$ 70,450.00	\$ 23,483				

1 6	Compteur à 5 touches, formule leucocytaire	1	10		10	6		6	11		11	11		11	9	9	23	23	5	5	8	8	83	83	\$ 60.00	\$ 4,980	\$ 4,980																					
1 7	Glucomètre	3	30		30	18		18	33		33	33		33	27	27	69	69	15	15	24	24	249	249	\$ 7.00	\$ 1,743	\$ 1,743																					
1 8	grandes compresses abdominales,	5	50		50	30		30	55		55	55		55	45	45	115	115	25	25	40	40	415	415	\$ 7.00	\$ 2,905	\$ 2,905																					
1 9	Grands champs fendus pour opéré,	5	50		50	30		30	55		55	55		55	45	45	115	115	25	25	40	40	415	415	\$ 7.00	\$ 2,905	\$ 2,905																					
2 0	grands champs pour gynécologie,	1	10		10	6		6	11		11	11		11	9	9	23	23	5	5	8	8	83	83	\$ 60.00	\$ 4,980	\$ 4,980																					
2 1	Hemoglobinomètre de Salhi,	1	10		10	6		6	11		11	11		11	9	9	23	23	5	5	8	8	83	83	\$ 6.00	\$ 498	\$ 498																					
2 2	Irrigateur,	1	10		10	6		6	11		11	11		11	9	9	23	23	5	5	8	8	83	83	\$ 0.60	\$ 50	\$ 50																					
2 3	Matelas,	4	40		40	24		24	44		44	44		44	36	36	92	92	20	20	32	32	332	332	\$ 0.84	\$ 279	\$ 279																					
2 4	Mètre ruban,	1	10		10	6		6	11		11	11		11	9	9	23	23	5	5	8	8	83	83	\$ 0.70	\$ 58	\$ 58																					
2 5	Micro pipette,	1	10		10	6		6	11		11	11		11	9	9	23	23	5	5	8	8	83	83	\$ 50.00	\$ 4,150	\$ 4,150																					
2 6	Otoscopes,	5	50		50	30		30	55		55	55		55	45	45	115	115	25	25	40	40	415	415	\$ 6.50	\$ 2,698	\$ 2,698																					
2 7	Panne de lit,	1	10		10	6		6	11		11	11		11	9	9	23	23	5	5	8	8	83	83	\$ 74.00	\$ 6,142	\$ 6,142																					
2 8	Poupinel,	1	10		10	6		6	11		11	11		11	9	9	23	23	5	5	8	8	83	83	\$ 100.00	\$ 8,300	\$ 8,300																					
2 9	Stéthoscope obstétrical,	5	50		50	30		30	55		55	55		55	45	45	115	115	25	25	40	40	415	415	\$ 10.00	\$ 4,150	\$ 4,150																					
3 0	Stéthoscope double membrane,	10	100		100	60		60	110		110	110		110	90	90	230	230	50	50	80	80	830	830	\$ 10.00	\$ 8,300	\$ 8,300																					
3 1	Tensiometre,	10	100		100	60		60	110		110	110		110	90	90	230	230	50	50	80	80	830	830	\$ 15.00	\$ 12,450	\$ 12,450																					
3 2	Bassin reiniforme	5	50		50	30		30	55		55	55		55	45	45	115	115	25	25	40	40	415	415	\$ 88.64	\$ 36,786	\$ 36,786																					
3 3	Thermometre digital	10	100		100	60		60	110		110	110		110	90	90	230	230	50	50	80	80	830	830	\$ 9.59	\$ 7,960	\$ 7,960																					
Total																																														\$ 423,983	\$ 423,983	\$ 3

OUTILS DE GESTION COMMANDEE

No	DESIGNATION	Quantité Commandée
1	FORMULAIRE PEV 2	440
2	FORMULAIRE PEV 3	440
3	REGISTRE DE LABORATOIRE	543
4	SNIS CS (LUIZA)	4,152
5	SNIS CS (MWENE DITU)	77,280
1	FICHE DE POINTAGE	440
2	FORMULAIRE PEV 1	806
3	REGISTRE CPON	1,042
4	REGISTRE CPS/VACCINATION	1,006
5	REGISTRE D'ACCOUCHEMENT	994
6	REGISTRE CPN/CS	1,042
1	CANEVAS SNIS BCZS	162
2	CANEVAS SNIS HGR	648
3	CANEVAS SNIS BCZS(8 pages)	240
4	CANEVAS SNIS HGR	216
5	CANEVAS SNIS BCZS(16 pages)	80
6	CANEVAS SNIS HGR	7,728
7	CANEVAS SNIS BCZS	2,112
8	CANEVAS SNIS CS	2,620
9	CANEVAS SNIS HGR	168
10	CANEVAS SNIS BCZS	168
11	CANEVAS SNIS CS	2,016
12	CANEVAS SNIS HGR	162
13	CANEVAS SNIS BCZS	168
14	RELEVÉ EPIDEMIOLOGIQUE	6,000
15	PCIME FICHE INDIVIDUELLE	250,000
16	PCIME DE 0 a 2 mois	93,280
17	FICHE DE CONSULTATION	1,079,240
18	FICHE DE PARTOGRAMME	279,840
19	FICHE DE CPON	326,480
20	FICHE DE COLLECTE DES DONNEES SR	14,530
21	FICHE D'AUDITS DE DECES MATERNEL	800
22	FICHE DE CPN	419,760
23	FICHED DE CPS	419,760
24	FICHE DE COLECTE DES DONNEESDES AIVITES DE PF	9,258
25	CARTE DE RENDEZ-VOUS PF	269,346
26	FICHE DE PF	269,346
27	FICHE RAPPORT MENSUEL PF	3,634
28	FICHE CANEVAS SYNTHESE MENSUEL DBC	2,525
29	FICHE DE COLLECTE DES DONNEES DES DBC	5,760
30	LIVRE DE CAISSE	160
31	RAPPORT FINANCIER MENSUEL CS	1,543
32	RAPPORT FINANCIER MENSUEL HGR	80
33	RAPPORT JOURNALIER DE CAISSE	80

34	FORMULAIRE I; RAPPORT MENSUEL D'ACTIVITES PNL P HGR	240
35	FORMULAIRE II; RAPPORT MENSUEL D'ACTIVITES PNL P CS	4,629
36	FORMULAIRE III; RAPPORT MENSUEL D'ACTIVITES PNL P BCZS	240
37	BON DE REQUISITION/LIVRAISON/PV DE RECEPTION	1,703

Family planning commodities received from USAID and distributed to supported health zones

	DESIGNATION	LUIZA	KOLE	BUKAVU	MWENE DITU	TSHUMBE	KOLWEZI	UVIRA	KAMINA	TOTAL	
1	DEPO-PROVERA	32,200	24,800	28,400	32,200	24,800	24,800	28,400	24,800	220,400	doses
2	DIU	300	200	300	300	200	200	300	300	2,100	units
3	MICROLUT	2,880	2,160	2,160	2,880	2,160	2,880	2,880	2,160	20,160	cycles
4	MICROGYNON	51,120	51,120	51,840	51,840	51,120	51,840	51,120	51,840	411,840	cycles
5	JADELLE	150	100	100	150	100	100	100	200	1,000	units
6	CONDOM MALE	500,000	500,000	500,000	500,000	500,000	500000	500,000	500,000	4,000,000	units
7	CONDOM FEMININ	13,000	12,000	10,000	10,000	13,000	13,000	14,000	15,000	100,000	units
8	COLLIER DU CYCLE	15,000	10,000	10,000	10,000	10,000	5,000	5,000	5,000	70,000	units

Fiche d'information _FOSA

Province de:..... Zone de sante de :..... Aire de Sante:..... FOSA:.....

Infirmier Titulaire:..... Total de personnel salarie: Total de personnel volontaire: Moyenne de malades recu par jour

Les 2 premieres pathologie les plus rencontrees:..... Les 2 villages d'origine du plus de patients:.....

Dernieres activites engagees avec le superviseur Eau et Assainissement du BCZ:.....

Bâtiment /structure: :

	<i>Terre</i>	<i>B oi s</i>	<i>Briques cuites</i>	<i>Briques ciment</i>					
Construction en	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	Propriété	<i>Communauté</i>	<i>Institution</i>	<i>en location</i>	<i>Autre(préciser)...</i>
Toiture en		<i>Tole:</i> <input type="text"/>	<i>Paille</i> <input type="text"/>			<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

Eau:

Ou prend-t' on l'eau?	Distance en km	Distance en (mn)
<i>Réseau gravitaire (Robinet/fontaines)</i>	<input type="text"/>	<input type="text"/>
<i>Source aménagée</i>	<input type="text"/>	<input type="text"/>
<i>Sources non aménagées</i>	<input type="text"/>	<input type="text"/>
<i>Riviere/étang</i>	<input type="text"/>	<input type="text"/>
<i>Puits moderne</i>	<input type="text"/>	<input type="text"/>
<i>Puits traditionnel</i>	<input type="text"/>	<input type="text"/>
<i>Eau pluviale / gouttière</i>	<input type="text"/>	<input type="text"/>

Quantité d'eau utilisée par jour:

.....litres	<input type="text"/>
-------------	----------------------

Récipient de stockage:

	Combien?	Volume
<i>Jerrycan</i>	<input type="text"/>	<input type="text"/>
<i>Seau</i>	<input type="text"/>	<input type="text"/>
<i>Fut</i>	<input type="text"/>	<input type="text"/>
<i>Autre:(préciser)</i>	<input type="text"/>	<input type="text"/>

Qui se charge l'approvisionnement en eau:.....

.....

.....

Traitement eau a boire ou pour soins:

<i>Chlore</i>	<input type="text"/>
<i>Javel</i>	<input type="text"/>
<i>Filtre</i>	<input type="text"/>
<i>Bouillie</i>	<input type="text"/>
<i>Pas de traitement</i>	<input type="text"/>

Gestion des déchets/ordures

Ordures divers:	Trou a ordures		Objet tranchants/Aiguille		Déchets organiques:	Enterre selon le cas		
	Dans la brousse			Enterre fosse spéciale			Fosse spéciale	
	Bruler sur un tas d'ordures			Bruler/inciner			Emporte par les parents	
	Bruler dans une fosse			Receptacle				
	Bruler dans un fut			retur BCZ				
	bruler dans un incinérateur maçonné							

Assainissement

Il y a :	Combien ?		
Douche		
Latrine/WC		
Lave mains		
Place lessive			
Place vaisselle			